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4. INTRODUCTION 
4.1 Development of cancer  
Cancer encompasses a group of diseases characterized by uncontrolled cell proliferation. 
Malignant tumours, in contrast to benign tumours, possess the ability to invade adjacent 
tissues and metastasize to more distant locations. The different cancer forms are classified 
according to the tissue and cell type from which they are believed to arise. For example, 
ovarian carcinoma (OC) is believed to arise from the ovarian surface epithelium. 
Development of cancer is a multistep process involving several sequential alterations, 
resulting in several biological properties required for cancer development. 
 
4.1.1 Cancer and genetics 
Cancer develops as a result of changes in gene expression caused by genetic or epigenetic 
alterations. Genetic alterations are caused by stable changes in the DNA sequence 
(mutations), whereas epigenetic alterations involve non-DNA changes, which are functionally 
relevant modifications of the genome, such as DNA methylation and histone modifications. 
Genetic and epigenetic alterations inflict varying biological effects depending on where in the 
genome or epigenome they occur and whether they alter a gene product. For cancer to 
develop, it is required that these changes result in altered gene expression that causes specific 
biological properties. 
Mutations may occur in a number of ways. According to effect on structure, mutations can be 
classified as small-scale mutations and large-scale mutations. Small-scale mutations affect a 
small genetic region of one or a few nucleotides, and include point mutations, deletions and 
insertions, where nucleotides are substituted, removed or added, respectively. Large-scale 
mutations affect larger genetic regions such as chromosomal structures, and include 
amplifications, deletions and translocations, causing chromosomal regions to be copied, lost 
or exchanged, respectively. 
Genetic and epigenetic alterations are usually not hereditary, although germline mutations 
may predispose for the development of cancer. It is currently accepted that development of 
cancer is the result of accumulation of several genetic errors (1-3). Subsequent genetic 
alterations in a malignant cell may lead to tumour heterogeneity, which contributes to 
differences in phenotype and response to treatment. 
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4.1.2 Cancer genes 
An adult human being is composed of approximately 1015 cells (3). Cell turnover involves cell 
division and differentiation, approximately 1012 cell divisions per day in humans (3). 
Complex molecular mechanisms ensure a strict balance between cell proliferation and cell 
death, and the total number of cells remains quite stable under normal conditions. Genome 
errors that occur during cell division are normally corrected by DNA repair mechanisms. 
However, if mutations in key regulatory genes, so-called “cancer genes”, are not repaired, the 
balance between cell proliferation and cell death may be disturbed, and cancer may develop.  
Cancer genes may encode proteins involved in the control of cell proliferation and cell death. 
These genes include oncogenes and tumour-suppressor genes (4;5). Oncogenes are mutated 
genes (proto-oncogenes) that stimulate proliferation. An activating mutation (“gain of 
function mutation”) of proto-oncogenes may therefore contribute to the development of 
cancer. Tumour-suppressor genes inhibit proliferation and/or promote cell death, and an 
inactivating mutation (“loss of function mutation”) may likewise contribute to development of 
cancer.  
The tumour suppressor gene TP53 is frequently mutated in human cancer (6). Its protein p53 
(protein 53) has been called the “guardian of the genome”, acting as a “molecular policeman”, 
monitoring the integrity of the genome (7) and deciding whether a cell proliferates or dies. 
Based on the intracellular level of stress and abnormality, such as a DNA damage or the 
presence of aberrant growth signals, p53 has the capacity to either delay replication by 
causing cell cycle arrest or induce cell death if repair fails (6;8).  
The recently discovered microRNAs (miRNAs), a class of small non-coding RNAs that 
regulate gene expression post-transcriptionally, may act as tumor suppressor genes or 
oncogenes (9), depending on whether they target oncogenes or tumor suppressor genes, 
respectively. 
 
4.1.3 mRNA and miRNA expression  
A gene is the molecular unit of heredity in all living organisms, and may be defined as a 
sequence of nucleic acids encoding a functional gene product, such as protein and RNA. If a 
certain gene encodes a protein, the result of transcription is a messenger RNA (mRNA), 
which is an information carrier encoding information necessary for synthesis of one or more 
proteins. A gene may also encode a non-coding RNA (ncRNA), which is a functional RNA 
molecule involved in the regulation of several cellular processes such as gene expression. The 
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miRNAs are a class of short ncRNAs first discovered in the roundworm Caenorhabditis 
elegans in 1993 (10). However, they were not recognized as a distinct class of biological 
regulators until the early 2000s, and have recently been found to be present and highly 
conserved in a wide range of species (11).  
Gene expression is the process by which information from a gene is used in the synthesis of a 
functional gene product. The gene expression process encompasses several steps, including 
transcription and post transcriptional modification as well as translation and post-translational 
modification of proteins. An overview of mRNA and miRNA expression is given in Figure 1. 
 
Figure 1. mRNA and miRNA expression. 
TF: Transcription factor. RNApol: RNA polymerase. RISC: RNA-induced 
silencing complex. Pasha, Drosha and Dicer: Enzyme complexes. 
 
Transcription is the first step in gene expression, in which a particular segment of DNA is 
copied into RNA by the enzyme RNA polymerase in the nucleus. In eukaryotes, transcription 
is initiated by the binding of RNA polymerase to a promoter sequence in the DNA in the 
presence of various specific transcription factors. To create a RNA copy of the DNA 
template, RNA polymerase adds one RNA nucleotide at a time to a growing RNA strand by 
using base pairing complementarity to the DNA template.  
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Transcription produces a precursor, which matures through several post-transcriptional 
modifications. For mRNAs, a primary RNA (pre-mRNA) is transcribed and subsequently 
modified by 5' capping, 3' cleavage and polyadenylation as well as RNA splicing. These 
modifications protect the RNA from degradation and are necessary for the mRNA export 
from the nucleus to the cytoplasm for translation into proteins. Alternative splicing, a process 
where exons of a pre-mRNA are included or excluded from the finally processed mRNA, 
implies that one specific gene may encode multiple different mRNAs, contributing to mRNA 
and protein heterogeneity.  
The majority of the miRNAs is believed to be produced from their own independent genes, 
but may possibly also originate from introns (12-14). Initially, primary miRNAs (pri-
miRNAs) are transcribed as long double stranded precursors, which are processed into 
stemloop structures (70-100 nucleotides) known as precursor miRNAs (pre-miRNAs) by the 
enzyme Drosha and its cofactor Pasha. The pre-miRNAs are exported to the cytoplasm, where 
they are further cleaved by the enzyme Dicer into 17-25 nucleotides long mature miRNAs. 
The mature miRNAs may incorporate into an RNA-induced silencing complex (RISC), and 
target mRNAs by complementary base pairing (13;14). This process may result in 
translational repression or mRNA degradation (15). However, it has also been reported that 
miRNAs can activate translation (14;16). Therefore, miRNAs play a central role in regulating 
gene expression and are likely to be involved in multiple biological processes (13;14). 
At present, about 1600 miRNAs encoded by the human genome have been identified 
(www.mirbase.org, Manchester University, UK). It has been estimated that a single miRNA 
may have about 200 targets and that miRNAs may control the expression of about one-third 
of all human mRNAs (13;17;18). The reason for this may be that human miRNAs do not 
seem to require perfect complementarity for functional interactions with mRNA targets. 
However, continuous base-pairing of the miRNA nucleotides 2 to 8 (the seed region) is 
apparently required for efficient mRNA targeting (14). Therefore, a single miRNA may have 
multiple different mRNA targets and conversely, a given mRNA might be targeted by 
multiple miRNAs. Consequently, alterations in miRNA expression may alter the level of a 
wide specter of mRNAs and proteins and consequently affect cellular functions.   
The regulation of gene expression gives the cell control over structure and function, and is the 
basis for morphogenesis and cellular differentiation as well as the diversity and adaptability of 
any organism. Accordingly, gene expression varies between different cell types based on 
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specific cell function, and also within the same cell type according to variable cell 
requirements. Each cell transcribes RNAs from only a fraction of the genes, which is 
considered "on" when it is transcribed, otherwise "off". The aberrant mRNA and miRNA 
expression in cancer is a result of complex multifactorial processes, based on genetic and 
epigenetic alterations. Interestingly, at least half the miRNA encoding genes are located in 
cancer-associated genomic regions or in fragile sites, frequently exposed for mutations (19). 
 
4.1.4 The hallmarks of cancer 
Hanahan and Weinberg published in 2000 a review listing “The hallmarks of cancer” (20), 
revised in 2011 (1), encompassing a set of biological capabilities needed for the development 
of cancer, enabling tumour growth and metastasis. Well accepted are six capabilities, 
illustrated in Figure 2A. 
1. Sustaining proliferative signalling, the most fundamental hallmark of cancer. Cancer cells 
are able to sustain proliferation through growth-promoting signals, mainly growth factors 
produced by cancer cells themselves or normal cells in the tumour-associated stroma as a 
consequence of signalling from the cancer cells (21). 
2. Evading growth suppressors. Cancer cells evade inhibition of cell proliferation, frequently 
dependent on tumour-suppressor genes such as TP53.  
3. Resisting cell death. Cell death is triggered by physiologic stress factors including DNA 
damage and oncogenic signalling. Cancer cells may circumvent cell death in different 
ways, for instance by the loss of p53 tumour suppressor function.  
4. Enabling replicative immortality. Normal cells are able to divide only a limited number of 
times due to shortening of the chromosomal ends at each cell cycle. This leads to 
senescence, an irreversible entrance into a nonproliferative state, and eventually to a crisis 
with cell death. Apparently, telomeres, which protect the ends of the chromosomes as well 
as its enzyme telomerase, are centrally involved in the immortalization process in cancer 
(22). 
5. Inducing angiogenesis. The formation of new vasculature is essential for tumour growth, 
to meet the tumour’s increasing need for nutrients and oxygen as well as for removal of 
metabolic waste products. The VEGFA (vascular endothelial growth factor A) protein 
binds to stimulatory cell surface receptors displayed by vascular endothelial cells and is a 
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well known angiogenesis inducer. Different factors influence the expression level of 
VEGFA, such as hypoxia (23). 
6. Activating invasion and metastasis. This is a multistep process involving a sequence of 
biological changes (1;24). Initially, the cancer cells are released and adhere to other cells 
and to the extracellular matrix by local invasion. For carcinoma cells, this process often 
involves down regulation of E-cadherin and up regulation of N-cadherin (25). By 
haematogenous and lymphatic spread cancer cells are transported to a distant location by 
extravasation. Cancer may also spread via a fluid-filled cavity which is the main route for 
metastasis in ovarian cancer. At the distant site, the cancer cells may form small nodules 
(micrometastases) and finally grow into macroscopic tumours. 
Two emerging hallmarks of cancer have recently been introduced by Hanahan and Weinberg 
as shown in Figure 2B (1). 
1. Deregulating cellular energetics, involving reprogramming of the cellular energy 
metabolism in order to meet the increasing energy demand due to the cell proliferation. 
2. Avoiding immune destruction, which involves avoidance of attack and elimination by the 
immune system.  
Requirements for the development of these hallmarks are the presence of genome instability 
and mutation (genetic and epigenetic alterations) as well as a tumour-promoting inflammation 
(Figure 2B). The hallmarks of cancer act both independently and complementary. 
The tumour-associated stroma, constituting the tumour microenvironment, participates in the 
tumourigenesis. This was hypothesised already in 1889 by Pagets “seed and soil” hypothesis, 
suggesting that the cancer cells (seeds) need a specific microenvironment (soils) to proliferate 
(26). Tumour progression has quite recently been recognized as the product of a crosstalk 
between cancer cells and other cells within the tumour and its surrounding stroma (27). The 
microenvironment encompasses immune inflammatory cells, endothelial cells, pericytes and 
cancer associated fibroblasts. For example, the immune cells produce several biologically 
active factors that generate a tumour-promoting inflammatory state. The cancer cells 
communicate with the tumour microenvironment, producing gene products which may  
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Figure 2A. The hallmarks of cancer.  
Reprinted from Cell 2011; 144(5):646-74. Hanahan D, Weinberg RA. Hallmarks of 
cancer: the next generation. Copyright (2013), with permission from Elsevier (1).  
 
 
Figure 2B. Emerging hallmarks and enabling characteristics.  
Reprinted from Cell 2011; 144(5):646-74. Hanahan D, Weinberg RA. Hallmarks of 
cancer: the next generation. Copyright (2013), with permission from Elsevier (1). 
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promote tumour progression by processes as angiogenesis, inflammation and remodelling of 
the extracellular matrix (28). 
 
4.2 Ovarian cancer 
4.2.1 Epidemiology 
Ovarian cancer is the fourth and fifth most frequent cause of cancer death in women in 
Norway and the United States, respectively (29;30). The ovarian cancer death rate is only 
ranging behind lung, breast and colorectal cancer, and in the United States also behind 
pancreas cancer (29;30), as shown in Figure 3. Worldwide, it is the seventh most frequent 
cause of cancer death in females, ranging behind breast, lung, colorectal, cervical, stomach 
and liver cancer (31). Whereas the overall cancer death rate since 2002 has consistently 
decreased by 1.6 percent per year females, the death rate has been quite stable for ovarian 
cancer patients (30). Despite the high death rate, ovarian cancer is only about one-tenth as 
common as breast cancer (30). 
The incidence in the Scandinavian countries is among the highest in the world (32). In 
Norway, the incidence during the last decade was about 450 patients per year (33). The 
median age at diagnosis of OC, the most common histological type of ovarian cancer, is 
between 60 and 65 years (34). 
 
4.2.2 Etiology 
The etiology of OC remains uncertain, though several etiologic hypothesis have been 
proposed and evaluated (32;34). Apparently, ovulation causes disruption and repair of the 
ovarian surface epithelial cells, involving a risk of spontaneous mutations in cancer genes. 
The number of ovulatory cycles appears to influence the ovarian cancer incidence, as low 
parity, infertility, early menarche and late menopause increase the risk of developing ovarian 
cancer (34-36).  
Ninety percent of OC occur sporadically, whereas 10% have a strong hereditary component, 
predisposed by mutations predominantly in BRCA1 or BRCA2 genes in hereditary breast and 
ovarian cancer syndrome or in DNA mismatch repair genes in the hereditary nonpolyposis 
colorectal cancer syndrome (32;34).  
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Figure 3. Trends in death rates among females for selected cancers, United States, 1930 
to 2008. 
Rates are age adjusted to the 2000 US standard population. Due to changes in International 
Classification of Diseases (ICD) coding, numerator information has changed over time. 
Rates for cancers of the uterus, ovary, lung and bronchus, and colorectum are affected by 
these changes. *Uterus includes uterine cervix and uterine corpus. Reprinted from CA: 
Cancer Journal for Clinicians 2012; 62(1):10-29.  Siegel R, Naishadham D, Jemal A. Cancer 
statistics, 2012. Copyright (2013), with permission from John Wiley and Sons (30). 
 
4.2.3 Origin  
OC is presumed to originate in the ovarian surface epithelium (OSE) or its derivatives as 
epithelial inclusion cysts through “Müllerian neometaplasia” (37), a process where epithelial 
cells redifferentiate into cells morphologically resembling those derived from the Müllerian 
ducts (embryonic ducts that have developed into most of the female genital tract). The basis 
for this theory is that the OSE cells closely resemble the continuing mesothelium lining the 
peritoneal cavity, in contrast to the OC cells, which resemble Müllerian phenotypes.  
An alternative origin of a subset of OC has recently been proposed, implying that Müllerian 
derived non-OSE cells involve the ovary secondarily. For serous ovarian carcinoma (SC), the 
model describes an additional carcinogenetic pathway postulating that exfoliated carcinoma 
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cells originated in the tubal fimbria implant the ovary or alternatively, that SC develop via 
malignant transformation of implanted tubal epithelial cells (endosalpingiosis). Likewise, it 
has been proposed that endometrioid ovarian carcinoma and clear cell ovarian carcinoma 
(CCC) develop via malignant transformation of implanted endometrial epithelial cells 
(endometriosis) (38). The basis for this model are studies of the tubes of women predisposed 
to or operated for OC. Women with germline BRCA1 or BRCA2 mutations, who are 
predisposed to developing mainly high-grade serous ovarian carcinoma (HGSC) (39), have 
recently been shown to be burdened with a high frequency of dysplasia (40) and (serous) tubal 
intraepithelial carcinoma (TIC) (41) in the tubal fimbria. Cytological and molecular 
resemblance between TIC and HGSC has also been found (38;42-45). Moreover, a recent 
study of the Fallopian tube in patients with serous carcinoma, OC included, showed 
involvement of the endosalpinx in about 70% and TIC in about 50% (45). Recently, Fallopian 
tube precursor lesions have also been found in low-grade serous ovarian carcinoma (LGSC) 
(46;47). Based on these findings, the tubal fimbria has been proposed as a possible site of 
origin for SC (41;42;48). However, a direct transition from lesions in the Fallopian tube to OC 
has still not been demonstrated although a common embryological origin of fimbrial 
epithelium and OSE has been hypothesized (49). 
 
4.2.4 Classification   
Surface epithelial-stromal tumours comprise a heterogeneous group of tumours (50). 
According to the WHO (World Health Organization) histological classification, they are 
classified histologically into serous, mucinous, endometrioid, clear cell, transitional cell, 
squamous cell, mixed epithelial and undifferentiated/unclassified tumours (50). Most of these 
tumours are further subdivided into malignant, borderline and benign, based on the degree of 
cell proliferation and nuclear atypia as well as the presence or absence of stromal invasion 
(50). Malignant surface epithelial-stromal tumours, commonly referred to as OC or epithelial 
ovarian cancer, constitutes about 90% of all ovarian cancers in North America and Western 
Europe (50). 
OC are graded as well differentiated (WD; grade 1), moderately differentiated (MD; grade 2) 
or poorly differentiated (PD; grade 3). There is currently no universally accepted histological 
grading system for OC (51). However, the International Federation of Gynecology and 
Obstetrics (FIGO) grading system (52) is one of the most widely used. This grading system is 
based on architectural pattern, characterizing WD, MD and PD tumours by <5%, 5%-50% 
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and >50% solid growth, respectively. Another frequently used grading system is Silverberg’s 
grading system (53), which includes the assessment of architectural pattern, nuclear grade and 
mitotic activity.  
It is now generally accepted that OC is not a single homogenous disease, but encompasses 
several distinct diseases, each with different oncogenesis and clinical aspects. Therefore, new 
classification models for OC have been proposed. Based on similarity, MD and PD tumours 
are merged and generally referred to as high-grade (HG) tumours, whereas WD tumours are 
referred to as low-grade (LG) tumours. A dualistic model, separating the tumours in Type I 
tumours (LG serous, LG endometrioid, clear cell and mucinous carcinomas) and Type II 
tumours (HG serous, HG endometrioid and undifferentiated carcinomas) was proposed more 
than a decade ago (54;55). Since tumour subgroups within this dualistic classification 
represent distinct diseases both clinically, morphologically and molecularly, a broader 
classification system has recently been proposed (38). In this model OC is divided into at least 
five subgroups; HG serous (about 70%), clear cell (about 10%), endometrioid (about 10%), 
mucinous (about 3%) and LG serous carcinomas (<5%), comprising 98% of OC. These five 
subgroups are different regarding predisposing genetic risk factors, putative precursor lesions, 
patterns of spread, molecular alterations, chemosensitivity and prognosis (38;56) and 
furthermore, they can be distinguished histopathologically (38).   
SC is the most common histological subtype of OC (51;57), of which the MD and PD are 
predominant compared with the WD (51). The merging of MDSC and PDSC into HGSC is 
based on several studies showing that patients with WDSC have a substantially better survival 
than those with MDSC or PDSC (51;58;59). MDSC and PDSC apparently represent one 
common tumour subclass distinct from WDSC and also from serous ovarian borderline 
tumour (SBOT) with respect to origin, pathogenesis, molecular abnormalities and clinical 
outcome (54;60-66). SBOT is a tumour subgroup exhibiting histological malignant 
characteristics, but lack stromal invasion. The LGSC are generally thought to develop in a 
stepwise manner from OSE via precursor lesions in benign serous cyst adenomas and SBOT. 
Progression from SBOT to LGSC has been found in about seven percent (67). The HGSC are 
generally believed to originate directly from the OSE and not via a defined precursor lesion 
(54;62;63). Other postulated origins than OSE are discussed above. Mutations of TP53 and 
BRCA1/2 genes are typical in HGSC, whereas KRAS and BRAF mutations are common in 
LGSC and SBOT (61;62).  
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CCC is the second most common histological subtype of OC in North America and Europe, 
with a prevalence of 1–12% (68;69). The prevalence varies among different populations, 
being 15–25% in Japan (68;69).  As shown in Table 1, there are several characteristics 
discriminating CCC from HGSC, including age and stage at diagnosis, putative precursor 
lesions, prevalence in different populations, chemosensitivity, molecular alterations and 
outcome (68).  
Table 1. Discriminating features of clear cell (CCC) and high-grade serous carcinomas 
(HGSC)  
Clear cell carcinoma High-grade serous carcinoma 
Presents at younger age and low stage (pelvic 
mass) 
• 57–81% stage I/II at presentation 
Present at older age and high stage (ascites 
common) 
• ~ 80% stage III/IV at presentation 
Associated with endometriosis 
(putative precursor lesion) 
Associated with serous tubal intraepithelial 
carcinoma (STIC; putative precursor lesion) 
Low-stage outcome better than (stage matched) 
HGSC 
High-stage outcome better than (stage matched) 
CCC 
Higher proportion in Japanese/Asian 
populations (up to 25% of OC) 
Higher proportion in European populations 
Higher frequency of thromboembolic 
complications 
Lower frequency of thromboembolic 
complications (compared to CCC) 
Inherently chemoresistant to current treatment 
standards (Platinum/taxane) 
Good initial response rates to current treatment 
standards (Platinum/taxane) 
Low frequency of BRCA1/2 mutations BRCA dysfunction 
• Higher proportion of hereditary (germline) 
BRCA1/2 mutation carriers 
TP53 wild-type TP53 mutant 
Genomically stable Genomically Unstable 
High frequency of PIK3CA mutations 
(activating) 
Low frequency of PIK3CA mutations 
High frequency ARID1A mutations 
(loss of function) 
No detectable mutation of ARID1A 
Reprinted from Gynecologic Oncology 2011; 121(2):407-15. Anglesio MS, Carey MS, Köbel 
M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first 
Ovarian Clear Cell Symposium, June 24th, 2010. Copyright (2013), with permission from 
Elsevier (68).  
 
 
4.2.5 mRNA and miRNA expression 
The development of OC is apparently a result of accumulation of multiple genetic changes 
(70;71). However, the molecular mechanisms involved are not fully understood. Several 
oncogenes have been shown to be activated, and tumour suppressor genes inactivated (34;70). 
These mutations may lead to altered expression of genes controlling critical regulatory 
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processes, which finally may result in cancer. The spectrum of genes and pathways involved 
in OC development is generally wide and varied.  
Until recently, most OC biomarker studies have evaluated only one or a few biomarkers at a 
time. These studies have shown that ovarian carcinogenesis is a complex, multifactorial 
process associated with abnormalities in multiple genes (71). Gene expression profiling 
performed by the use of DNA microarrays allows the expression level of thousands of 
previously identified genes to be simultaneously measured, enabling the identification of the 
most important differentially expressed genes as well as deregulated key molecular pathways 
in the specimen examined. This technique may provide a better biological understanding of 
the oncogenesis and be useful in identifying biomarkers of clinical importance, improving 
diagnostic and prognostic classifications and facilitating development of a better anticancer 
treatment.  
mRNA expression profiling based on DNA microarrays has been used for different purposes 
in OC research (72-74). Several studies have tentatively classified OC into clinically relevant 
subtypes by identifying mRNA expression profiles able to predict response to chemotherapy 
(75-78) or clinical outcome (79-83). Gene expression patterns in relation to suboptimal versus 
optimal cytoreduction (84) and in metastasis versus primary tumour (85;86) have also been 
studied. These studies have moreover been used for molecular classification of OC (60;64;87-
93), of which a few have included OSE (60;83;89) as control material, by identifying several 
differentially expressed genes distinguishing subgroups of OC. 
Gene expression analyses of miRNAs have in recent years been increasingly explored. 
Several miRNAs show abnormal expression patterns in different cancer forms, including OC 
(94). Some of these miRNAs may act as tumour suppressor genes or oncogenes and may be 
important in cancer development. Expression profiling of miRNAs in different cancer forms 
has revealed miRNAs to be tumour specific and may hopefully become potential diagnostic 
and prognostic markers (95). In addition, they may represent targets for therapy, which is 
currently under investigation (96;97).  
Various gene expression analysis approaches have identified several differentially expressed 
miRNAs in OC (9;98-100). A limited number have been based on microarrays (101-110), of 
which some have employed OSE as control material (102-104). These studies have shown 
that miRNAs may be useful in prediction of ovarian cancer outcome (106-112) and 
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chemotherapy resistance (107;108;113), and that they may play important roles in tumour 
progression (105). Furthermore, studies have shown that miRNAs may have potential as 
circulating diagnostic biomarkers (114-116). Unfortunately, these studies have almost 
exclusively utilized non subgroup specific patient cohorts (100), which is inappropriate with 
respect to the molecular differences between OC subgroups (117). Still, a limited number of 
miRNAs have been found aberrantly expressed in more than one study, including miRNAs 
belonging to miR-200 family (9;101;106;108).  
The clinical relevance of gene expression profiling studies has been questioned due to 
inconsistency of the gene expression patterns in the different studies and lack of 
reproducibility. This is apparently due to diversity in the experimental design, including 
analysis of tumours of various histological type, small sample sizes as well as lack of 
appropriate controls. The application of different microarray techniques and analytical tools 
has also contributed to this disagreement (118). Still, the microarray studies have greatly 
increased our understanding of OC oncogenesis. An inspiring example of the value of gene 
expression profiling studies are the multigene expression assays used in clinical practice for 
quantifying risk of distant recurrence in breast cancer patients. However, such assays are not 
yet part of the clinical practice for OC patients. A classification of tumours based on gene 
expression profiles in relation to outcome parameters, resulting in a more individualized 
treatment and subsequently an improved survival for OC patients will hopefully be 
accomplished in the future.  
 
4.2.6 Staging and metastasis 
Tumour staging of OC is according to the FIGO classification (Table 2), based on findings 
mainly at surgery, but also findings from clinical evaluation and diagnostic imaging (119).  
OC metastasize mainly within the peritoneal cavity, by exfoliation of cancer cells from the 
tumour into the peritoneal cavity and formation of solid lesions on the peritoneal surface. 
However, spread via lymphatic vessels to paraaortal and pelvic lymph nodes is also common. 
The extent of spread, which is essential for correct staging, can only be determined with any 
certainty by surgery. When diagnosed, about 65% of OC patients have distant spread of 
disease (stage III-IV) (30;33). Haematogenous spread is uncommon at diagnosis, but may 
occur later as the disease progresses (34).  
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Table 2. Carcinoma of the ovary: FIGO nomenclature (Rio de Janeiro 1988)  
Stage I Growth limited to the ovaries 
      Ia  Growth limited to one ovary; no ascites present containing malignant cells. No 
tumour on the external surface; capsule intact 
       Ib Growth limited to both ovaries; no ascites present containing malignant cells. 
No tumour on the external surfaces; capsules intact 
        Ica Tumour either Stage Ia or Ib, but with tumour on surface of one or both 
ovaries, or with capsule ruptured, or with ascites present containing malignant 
cells, or with positive peritoneal washings 
Stage II  Growth involving one or both ovaries with pelvic extension 
        IIa Extension and/or metastases to the uterus and/or tubes 
        IIb Extension to other pelvic tissues 
         IIca Tumour either Stage IIa or IIb, but with tumour on surface of one or both 
ovaries, or with capsule(s) ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings 
Stage III  Tumour involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
inguinal nodes. Superficial liver metastases equals Stage III. Tumour is 
limited to the true pelvis, but with histologically proven malignant 
extension to small bowel or omentum 
         IIIa Tumour grossly limited to the true pelvis, with negative nodes, but with 
histologically confirmed microscopic seeding of abdominal peritoneal surfaces, 
or histologic proven extension to small bowel or mesentery 
         IIIb Tumour of one or both ovaries with histologically confirmed implants, 
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm in 
diameter; nodes are negative 
         IIIc Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes 
Stage IV  Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to Stage 
IV. Parenchymal liver metastasis equals Stage IV 
a In order to evaluate the impact on prognosis of the different criteria for allotting cases to 
Stage Ic or IIc, it would be of value to know if rupture of the capsule was spontaneous, or 
caused by the surgeon; and if the source of malignant cells detected was peritoneal 
washings, or ascites. 
Reprinted from International Journal of Gynecology & Obstetrics. 2006; 95: Suppl.1:S161-92. 
Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, 
Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of 
Treatment in Gynecological Cancer. Copyright (2013), with permission from Elsevier (119). 
 
4.2.7 Symptoms and examination  
The symptoms of early stage ovarian cancer are vague and unspecific, and the majority of 
patients are diagnosed with advanced disease. However, more than 90% of ovarian cancer 
patients have experienced symptoms during the last year before diagnosis, most commonly 
bloating, increased abdominal size, fatigue, urinary tract symptoms as well as pelvic or 
abdominal pain (120).  
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The level of CA125 (cancer antigen 125), currently the most clinically relevant biomarker for 
OC, is elevated in about 80% of patients with advanced ovarian cancer, but only in 50-60% of 
early stage ovarian cancer patients (32). Due to the high proportion of false positive tests 
relative to the low incidence of ovarian cancer, CA125 is not useful for detecting early stage 
OC (121). Recently, HE4 (human epididymis protein 4) has shown promising results in 
distinguishing benign from malignant adnexal masses in the premenopausal women (122). 
Ovarian tumours can be visualized by ultrasound, and by CT and MR imaging. Examination 
of the ovarian cancer patient normally includes a CT scan of the thorax, abdomen and pelvis 
to assess abdominal spread and lymph node status. In advanced disease, a biopsy from the 
tumour is collected to ensure a correct histological diagnosis. 
 
4.2.8 Treatment  
Primary maximal cytoreductive surgery, followed by postoperative chemotherapy is the 
standard primary treatment for patients with OC. However, for patients with low risk FIGO 
stage I disease, only surgery is indicated. The aim of surgery is cytoreduction to microscopic 
(zero macroscopic) residual disease (RD), in addition to correct FIGO staging and a 
histological diagnosis. A standard surgery procedure includes bilateral salpingo-
oophorectomy, hysterectomy, omentectomy, bilateral para-aortic and pelvic lymph node 
resection, complete removal of macroscopic tumour tissue from all other locations, and 
collection of ascites or peritoneal washing for cytological evaluation. A delayed primary 
surgery after preoperative chemotherapy is an option for selected patients with stage IIIC or 
IV ovarian cancer (123-125).  
The intravenously administrated combination treatment of platinum (carboplatin) and taxane 
(paclitaxel) is standard postoperative first line treatment for OC patients (126). At Oslo 
University Hospital (OUH), six courses of carboplatin (AUC=5-6) and paclitaxel (175 mg/m2) 
given every third week is currently the recommended regimen. Treatment alternatives include 
carboplatin in combination with docetaxel, pegylated liposomal doxorubicin (PLD) or 
gemcitabine, as well as carboplatin single. Selected patients may be considered for 
intraperitoneal chemotherapy treatment with cisplatin or paclitaxel (www.oncolex.no).   
The majority of OC patients responds to surgery and chemotherapy temporarily, but the 
disease persists and recurs in most patients (34). In recurrent disease chemotherapy is 
indicated for the majority of patients and depends on prior treatment response and platinum 
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treatment-free interval. The disease is traditionally classified as platinum resistant, partially 
platinum sensitive or platinum sensitive, corresponding to a platinum treatment-free interval 
until recurrence of <6 months, 6-12 months and >12 months, respectively. Platinum refractory 
disease recurs during first-line therapy.  
A platinum-based combination therapy, often carboplatin and paclitaxel, is currently the 
recommended regimen for patients with platinum sensitive or partially sensitive disease (126). 
Other treatment options include carboplatin plus PLD (126;127) and carboplatin plus 
gemcitabine (126;128). Surgery may be appropriate in recurrent disease for selected patients 
(126;129). 
Chemotherapy for patients with platinum-resistant or platinum-refractory disease has shown 
significant effect on tumour control but not on overall survival (OS) (130). Treatment options 
include nonplatinum-based monotherapy with paclitaxel, docetaxel, PLD, topotecan or 
gemcitabine (126;130).  
After recurrence OC is incurable. As the disease relapses and progresses, most OC patients 
receive multiple lines of chemotherapy, and finally develop multiresistance to chemotherapy.  
 
Targeted therapy 
In targeted therapy, specific molecules needed for carcinogenesis and tumour growth are 
targeted, as opposed to traditional chemotherapy, which interferes with rapidly proliferating 
cells. Targeted therapies are expected to be more effective and less harmful to normal cells 
than chemotherapy.  
Targeted therapies for OC are now under evaluation in randomized trials, and those targeting 
angiogenesis seem most promising. The antiangiogenetic agent bevacizumab is a humanized 
monoclonal antibody against the VEGFA protein, which induces angiogenesis and endothelial 
cell growth, promotes cell migration and inhibits apoptosis. Bevacizumab in combination with 
standard chemotherapy have shown to improve progression-free survival (PFS) in OC patients 
in several phase III trials, including front line (131;132) and second line recurrent platinum 
sensitive (128) and platinum resistant disease (133).  
Other anti-angiogenic agents under evaluation are tyrosine kinase inhibitors (TKIs), which 
target receptors involved in the formation of blood vessels, i.e. receptors of VEGFs, PDGFs 
and FGFs. Ongoing phase III trials investigating TKIs effect on primary PFS include 
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nintedanib and pazopanib. Trebananib is another antiangiogenic agent under evaluation in 
several phase III trials, targeting the proteins angiopoietin 1 and 2, which are important in 
angiogenesis binding to tyrosine kinase receptors (126) (www.clinicaltrials.gov). 
Other targeted therapies under evaluation include poly-ADP-ribose-polymerase (PARP) 
inhibitors, targeting the PARP enzyme needed for compensatory DNA repair in tumours with 
BRCA (and other homologous recombination genes) dysfunction to prevent cell death. The 
PARP inhibitor olaparib has in phase II studies shown improved PFS in patients with 
platinum-sensitive, relapsed serous (134) and high-grade serous (135) OC. Evaluation of other 
PARP inhibitors is ongoing (126) (www.clinicaltrials.gov). 
 
4.2.9 Prognostic factors and clinical course 
Ovarian cancer is associated with poor survival since most women are diagnosed at an 
advanced stage due to lack of specific symptoms and effective screening methods, when cure 
is rare. About 65% of the patients have distant spread of disease (stage III-IV) at diagnosis, 
and their 5-year relative survival rate is less than 30% (30;33). From 1970 to 2009, the 5-year 
relative survival rate for ovarian cancer patients in Norway has improved from 39% to 44% 
for all stages and from 15% to 29% for patients with distant spread of disease (33).   
Many prognostic clinicopathological factors have been described for OC patients. The most 
important are the FIGO stage, RD (after initial surgery), histological subtype, differentiation 
grade, age, performance status, presence of ascites, CA125 levels and DNA ploidy (32;34). 
FIGO stage, RD and differentiation grade correlate best with outcome (34). In stage III OC, 
histological subtype, RD, age and performance status have been shown to be independent 
predictors of prognosis (136). The most important prognostic factors for survival at diagnosis 
of OC is the FIGO stage (32), and the 5-year survival rate vary from 89% in stage 1a to 13% 
in stage IV (137).  
Even though the ideal surgical outcome implies zero RD, a reduction of macroscopic RD to 
one cm or less is probably associated with some benefit (123).  The Cochrane database 
systematic review has recently evaluated the impact on various RD sizes (0 cm, 1 cm and 2 
cm) on survival in patients with advanced OC (stage III and IV), and concluded that patients 
with no macroscopic RD after surgery had a significantly prolonged PFS and OS (138). Also, 
significantly better survival was found for women with RD<1cm compared to those with 
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RD>1cm. There was no significant difference in OS and only borderline differences in PFS 
when RD< 2cm and RD>2 cm were compared (138). 
Mucinous and clear cell carcinomas are independently associated with a poor prognosis when 
compared with SC after standard first line therapy in stage III/IV OC (139). Patients with 
CCC have a much shorter OS (21 months) compared to SC (41 months) in stage III/IV 
disease (139). 
Serum CA125 is the best studied biomarker for OC. Whereas several studies have shown that 
the CA125 level during chemotherapy has prognostic relevance (71;140;141), the clinical 
significance of pre-treatment CA125 level is controversial (71). The CA125 kinetics during 
early chemotherapy has been evaluated in different ways, including the absolute value after 
two or three cycles of chemotherapy, the nadir level, the time to reach nadir level, and the 
CA125 half-life (71). For example, patients with normalization of CA125 after the third 
chemotherapy cycle have a significantly better (doubled) PFS and OS compared with patients 
without normalization (140;141). Moreover, it is hypothesized that normalization of the 
CA125 level after the third chemotherapy cycle is an independent predictor of survival for 
patients with advanced OC, regardless of RD status (140).  
Several other biomarkers than CA125 have been evaluated both in sera and tissue samples 
from OC patients in order to detect prognostic or predictive biomarkers (71;142). However, 
only a few have shown a reliable function as prognostic or predictive biomarkers. An elevated 
preoperative serum VEGF level has shown to be an independent prognostic variable for poor 
survival, whereas the prognostic relevance of p53 gene status is still under discussion (71). 
Other potential circulating markers include HE4, mesothelin, M-CSF, FGF-1, cyclin D1/E 
and IL6-8, whereas potential tissue specific markers include claudin 3, MMP2/9, MT1-MMP, 
FAK, levels of the microRNAs miR-200, miR-141, miR-18a, miR-93, miR-429, let-7b, miR-
199a as well as Dicer and Drosha expression (142). However, a multivariate analysis on 
larger series of patients followed for a longer period of time is needed to further evaluate their 
prognostic relevance.  
 
 
 
 
 
32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33
5. AIMS OF THE THESIS  
Malignant tumours which apparently have the same tissue and cytological origin may have 
very different biological and clinical properties such as cellular growth, tendency to 
metastasize and variable sensitivity to therapy. Such differences are understood to reflect 
molecular heterogeneity, which will characterize the tumour both phenotypically and 
clinically. Identification of molecular regulatory genes and pathways involved in the 
development of different cancer subgroups will not only be an important supplement to 
tumour classification, but will apparently also have a diagnostic, prognostic, predictive and 
therapeutic impact. 
Ovarian cancer is one of the most frequent causes of cancer death in women. About 65% of 
the patients have distant spread of disease at diagnosis, and their 5-year survival rate is less 
than 30%. OC, constituting more than 90% of the ovarian cancers, encompasses several 
distinct tumour subgroups with respect to molecular profiles, biological behavior and clinical 
features. However, due to lack of understanding of ovarian carcinogenesis and the biological 
differences between these tumour subgroups, the OC patients generally receive similar 
treatment. For example, whereas the initial response rate to current chemotherapy treatment 
for HGSC, the most common form of OC, is high, it is low for CCC. This may explain the 
poorer prognosis for patients with late stage CCC compared with that of late stage HGSC 
(68). Therefore, improved insight into the carcinogenesis and the molecular characteristics of 
different OC subgroups is needed to identify new therapeutic targets and subsequently to 
develop novel, more subgroup-specific and effective treatment regimens that hopefully will 
improve the poor prognosis for these patients. 
The overall aim of this thesis was to increase the understanding of the carcinogensesis and the 
molecular characteristics of different ovarian cancer subgroups. More specifically, the aim 
was to identify differentially expressed mRNAs and miRNAs and key molecular markers and 
pathways focusing on HGSC and CCC and to evaluate their association with clinical 
parameters, including survival. The specific aims of the thesis are as follows: 
1.  To a) evaluate the expression of six mRNAs previously found to be strongly 
overexpressed in other malignancies in PDSC, MDSC and CCC compared primarily with 
OSE, but also with biopsies from normal ovaries (BNO) and benign ovarian cysts 
(BBOC), by RT-qPCR (Quantitative Reverse Transcription-Polymerase Chain Reaction) 
and b) evaluate their correlation with clinical parameters (Paper I).  
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2.  To a) identify differentially expressed mRNAs between HGSC (MD/PD SC), SBOT and 
OSE by global gene expression profiling, b) validate selected differentially expressed 
mRNAs by RT-qPCR in an extended patient cohort, c) evaluate the prognostic role of 
validated differentially expressed mRNAs in HGSC compared with OSE and d) search for 
key molecular pathways of HGSC through IPA (Ingenuity Pathway Analysis) (Paper II). 
3.  To a) identify differentially expressed miRNAs between HGSC, CCC and OSE by global 
gene expression profiling, b) validate selected differentially expressed miRNAs by RT-
qPCR in an extended patient cohort and c) evaluate the prognostic role of differentially 
expressed miRNAs in HGSC and CCC compared with OSE (Paper III). 
4.  To map interactions between differentially expressed mRNA identified in Paper II and 
differentially expressed miRNAs identified in Paper III in HGSC (Paper III).  
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6. MATERIALS AND METHODS 
All studies provided patient data and biological samples and were approved by the Regional 
Committee of Medical and Health Research Ethics in South-Eastern Norway (OUH, Ullevaal: 
ref.no.530-02163, OUH, The Norwegian Radium Hospital (TNRH): ref.no. S-04300), and all 
participants signed informed consent. All analyses related to gene expression were performed 
at Department of Medical Biochemistry, OUH.  
 
6.1 Patients and tissue material 
The women were recruited prior to operations for gynaecological diseases at OUH, in the 
period 2003 to 2012. For all studies, patients were recruited from a research biobank at OUH, 
Ullevaal. In order to obtain a sufficient cohort of patients with CCC in the study presented in 
Paper III, additional nine women with CCC were recruited in the period 2003 to 2010 from a 
biobank at OUH, TNRH.  
The samples from OUH, Ullevaal were from a research biobank (“Gynaecological tumours 
and invasion potential”) at the Departments of Obstetrics and Gynaecology, of which Bente 
Vilming Elgaaen has included more than 100 patients. Professor Anne Cathrine Staff is 
responsible for the research biobank study. At the time of patient selection for the last paper 
of this thesis, this biobank comprised benign and malignant ovarian tissue samples from more 
than 450 patients. Patient recruitment, preoperative patient interviews, as well as tissue- and 
blood sampling for this thesis has been performed almost exclusively by two PhD students 
(Bente Vilming Elgaaen and Elin Ødegaard) and a technician (Lise Levy), who have 
contributed after careful instruction in patient recruitment, material sampling and storage 
procedures. In order to avoid mRNA degradation, the tissue samples and the OSE scrapings 
were immediately harvested from the removed ovaries at surgery and snap-frozen in liquid 
nitrogen or transferred to TRIzol or QiaZol solution (Invitrogen, Carlsbad, CA, United 
States), respectively. 
The tissue samples obtained at OUH, TNRH were taken from a tumour and effusion biobank 
at the Department of Pathology. The specimens were immediately collected and snap-frozen 
under the supervision of Associate Professor Ben Davidson, after immediate transport of the 
removed ovaries to the Department of Pathology. All samples from OUH were stored at 
-80°C until processed.  
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An overview of number of patients included in the present papers based on histopathology 
and analysis method used is given in the flowchart below (Table 3). In total, 109 patients 
were included, from which biopsies from 49 MDSC and PDSC, referred to as HGSC, 22 
CCC, 13 SBOT, 19 OSE samples, 3 BNO and 3 BBOC were utilized. Patients with HGSC 
were included in all papers, whereas patients with CCC were included in Paper I and III. 
Figure 4 shows number of separate and shared patients with HGSC (A) and CCC (B) 
included in Paper I-III, regardless of the analysis method used. SBOT was employed for gene 
expression comparison in Paper II.  Control material was collected from patients operated for 
benign gynaecological diseases. A small number of BNO and BBOC was evaluated in Paper 
I, wheras OSE samples were employed in all papers. Initially, cervical PAP smear brushings 
of OSE were harvested. However, since these samples yielded insufficient amount of 
material, a new procedure for OSE sampling was developed (Bente Vilming Elgaaen and 
Professor Torill Sauer) and subsequently employed. The surface of normal ovaries was gently 
scraped with a scalpel, and the vast majority of the harvested cells were verified cytologically 
as normal OSE cells, being positive for pan-cytokeratin by immunocytochemistry, evaluated 
by Torill Sauer. Bente Vilming Elgaaen harvested these samples. 
The histological classification and clinical stage were according to the WHO classification of 
tumours and the International Federation of Gynecology and Obstetrics classification, 
respectively.  
The diagnoses of all tumours were re-evaluated by at least one senior pathologist specialized 
in gynaecological pathology, including Vibeke Engh for the biobank at Ullevaal and Ben 
Davidson for the biobank at TNRH. Further re-evaluation of the tumours from Ullevaal was 
done by Torill Sauer (Paper I-II) and Ben Davidson (Paper II-III). To ensure satisfying sample 
quality and representativeness frozen sections from the biopsies were examined prior to RNA 
isolation. Only carcinomas presenting histologically more than 50% tumour cells were 
included for RT-qPCR analyses in Paper II and all analyses in Paper III, evaluated by Ben 
Davidson. All cancer specimens were from primary tumours, obtained pre-chemotherapy at 
primary surgery. 
Clinicopathological and laboratory data were obtained from hospital records, and for patients 
recruited from OUH, Ullevaal, additional preoperative patient interviews. This information 
included age, preoperative condition, preoperative CA125 level, FIGO stage, volume of RD 
after surgery, time until start of chemotherapy after surgery, CA125 response and optimal  
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Table 3. Flowchart for number of patients included in the thesis based on histology and 
analysis method. 
HGSC: High-grade serous carcinoma. CCC: Clear cell carcinoma. SBOT: Serous borderline
tumour. OSE: Ovarian surface epithelium. BNO: Biopsies from normal ovaries. BBOC: 
Biopsies from benign ovarian cysts. *Patients not previously included in this thesis. ^9 
samples from biobank at OUH, TNRH, the remainder from biobank at OUH, Ullevaal.
Figure 4. Venn diagram showing separate and shared number of patients with HGSC 
(A) and CCC (B) included in the thesis. 
Paper I Total
RT-qPCR Microarray RT-qPCR Microarray RT-qPCR
HGSC 23 9 7 7 7
  2* 1 1 1
6 3 2
3
  7* 1 1
2
2
 17*
HGSC, total 23 11 21 12 35 49
CCC 8 5 5
  4* 4
    10*^
CCC, total 8 9 19 22
SBOT 8 8
  5*
SBOT, total 8 13 13
OSE 6 2 2
  2* 2
1   9* 9
  2*
OSE, total 6 4 7 9 9 19
BNO, total 3 3
BBOC, total 3 3
Paper II Paper III
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CA125 normalization after treatment, time until progression, time until death as well as status 
at last follow-up. Clinical parameters of the OC patients, including time until progression and 
time until death, optimal CA125 normalization and RD were evaluated for correlation with 
selected mRNAs/miRNAs. 
Primary surgery was performed in all patients, and when indicated they received standard 
chemotherapy. The patients included had no other diseases influencing survival, and had not 
previously received chemotherapy. Detailed clinicopathological information is given in the 
manuscripts. 
Follow-up data including clinical examinations, standard laboratory analyses and 
complementary diagnostic imaging were available for all patients. The protein CA125 was 
generally measured prior to each chemotherapy cycle and was used as a marker for response 
to therapy. A CA125 response was defined according to The Gynecologic Cancer Intergroup 
(GCIG) criteria, including at least a 50% reduction in CA125 levels from a pre-treatment 
sample. A CA125 normalization was defined as optimal when normalized (<35 kU/L) within 
four cycles of chemotherapy. After completion of treatment, the patients were evaluated every 
third month for two years, every six months for the next three years, and thereafter once a 
year. Time until progression and time until death were defined as the time interval from the 
date of surgery to the date of first confirmed disease recurrence and to the date of death, 
respectively. Disease progression was based on an increase in the CA125 level according to 
the GCIG criteria and a verified clinical relapse, and the date of the first event was used.  
 
6.2 Gene expression quantification 
Gene expression was measured at the steady-state levels of mRNAs and miRNAs, and 
represent the amount of RNA species taken at the timepoint of operation. The amount of RNA 
is the result of transcription and RNA degradation, and the half-life of RNAs is regulated and 
differ from one cell to another. The amount of mRNA generally parallels the amount of 
translated protein. According to general knowledge, the expression levels of mRNAs and 
miRNAs within a biological material will give relevant and important information about 
ongoing fundamental biological processes. 
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6.2.1 RNA isolation 
Upon preparation, all samples were handled carefully to ensure correct instant “mirror image” 
of the original RNA levels as possible. To avoid further enzymatic reactions and RNA 
degradation the samples were handled under RNAse free conditions, exposed to room 
temperature as short as possible and treated with a lysis reagent. 
For mRNA isolation (Paper I and II), tissue specimens were either crushed frozen (Paper I) or 
homogenized directly in TRIzol lysis reagent using a tissuelyzer (Qiagen, Hilden Germany) 
(Paper I and II). Total RNA was extracted using the Trizol method (Invitrogen) and further 
purified by the RNeasy MinElute cleanup spin columns (Qiagen) according to the 
manufacturer’s instructions.  
For miRNA isolation (Paper III), tissue specimens were homogenized directly in QIAzol lysis 
reagent using a tissuelyser (Qiagen). Total RNA was extracted using the QIAzol method of 
the miRNeasy Mini Kit (Qiagen) and Phase Lock Gel Tubes (5 PRIME GmbH, Biocompare 
Hamburg, Germany) to increase yields according to the manufacturer’s instructions.  
To determine the quantity as well as to assess the purity of the isolated total RNA, a Nano 
Drop spectrophotometer (Saveen Werner, Malmö, Sweden) was used.  This 
spectrophotometer requires a very small sample amount to quantitatively measure the 
different molecule’s absorbance at different wavelength. In order to control for RNA 
degradation the BioAnalyzer 2100 system (Agilent Technologies, Palo Alto, CA, US) was 
used. This system uses a chip technology which is based on traditional polyacryl gel 
electrophoresis principles, allowing electrophoretic reactions of several RNA samples 
simultaneously. The RNA fragments are detected by laser induced fluorescence, and 
translated into electropherograms. The RNA quality can be determined through visual 
inspection of an electropherogram and through RNA integrity number (RIN), an algorithm for 
assigning integrity values to RNA measurements. All samples showed appropriate RNA 
quality and quantity. 
 
6.2.2 Global gene expression profiling - mRNA and miRNA  
By global gene expression profiling the expression of every gene present in a material can be 
measured simultaneously, creating a snapshot of the global gene expressional status in the 
material analysed. The DNA microarray technology is a method used for gene expression 
profiling, measuring the relative gene expression of thousands of previously identified genes. 
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Thus, by identifying changes in gene expression in i.e. malignant versus non-malignant 
material, DNA microarrays is used to identify diagnostic and prognostic markers as well as to 
achieve a better understanding of molecular pathways for cancer.  
A DNA microarray is a multiplex lab-on-a-chip, constituting tens of thousands of orderly 
microscopic DNA spots, each containing thousands of identical specific DNA sequences 
(probes) attached to a solid matrix. A brief overview of the DNA microarray analysis used in 
this thesis is given in Figure 5. Upon the mRNA experiment, mRNA of the isolated total 
RNA sample is initially reversely transcribed to single stranded (ss) cDNA (complementary 
DNA), which is further synthesised by DNA polymerase into double stranded (ds) cDNA. 
The ds cDNA is then amplified to cRNA and biotin labelled for detection by in vitro 
transcription. Optionally, the cRNA (complementary RNA) can be further transcribed to 
cDNA. The resulting biotin labelled cRNA/cDNA is then fragmented before hybridization. 
Upon the miRNA experiment, the miRNA of the isolated total RNA sample is labelled 
directly with biotin before hybridization. When subjected to the microarray, cRNA/cDNA 
molecules present in the sample (target) will hybridize to complementary DNA sequences on 
the chip. After washing off the non-hybridized sequences, a staining procedure involving a 
fluorescent molecule (streptavidin-phycoerythrin) that binds to biotin is performed. 
Hybridized fluorescent labelled DNA fragments will subsequently generate signals when 
shining a laser light on the array (fluorescence scanning). The total signal intensity generated 
from one spot depends on the amount of nucleic acid sequences binding to the probes of that 
specific spot, allowing detection as well as quantification of probe-target hybridization. 
A major challenge with microarray analyses is to handle the great amount of data generated, 
and also the choice of method for the identification of most differentially expression genes. 
Advanced bioinformatics and statistical analyses are therefore essential after the microarray 
experiment, involving several different processes to achieve meaningful biological results 
(briefly described in statistical analysis).  
In Paper II and III the DNA microarrays from Affymetrix (Santa Clara, CA, US) were 
employed for global gene expression analyses. In Paper II, the microarray Human Genome 
U133 Plus 2.0 Arrays, representing 47000 transcripts for 38500 well characterized human 
genes were used. In Paper III, the microarray miRNA 2.0 Arrays, representing 1105 mature 
human miRNAs were used. The microarrays were used according to Affymetrix’ 
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recommendations. Microarray signal intensities were thereafter detected by a Hewlett Packard 
Gene Array Scanner 3000 7G (Hewlett Packard, Palo Alto, CA, US).  
 
Figure 5. DNA microarray analysis of mRNA and miRNA.  
    : primer. Rt: Reverse transcriptase. ss: single stranded. ds: double 
stranded. RT: Reverse transcription. DNApol: DNA polymerase. RNApol: 
RNA polymerase. IVT: In vitro transcription. 
 
6.2.3 RT-qPCR - mRNA and miRNA 
Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) is one of the most 
powerful and sensitive gene analysis techniques available (143), and is regarded as the gold 
standard method for quantification of gene expression. This technique is also a valuable tool 
for validation of results obtained from global gene expression analyses.  
An overview of the RT-qPCR technique is given in Figure 6. RT-qPCR includes a reverse 
transcription (RT) reaction, generating a ss cDNA from an RNA transcript by the enzyme 
reverse transcriptase and predesigned specific RT primers (for miRNAs) or a mix of random 
RT and oligo(dT) primers (for mRNAs). The cDNA is used as a template for the polymerase 
chain reaction (PCR), a technology for exponential amplification, making multiple copies of a 
specific DNA sequence by repetitive enzymatic and temperature dependent reactions in order 
to produce measurable amounts of the DNA sequence of interest. A PCR analysis includes up 
to 40-45 cycles of three distinct steps: 1. Denaturation of ds cDNA into ss cDNA (95ͼC). 2. 
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Hybridisation of the cDNA and two specific PCR primers; nucleotide sequences 
complementary to the ends of the specific DNA sequence we intend to amplify (primer 
annealing, 50-60ͼC). 3. Polymerization by the enzyme DNA polymerase, resulting in the 
synthesis of a DNA copy of the specific DNA sequence (about 70ͼC). The amplified DNA is 
doubled at each PCR cycle, which is why this technique is called a chain reaction. 
 
Figure 6. RT-qPCR analysis of mRNA and miRNA.  
RT: Reverse transcription. PCR: Polymerase Chain Reaction.     : primer. 
Rt: Reverse transcriptase. ss: single stranded. DNApol: DNA polymerase. 
 
The amplified DNA (the PCR product) is measured at each cycle in the exponential phase of 
the PCR reaction, when the PCR product is exactly doubled at each cycle. qPCR (quantitative 
PCR) is often referred to as “real-time” PCR, since the results appear as the reactions 
progress. The PCR product is measured by the detection of a fluorescent signal, and the 
strength of the signal is proportional to the amount of the PCR product. There are two main 
categories of fluorescent DNA labelling techniques of the PCR product. The non-sequence 
specific DNA binding dyes (i.e. SYBR Green; Paper I) bind preferentially to any ds cDNA 
sequence, whereas the sequence specific fluorescent labelled probes (i.e. the TaqMan probe;  
Paper II, III) are designed for binding to the specific cDNA target of interest. The PCR cycle 
at which the reaction reaches a fluorescent intensity above background fluorescence is called 
the quantification cycle (Cq), which is used for the quantitative determination of the amount 
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of template cDNA. The greater the quantity of template cDNA, the faster a significant 
increase in fluorescent signal will appear, the lower the Cq.  
In Paper I, total RNA was reversely transcribed into cDNA and the mRNAs of interest further 
PCR amplified with specific primers designed by using the Invitrogen database. The primers 
were tested for homology with other sequences at the NCBI (National Center for 
Biotechnology Information) gene website (www.ncbi.nlm.nih.gov). The samples were 
analysed on a real-time fluorescence LightCycler instrument and detected by using a 
LightCycler Fast start SYBR Green kit according to the manufacturer’s instructions (Roche 
Diagnostics GmbH, Mannheim; Germany). 
RT-qPCR may be performed for multiple mRNA or miRNA simultaneously by employing 
microfluidic arrays, also called TaqMan Low Density Array (TLDA) cards, for the PCR-part 
of the analysis. These cards comprise up to hundreds of wells (n=384), each of which 
performs a specific qPCR reaction. cDNA samples generated by reverse transcription and 
optionally preamplified are mixed with necessary reagents including DNA polymerase, 
nucleotides and buffer, and applied to the 8 ports of the cards. All the wells are loaded with 
specific predesigned or custom designed primers of the corresponding DNA sequence of 
interest and sequence specific fluorescent labelled probes in advance. TLDA cards (Applied 
Biosystems, Life technologies, Carlsbad, CA, US), were custom designed to validate the 
expression of selected mRNAs (Paper II) and miRNAs (Paper III) obtained from the global 
gene expression analyses. For quantification, the ABI Prism 7900 HT system (Applied 
Biosystems, Life technologies) was used in Paper II, whereas, the ViiA7 System (Applied 
Biosystems, Life technologies) was used in Paper III.  
The data generated by the RT-qPCR can be used to calculate relative gene expression in 
several samples. In this thesis, gene expression levels were calculated using the comparative 
crossing threshold method of relative quantification (¨¨Cq method) (144), presented as 
relative quantification cycle (¨Cq) and fold change (FC) values. ¨Cq was designated as the 
mean Cq (mean of replicates) of an mRNA or miRNA in a sample subtracted by the mean Cq 
(mean of replicates) of a reference gene in the same sample. In general, FC was designated as 
2ǻǻCq , where ǻǻCq was ǻCq of one tumour/tumour group subtracted by ǻCq of another 
tumour/tumour group. Mean FC values were calculated for comparison of mean expression 
levels between different groups. For correlation to clinical parameters, ǻǻCq for each tumour 
sample was calculated as mean ǻCq of the control group subtracted by ǻCq of each tumour 
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sample. For comparison of mean expression levels between different groups in Paper I, 
similar calculation was used, and mean of the individual FC values for each tumour group 
were calculated. For comparison of mean expression levels between different groups in Paper 
II and III, ǻǻCq was calculated as mean ǻCq of one group (i.e. control group) subtracted by 
mean ǻCq of another group, and FC was 2ǻǻCq. 
Selection and quantification of reference genes (also known as endogenous gene controls or 
housekeeping genes) are required when using the ¨¨Cq method, as the relative changes of 
each transcript of interest will be calculated in comparison with the reference genes. 
Reference genes have relatively constant expression levels in all cells of an organism and 
preferentially independent of different conditions since their products are often required for 
the maintenance of basic cell functions. The most frequently employed reference genes are 
GAPDH (glyceraldehyd-3-phosphate dehydrogenase) and ȕ-actin, used in Paper I and II. In 
Paper III, hsa-miR-26a and hsa-miR-24, having the lowest variation detected among the 
global miRNA expression analyses, were selected as reference genes.  
 
6.3 Ingenuity Pathway Analysis (IPA) 
Ingenuity Systems (Ingenuity Systems, Redwood City, CA, US) is a company that provides 
software to aid researchers to explore, interpret and analyse complex biological systems. The 
Ingenuity products are linked to the Ingenuity Knowledge Base, a repository of functional 
annotations as well as biological and chemical interactions between proteins, genes, cells, 
tissues, drugs and diseases. This knowledge base is based on findings from primary literature 
sources, including articles and textbooks, as well as other sources such as several databases 
(i.e. targetScan Human, miRecords, TarBase) and Ingenuity Expert Findings. The findings are 
manually reviewed for accuracy, and include contextual details and link to the original article.  
The IPA software is used to analyse gene expression data that generate gene lists in order to 
achieve insight into molecular and chemical interactions, biological functions and related 
diseases. Furthermore, obtained information can be used to model biological systems and 
signalling pathways, derived from existing findings of the Ingenuity Knowledge Base. IPA 
thereby provides a tool for understanding causes and effects of gene expression changes 
observed in experimental data. In Paper II and III, IPA was used for identifying biological 
functions and related diseases (functional analyses) and for modelling signalling pathways 
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(network analyses) of differentially expressed mRNAs and miRNAs. In Paper III IPA was 
also used for identifying mRNA/miRNA interactions.  
 
6.4 Statistical analysis 
6.4.1 Global gene expression analysis  
In general, the scanned images of a microarray experiment are processed by appropriate 
software to convert signal intensities to raw data of signal values (CEL files). The raw data is 
then imported into suitable software for further processing, involving normalization 
(adjustment for technical variation) in addition to background correction and log-
transformation. Thereafter, significantly expressed genes may be identified, involving 
different statistical tests including t-tests, ANOVA (analysis of variance) as well as FDR 
(False Discovery Rate) and Benjamini-Hochberg correction, which take correction for 
multiple testing into account. The signal values may be further analysed by cluster analysis; 
grouping of similarly expressed genes, which may be visualized by heatmaps. Biological 
information as well as information of involved networks or pathways of selected genes may 
furthermore be obtained. 
In Paper II and III, the scanned images were processed with the Affymetrix GeneChip® 
Operating System v1.4 (GCOS 1.4) software and the Affymetrix GeneChip® Command 
Console (AGCC) software, respectively. In Paper II, the raw data (CEL files) were imported 
into Array Assist software (v5.2.0; Iobion Informatics LLC, La Jolla, CA), where the PLIER 
(probe logarithmic intensity error) algorithm was applied to generate relative signal values, 
including normalization and log-transformation. The MAS5 algorithm (Array Assist) was 
used to filter for background correction. In Paper III, the CEL files were imported into Partek 
Genomics Suite software (Partek, Inc. MO, US), where the Robust Multichip Analysis 
(RMA) algorithm was applied for generation of relative signal values, including 
normalization, log-transformation and background correction. Complete microarray 
expression data were deposited in NCBI's Gene Expression Omnibus (GEO) (145) (accession 
number GSE36668 for Paper II and GSE47841 for Paper III). GEO is one of several open-
source data warehousing facilities available, enabling integration of different datasets and also 
further analyses of the datasets by others. 
For expression comparisons of different groups, unpaired t-tests and Benjamini-Hochberg 
correction of p-values for multiple testing was used in Paper II, whereas a 1-way ANOVA 
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model followed by FDR was used in Paper III. The results were expressed as FC- and p-
values. Relative signal values were clustered by hierarchical cluster analysis and visualized by 
a heatmaps.  
 
6.4.2 RT-qPCR analysis 
As earlier described, gene expression levels of the RT-qPCR analyses were calculated using 
¨¨Cq method (144). When comparing ǻCq values in different histological subgroups, a two-
sided independent samples t-test was used since the ¨Cq values were close to normally 
distributed. A significance level of 5% (Paper I) and 1% (Paper II-III) was used for 
differential mRNA/miRNA expression. ¨Cq values were clustered by hierarchical cluster 
analysis and visualized by heatmaps.  
 
6.4.3 Evaluation of associations between gene expression and clinical parameters 
mRNAs and miRNAs expression levels given as FC were evaluated for association with 
clinical parameters in all papers. In Paper I, a linear regression model (146) was used. In 
Paper II and III, Cox regression analyses were used for evaluation of association of mRNA 
and miRNA expression with time until death and time until progression. When significant, 
Kaplan-Meier plots were used to estimate survival curves. To compare mRNA and miRNA 
expression levels in two groups of patients in Paper II and III, a two-sided Mann-Whitney U-
test was used, since the FC expression levels were not normally distributed. A significance 
level of 5% (all papers) was used for correlation of mRNAs and miRNAs with clinical 
parameters. The statistical analyses were performed by employing MATLAB (Paper I) and 
SPSS version 18/20 (Paper II-III).
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7. SUMMARY OF RESULTS 
7.1 Paper I 
“POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in 
ovarian carcinomas” 
In this study, a few mRNAs differentially expressed in HGSC and CCC was identified, 
including POLD2 and KSP37 as potential prognostic markers. 
Expression of six mRNAs previously found to be strongly overexpressed in human 
osteosarcomas and other malignancies were analysed by RT-qPCR in PDSC (stage III–IV, 
n=11), MDSC (stage III–IV, n=12) and CCC (stage I–IV, n=8). OSE, referred to as SNO 
(superficial scrapings from normal ovaries; n=6) as well as BNO (n=3) and BBOC (n=3) were 
analysed for comparison. Compared with OSE, POLD2 was significantly overexpressed in 
both PDSC (FC=19.4, p=3.4x10-8) and MDSC (FC=2.5, p=9.1x10-4), and also significantly 
overexpressed in PDSC compared with MDSC (p=1.7x10-8), increasing from 2.5- to almost 
20-fold (Paper I; Figure 1, 3 and Table 2). This increase might parallel the degree of 
dedifferentiation and reflect the slightly worse prognosis for PDSC compared with MDSC. 
Other significantly differentially expressed mRNAs in the carcinomas compared with OSE 
included PRAT4A (FC=2.8, p=8.1x10-5), NOLA2 (FC=3.0, p=1.3x10-4) and ANT2 (FC=3.1, 
p=6.3x10-5), all overexpressed in PDSC (Paper I; Figure 1, 3 and Table 2). Except for the 
higher overexpression of POLD2 in PDSC compared with MDSC, the SC showed a similar 
profile, being clearly different from CCC (Paper I; Figure 2). Similar profiles were found 
when OSE and BBOC were used as control material, but differed when BNO was used 
(Paper I; Figure 2, 3, S1 and S2).  
When dividing the CCC into stage I (n=4) and stage II-IV (n=4), KSP37 showed six- to eight-
fold higher levels in stage I CCC compared with the more advanced staged carcinomas 
(Paper I; Figure 3, Table 2). Evaluation of associations between the mRNAs and 
clinicopathological parameters revealed that KSP37 correlated positively (p<0.05) with FIGO 
stage I disease as well as PFS and OS (Paper I; Table 3). 
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7.2 Paper II 
“ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas 
and correlate with survival” 
This study revealed several differentially expressed mRNAs in HGSC, including a set with 
apparent prognostic role. 
Differentially expressed mRNAs between HGSC (MD/PD SC), SBOT and OSE, referred to 
as SNO, were identified by global gene expression profiling (n=23) and validated by RT-
qPCR (n=41). Thirty mRNAs differentially expressed between the three groups were selected 
from the global gene expression analyses, and 21 were verified (p<0.01) to be differentially 
expressed (Paper II; Table 4). A cluster analysis heatmap of the expression levels of these 
mRNAs showed an almost perfect segregation of the three groups, with differential mRNA 
expression between HGSC versus both SBOT and OSE, which showed similar patterns 
(Paper II; Figure 1).  
Thirteen mRNAs distinguished HGSC from OSE (p<0.01) (Paper II; Table 4) and were 
evaluated for association with clinical parameters. ZNF385B, the most aberrantly expressed 
mRNA, was underexpressed (FC=-130.5, p=1.2x10-7) and correlated with OS (p=0.03). 
Patients with the lowest ZNF385B tertile level had a much longer OS than patients with the 
highest ZNF385B tertile level, with a median time until death of 48 and 16 months, 
respectively (Paper II; Figure 3A). VEGFA was overexpressed (FC=6.1, p=6.0x10-6) and 
correlated with PFS (p=0.037), and patients with the lowest VEGFA expression levels had a 
much longer PFS than patients with the highest and intermediate levels, with a median time 
until progression of 28 and 11 months, respectively (Paper II; Figure 3B). Increased levels 
of TPX2 and FOXM1 mRNAs (FC = 28.5, p = 2.7x10-10 and FC = 46.2, p = 5.6x10-4, 
respectively) were associated with optimal normalization of CA125 after treatment (p=0.03 
and p=0.044, respectively).  
A molecular pathway for HGSC, including VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, 
five of the most overexpressed mRNAs in MD/PD SC vs. OSE, showed a direct molecular 
interaction with TP53 (Paper II; Figure 2) as generated through IPA.  
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7.3 Paper III 
“Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies 
differentially expressed miRNAs including miR-200c-3p as a prognostic marker” 
In this study, several differentially expressed miRNAs in HGSC and CCC were identified, 
including a few with apparent prognostic role. 
Differentially expressed miRNAs between HGSC, CCC and OSE were identified by global 
miRNA expression profiling (n=30) and validated by RT-qPCR (n=63). The global miRNA 
expression analysis showed that 78 miRNAs were differentially expressed between the groups 
applying a FDR <0.01%. A cluster analysis heatmap of the expression levels of these 
miRNAs showed an almost perfect segregation of the three groups with striking differences 
between HGSC and OSE, whereas CCC had an intermediate profile (Paper III; Figure 2). 
Eighteen of these miRNAs were selected for RT-qPCR analyses (Paper III; Table 2A) and 
all were verified (p<0.01) to be differentially expressed (Paper III; Table 2B). Compared 
with OSE, miR-205-5p was the most overexpressed miRNA in HGSC. miR-200 family 
members and miR-182-5p were the most overexpressed in HGSC and CCC compared with 
OSE, whereas miR-383 was the most underexpressed. miR-509-3-5p, miR-509-5p, miR-509-
3p and miR-510 were among the strongest differentiators between HGSC and CCC, all being 
significantly overexpressed in CCC compared with HGSC. Further three miRNAs were 
selected for validation by RT-qPCR based on possible association with survival. 
The miRNAs analysed by RT-qPCR were evaluated for association with clinical parameters. 
High miR-200c-3p expression was associated with poor PFS (p=0.031) and OS (p=0.026) in 
HGSC. Patients with the highest tertile level had shorter OS than patients with the 
intermediate or lowest levels, with median time until death of 18 and 30 months, respectively 
(Paper III; Figure 3A). Patients with the highest tertile level had also shorter PFS compared 
with patients with the lowest levels, with a median time until progression of 7 and 11 months, 
respectively (Paper III; Figure 3B). Reduced levels of miR-202-3p and miR-1281 were 
associated with macroscopic RD (p=0.018 and p=0.035, respectively). 
Interacting differentially expressed miRNAs and mRNA targets were mapped through the use 
of IPA for HGSC, including those of the TP53-related pathway presented previously (Paper 
III; Table 3 and Figure 4). 
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8. GENERAL DISCUSSION 
8.1. Considerations of patients and material 
8.1.1 Selection of patients and tissue material 
Patient material from two biobanks at OUH; the biobank at Ullevaal and the biobank at 
TNRH, was used in this thesis. Material from the biobank at Ullevaal was included in all 
studies, whereas nine CCC patients were included from the biobank at TNRH in the study 
presented in Paper III in order to increase the sample size of this OC subgroup.  
Since OC subtypes are regarded as different diseases in respect to molecular profiles, 
biological behaviour and clinical features (38), separate analyses of the subgroups is essential 
to achieve meaningful results. Hence, it is a strength that the patient selection primarily was 
based on histological subgroups. We focused on HGSC and CCC, aiming to find molecular 
and clinical distinctive features for these OC subgroups. CCC encompasses only about 10% 
of the OC (38), and available material may therefore be limited. Only primary ovarian 
tumours were included, and no patients had received preoperative chemotherapy.  
The preoperative data of the patients of the biobank at Ullevaal were based on hospital 
records as well as additional patient interviews, whereas the clinical information of the 
patients of the biobank at TNRH was based on hospital records only. Additional preoperative 
patient interviews involving collection of specific data will generally increase the probability 
that clinical information is complete. Preoperative information that potentially could be 
missing from the hospital records of the patients included from the biobank at TNRH included 
only information on past and existing diseases and ethnicity, but information about these 
subjects was present in the records.  
A limitation of the study is the relative small sample size, especially in Paper I and II. Both 
type I (false positive results) and type II (false negative results) may occur when studying 
small series. However, a small sample size implies primarily a risk for not revealing even 
strong associations (false negative results). Therefore, particularly negative results should be 
interpreted with great caution, and the results should be evaluated in larger patient cohorts. 
Furthermore, a too small sample size of a specific tumour type might not be representative for 
the tumour type in general due to intertumour heterogeneity. However, the gene expression 
patterns of the differentially expressed genes of the different subgroups were in general 
homogenous. 
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Sample size calculations were not performed prior to the studies, as no standard deviation of 
the expression levels of the genes in the tissues analysed was available.  
Another concern might be the general intratumour heterogeneity of OC, implying different 
molecular alterations and thereby gene expression patterns in different parts of the tumour. In 
our studies, only one tissue fragment from each tumour was analysed. However, as described 
below, all samples were quality controlled by experienced pathologists. 
 
8.1.2 Evaluation of histological diagnosis and sample quality 
Setting the correct histopathological diagnosis is of superior importance to obtain correct 
scientific results when biological material is utilized. In a large Norwegian study during a 10-
year period, the accuracy of ovarian cancer diagnosis was estimated to be 92% when 
reevaluated by a senior pathologist (147). In the present thesis, all specimens used were re-
evaluated by at least one senior pathologist specialized in gynaecological pathology, and most 
of the samples were further re-evaluated. Furthermore, frozen sections from the biopsies were 
examined prior to RNA isolation to ensure satisfying sample quality and representativeness. 
Therefore, we conclude that it is unlikely that the tissue material used is not of correct and 
appropriate histopathology. 
The molecular alterations within the cancer cell itself are believed to be of greater 
carcinogenetic importance than those of the microenvironment. Therefore, it is generally 
accepted that the proportion of tumour cells in a material examined should be at least 50%, 
preferably 80%. Hence, only carcinomas presenting histologically more than 50% tumour 
cells were included for RT-qPCR analyses in Paper II and for all analyses in Paper III.  
Since cells in the tumour microenvironment are important contributors to the development of 
cancer, cancer cells and the microenvironment should ideally be analysed separately to obtain 
a better understanding of the molecular alterations in these two tumour constituents. 
Presently, microdissection is very time-consuming and requires technology and diagnostic 
experience, and was not available.  
 
8.1.3 Control material 
One strong aspect of this thesis might be the use of OSE as control material. OC is generally 
believed to originate from the single-layered OSE (37;148-151), which therefore should be 
the optimal control material. However, a challenge related to the understanding the 
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carcinogenesis of ovarian cancer has been the use of different control tissue. The 
identification of differentially expressed genes in SC by microarray studies has been shown to 
be strongly influenced by the control material utilized, including OSE brushings, whole ovary 
samples, short-term cultures of normal OSE and immortalized OSE cell lines (152). It was in 
this study concluded that OSE brushings were the most representative control material, since 
it is not exposed to in vitro manipulations and does not contain stromal components, which 
apparently may cause changes in gene expression. In accordance we found a different gene 
expression pattern when whole normal ovaries were used as control material compared to 
OSE or benign ovarian cysts (Paper 1). Thus, the choice of control material is of great 
importance for achieving representative and relevant scientific results. The use of different 
control materials for gene expression analyses in ovarian cancer may be a reason for 
conflicting results presented in different studies. 
Because the OSE represents only a small fraction of the total ovary, the availability of OSE 
RNA is limited. Since we experienced that brushing of normal ovaries yielded insufficient 
amount of material, we developed a procedure for superficial scrapings of the ovaries. Sample 
evaluation revealed that the vast majority of the cells was OSE, and therefore appropriate as 
control material. Still, stromal cells accounted for a small portion of the samples.  
In this thesis, OSE, as represented by superficial scrapings from normal ovaries, have been 
used as reference material in all studies. Furthermore, BNO and BBOC were included for 
additional comparisons in Paper I. Our results from Paper I showed that the investigated 
mRNAs were similarly expressed in the carcinoma when compared to OSE scrapings and 
BBOC, but differed when compared to BNO (Paper I; Figure 2, 3, S1 and S2). These 
findings are not unexpected, since the benign ovarian cysts are believed to originate from 
OSE, whereas whole normal ovaries mainly consist of stromal tissue (151). Based on these 
findings benign ovarian cysts appear to be an alternative to OSE as control tissue for OC. 
However, since only six mRNAs were analysed in a small numbers of controls, and an altered 
global gene expression during the development from OSE to benign ovarian cysts is likely, 
OSE scrapings was chosen as control tissue in Paper II and III. 
 
8.1.4 Collection of material 
All samples except for nine CCC from TNRH were taken from the biobank at Ullevaal, OUH, 
ensuring a similar harvesting procedure. After removal of the ovaries the tumour samples and 
the OSE scrapings were immediately harvested and snap-frozen or transferred to 
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Trizol/Qiazol, respectively, in order to prevent RNA degradation and altered gene expression. 
The samples at TNRH were collected and snap-frozen under the supervision of Ben Davidson 
after careful assessment of the removed ovaries immediately after their arrival at the 
Department of Pathology, TNRH. The transportation of the ovaries was done as soon as 
possible after removal. Thus, the collection procedures of the samples from the biobank at 
Ullevaal and TNRH are somewhat different. The samples from Ullevaal were generally 
harvested and frozen after a shorter time of exposure to room temperature than the samples 
from TNRH, thereby reducing the risk of RNA degradation and altered gene expression. The 
samples from TNRH were harvested under the supervision of a specialist in gynecological 
pathology, assuring high sample quality. However, isolated total RNA was quantified and 
quality assessed before the analyses, documenting adequate RNA quality and quantlty for all 
samples. Although not likely, we cannot entirely rule out the possibility that the time from 
removal to freezing may have affected the results. 
  
8.1.5 Follow-up data 
Follow-up data were available for all patients included. The patients were routinely evaluated 
every third months for two years, every six months for the next three years and thereafter once 
a year, or more frequently when indicated, and the PFS data are based on findings at these 
consultations. Since the increase of CA125 level (according to the GCIG criteria) is not 
always the first sign of disease recurrence, a verified clinical relapse was used for estimating 
PFS when this was the first sign of disease recurrence.  
In all studies gene expression levels of the RT-qPCR analyses were evaluated for associations 
with clinical parameters, including survival. Parameters possibly influencing these parameters 
are discussed under 8.3.3. 
 
8.2 Methodological considerations 
Before performing gene expression quantification analyses, study design considerations are of 
great importance, as appropriate sample selection is a basic criterion for obtaining biologically 
meaningful results. Careful assessment of material selection with respect to histopathological 
diagnosis, sample quality and clinicopathological variables has been performed upon all 
studies as described above.  
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8.2.1 RNA quality 
In all studies we have handled samples as carefully as possible to prevent RNA degradation, 
altered gene expression and DNA contamination, which is of critical importance. Evaluation 
of the quality of the isolated RNA is a prerequisite for correct results, and has been performed 
in all studies. 
 
8.2.2 Global gene expression analysis 
The microarray technology has during the last two decades had a great impact on gene 
expression research. However, this technology and the subsequent data analyses are burdened 
with several potential pitfalls. The microarray data sets are usually very large, and the results 
are influenced by a number of variables. Therefore, several methodological aspects should be 
considered carefully if valid conclusions are to be drawn. Some of the most important 
considerations of the microarray experiment and the data processing in general are briefly 
described below. 
Pitfalls of the probe-target hybridization process include a possibility for cross-hybridization 
of targets to probes that are supposed to detect other targets. Errors during cDNA synthesis 
and in vitro transcription may occur, and probes may be incorrectly designed. The small size 
of miRNAs and the challenges of obtaining uniform hybridization conditions across the 
microarray imply a risk for cross-hybridization of miRNAs that are highly related in 
sequence. 
There are several challenges regarding the statistical analyses of the data. Correct data 
processing is dependent on appropriate subtraction of background noise as well as 
normalization and visualisation of spot intensities. For identifying differentially expressed 
genes correct statistical analyses must be used, including test accounting for multiple 
comparisons and type I errors. 
Concerns regarding the reliability of the microarray technology have been raised, as dissimilar 
results when using different microarray platforms analysing identical RNA samples in a few 
studies has been shown. One explanation is the lack of inter microarray platform experimental 
standardization for assay protocols, analysis methods as well as platform fabrication for “in-
house” arrays. Therefore, several projects have tried to standardize the microarray 
experiments. MIAME (Minimum Information About a Microarray Experiment) is a standard 
for reporting microarray experiments, though a specific format is not required. The 
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"MicroArray Quality Control (MAQC) Project" (performed by the US Food and Drug 
Administration) has developed standards and quality control metrics, aiming the use of 
microarray data in i.e. clinical practice and drug discovery. The MAQC project has shown 
both acceptable inter- and intraplatform reproducibility of gene expression measurements for 
genes identified as differentially expressed (153). Furthermore, high correlation between 
quantitative gene expression values, such as RT-qPCR, and microarray platform results has 
been found (153;154), as is demonstrated also in this thesis (Paper II and III).  
Other reasons for lack of overlap between gene lists from different studies include differences 
in experimental design and intra- and/or inter-tumoural heterogeneity. Moreover, overfitting 
may occur when large numbers of potential predictors are used to discriminate among a small 
number of outcome events (155). 
A limitation of the DNA microarrays is that they do not cover the whole genome. Whereas the 
DNA microarray technology may analyse the expression of all known genes, “next 
generation” RNA-sequencing technology is a technique that in theory can capture all genes 
present in the sample analysed. Therefore, possible unknown important genes not included in 
the microarrays, have not been captured in our experiments. However, next generation 
sequencing is time- and resource-consuming, as well as expensive. 
In this thesis, microarrays from Affymetrix, a pioneer in microarray technology and among 
the leaders in genomics, have been used. Procedures recommended by the manufacturer have 
been carefully followed, ensuring as reliable results as possible. Our studies followed the 
MIAME guidelines, which is required for releasing the data at GEO.  
 
8.2.3 RT-qPCR analysis 
The PCR is an extremely sensitive analysis with a high dynamic range for quantification. 
There are several potential pitfalls of the RT-qPCR analysis, and many standard procedures 
involved, of which some are described below. 
Upon the qPCR experiment, a correct reverse transcription of RNA to cDNA requires 
appropriate and sufficient amount of primers (i.e. oligo(dT) primers), enzyme (reverse 
transcriptase), buffer and nucleotides. However, the RT reaction is expected to be the 
uncertain step in gene expression analysis, having several potential sources of error (156). 
These include presence of secondary and tertiary RNA structures, variations in efficiencies of 
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primers and enzyme (156), reaction inhibitors present in the material examined (157) and 
abundance of transcripts (158). Because these errors are hardly controllable, the success of a 
given RT reaction is difficult to evaluate. However, optimizing reaction conditions employed 
in all analyses include high RNA quality, the use of equal RNA quantity in all reactions and 
simultaneously preparation of the reaction mix for all reactions.  
An appropriate qPCR reaction requires sufficient amount of correct designed primers, 
sufficient amount of high fidelity enzymes (DNA polymerase), appropriate concentration of 
MgCl2, adequate amount of nucleotides and buffer, and correct temperatures. Furthermore, the 
qPCR reaction may not work readily for DNA templates above the length of 2000-3000 base 
pairs. False negative qPCR reactions may occur due to insufficiently designed primers not 
able to hybridize with the cDNA or that result in primer-primer hybridization (“primer-
dimer”), or suboptimal reaction conditions including incorrect temperature and MgCl2 
concentration. Internal folds caused by base-pairing between nucleotides within the cDNA 
(“hairpins”) or the primer may also result in decreased product yield or reaction failure. False 
positive qPCR results may be caused by inappropriate designed primers that hybridize not 
only to the specific cDNA sequence of interest, but to several areas on the cDNA, resulting in 
several PCR products comprising not only the cDNA sequence of interest. Moreover, 
unsuitable temperature and DNA contamination may lead to false positive results.  
In all papers, the instructions of the manufacturers have carefully been followed and reaction 
conditions optimized as described to obtain as reliable results as possible. The PCR primers 
for Paper I was designed by our research group, whereas the PCR primers for Paper II and III 
were designed by Applied Biosystems, Life technologies, a company considered to be among 
the most trusted producers of PCR-related products worldwide. Negative PCR control 
reactions without cDNA/RT reaction (a reaction without reverse transcriptase) have been 
included for all analyses to control for DNA contamination.  Sufficient technical replicate 
number is important for obtaining a reliable result, and was taken into account in all papers, 
with replicate numbers of minimum two (Paper I and III) and three (Paper II). 
For correct quantification of the PCR product, efficient probes are needed. In Paper I, the non-
sequence specific DNA binding dye SYBR Green was used. This compound is easy to use 
since designing of specific probes is not necessary. However, since it binds to any ds cDNA 
sequence, it cannot discriminate between the ds cDNA segments from the PCR products and 
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those from unspecific PCR products like primer-dimers. Consequently, there is a risk for 
overestimation of the target quantification. 
In Paper II and III, the sequence specific fluorescent labelled TaqMan probe applied in the 
TLDA cards was used. Since the TaqMan probes are designed for binding to the specific PCR 
product of interest it gives a more accurate RT-qPCR results than SYBR Green. However, the 
TaqMan probe is expensive, since separate probes must be designed for each cDNA target 
analysed. TLDA cards greatly simplify the qPCR experiments, and minimize the variability 
due fewer pipettings. 
In qPCR analyses, reference genes are used to estimate relative gene expression values and 
for internal controls. For a gene to be valid as a reference gene, its expression should not vary 
in the material investigated. The most frequently used reference genes, GAPDH and ȕ-actin 
were both used in Paper I and II, since these have been shown to remain unchanged during 
different conditions (159) and to be useful as reference genes for normalization of qPCR 
analyses in cancer specimens (160). They showed overall similar results in our analyses. 
However, it has become clear that no single gene is constitutively expressed in all cell types 
and under all experimental conditions, implying that the reference gene(s) suitable for the 
actual material analysed should be validated upon each experiment (161-163). Apparently, 
accurate normalization may require averaging of multiple internal control genes (164). 
Accordingly, the miRNAs with lowest expression variation (n=2) of the global analysis in 
Paper III were selected as reference genes, and since their mean value reduced the variation, 
this value was used for calculations. 
Based on a lack of consensus on how to best perform and interpret qPCR experiments, 
standardisation protocols have been developed (157;165), including the MIQE (Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments) guidelines (165).  
 
8.3 Interpretation of results   
8.3.1 Differential mRNA and miRNA expression and correlation with prognostic factors 
and survival in HGSC 
In Paper I, overexpression of POLD2 in PDSC compared with three different control tissues 
(OSE, BBOC, BNO) as well as with MDSC and CCC was found (Paper I; Figure 1, 3 and 
Table 2). POLD2 encodes a protein involved in DNA replication and repair (166), and is 
downregulated by the PTEN tumour suppressor gene (167), already known to be involved in 
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ovarian carcinogenesis (54;168-170). Repression of POLD2 by p53 in breast cancer cells 
arrested in G0-G1 phase of the cell cycle has also been identified (171). The fact that POLD2 
mRNA expression increased from 2.5-fold in MDSC to almost 20-fold in PDSC implies a 
possible prognostic relevance for this gene, since patients with PDSC generally have a 
slightly worse clinical outcome than patients with MDSC (53;172). Hypothetically, a possible 
prognostic disadvantage for patients with tumour cells overexpressing POLD2 may be 
explained by a replicative advantage in these cells, as the protein of POLD2 is involved in 
replication. Moreover, since POLD2 is involved in DNA repair, a lower degree of 
differentiation, possibly implying a higher need of repair, may furthermore explain a higher 
level of POLD2 in PDSC compared to MDSC. In support of this theory, chromosomal 
alterations involving altered regions harbouring genes associated with patient survival 
including POLD2, have been found in glioma (173), and overexpression of POLD2 has 
previously been found in OC (174). 
The global mRNA expression analyses of Paper II confirmed an overexpression of POLD2 in 
HGSC vs. OSE (p=0.001), although a lower FC was found (FC=2). Differential POLD2 
expression between MDSC and PDSC was however not found. The somewhat diverging 
findings in Paper I and II may be explained by inter- and intra- tumour heterogeneity and 
sample size. Among the 23 patients included in Paper I only nine were included in the 
microarray analyses of Paper II (Table 3) and the samples from these nine patients were not 
identical in Paper I and II. Furthermore, the sample size of the microarray analyses might 
have been too small to capture the differential POLD2 expression between MDSC and PDSC 
found in Paper I. For example, only one pure MDSC group comprising three patients was 
included (Paper II; Table 1). 
Similar mRNA expression profiles in MDSC and PDSC were shown both in Paper I and II, 
and is in agreement with previous findings and their assumed common carcinogenesis 
(38;54;64). In Paper I, the mRNA expression was similar for PDSC and MDSC compared 
with OSE (Paper I; Figure 2), although not all comparisons demonstrated statistically 
significant results, possibly due to a small sample size. As for POLD2, this mRNA was 
significantly overexpressed in both MDSC (p=9.1x10-4) and PDSC (p=3.4x10-8) compared 
with OSE (Paper I; Figure 1), but also in PDSC compared with MDSC (p=1.7x10-8). In 
Paper II, no statistically significant differences were found when comparing expression of 
thirty mRNAs in MDSC versus PDSC (t-test of ¨Cq values, p<0.01). When MDSC and 
PDSC were separately compared with OSE and SBOT, (t-test of ¨Cq values, p<0.01) only 
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three (A2BP1, CRISP2 and DNAH9) and two (A2BP1, CRISP3) mRNAs had dissimilar 
expression, respectively. Based on the similarity between MDSC and PDSC, evaluated in 
Paper I and II and also by others (38;54;64), MDSD and PDSC were merged when analysing 
miRNA expression in Paper III, in accordance with the general opinion (38). 
In Paper II, several known and hitherto partly unrecognized mRNAs were identified as 
significantly differentially expressed between HGSC, SBOT and OSE (Paper II; Table 4). 
Compared with OSE, ZNF385B was 130 times less expressed in HGSC and was significantly 
associated with OS. The more underexpressed, the longer was the OS (Paper II; Figure 3A). 
The present knowledge about the biological functions of ZNF385B is limited. It belongs to 
the family of zinc-finger genes, which encode transcription factors, playing an essential role 
in gene expression. This mRNA is supposed to be a repressor of transcription, but the specific 
function is not known (175).  However, it has been found expressed in Burkitt's lymphoma 
and also in its healthy B cell counterpart, and has been shown to interact with p53 and induce 
B cell apoptosis (176). Based on our findings, one might postulate that ZNF385B has a 
stimulating effect on carcinogenesis, and that defense mechanisms might inhibit its function. 
Consequently, the more effective the repression of ZNF385B, the more inhibited is the 
carcinogenesis, and the longer is the OS supposed to be. To our knowledge, this is the first 
time ZNF385B has been linked to OC and implied in outcome.  
Other mRNAs found to be differentially expressed and correlating with prognostic factors and 
survival in HGSC (Paper II) included VEGFA, TPX2 and FOXM1, all being overexpressed in 
HGSC compared with both OSE and SBOT. VEGFA, an important mediator of tumour 
angiogenesis (177) was significantly overexpressed in HGSC, and high expression was 
associated with a short PFS (Paper II; Figure 3B). Overexpression of VEGFA and its 
association with poor prognosis have previously been found in several malignant tumours 
including OC (178-181), underscoring VEGFA as a possible prognostic marker. A humanized 
monoclonal antibody targeting VEGFA, bevacizumab, has been approved for the treatment of 
several cancers, including OC (131;132;177). For ovarian cancer patients bevacizumab in 
combination with standard chemotherapy has shown to improve PFS in several phase III 
trials, including front line (131;132) and platinum-resistant recurrent (133) treatment. 
However, an improvement in OS has not yet been established.  
High expression levels of TPX2 and FOXM1 correlated with optimal CA125 normalization 
(Paper II), implying that effective chemotherapy appears to be associated with overexpression 
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of these genes. TPX2, which has an important function in spindle assembly during cell 
division (182), has previously been shown to be overexpressed in ovarian cancer and other 
malignancies (64;183-187). In accordance with our findings, a higher expression of TPX2 in 
MDSC and PDSC compared with SBOT and WDSC was found in an oligonucleotide array 
profiling study (64). TPX2 activates AURKA, which is overexpressed in cancer and 
apparently is a key regulator of mitosis. Co-overexpression of AURKA and TPX2 has been 
found in many cancer forms, including ovarian cancer (178;184), and TPX2 and AURKA 
have been proposed to be a functional unit with oncogenic properties (184). Accordingly, the 
global mRNA analyses retrospectively showed that AURKA was overexpressed in HGSC 
compared with OSE (p=0.10, FC=3.8) and SBOT (p=5.9x10-4, FC=6.3).  
FOXM1 encodes a transcriptional activator involved in cell proliferation, and is 
overexpressed in various human malignancies, including carcinomas of the ovary, prostate, 
breast, lung, colon, pancreas, stomach, bladder, liver and kidney (188). In HGSC 
overexpression of FOXM1 has previously been described (65;91), also when compared with 
SBOT (91). FOXM1 seems to stimulate tumor progression (189;190) and activate metastasis 
(191), and overexpression correlates with poor prognosis in breast and gastric cancer 
(190;192). FOXM1 regulates several genes involved in the cell cycle progression, including 
BIRC5 and TP53 (193). FOXM1 expression is stimulated by oncogenes (194) and is 
regulated by tumor suppressor genes such as TP53 (195;196).  
A molecular pathway of HGSC was identified, involving five markedly overexpressed 
mRNAs (BIRC5, FOXM1, TOP2A, TPX2 and VEGFA), all directly interacting with TP53 
(Paper II; Figure 2, Table 4). The p53 tumor suppressor is important in preventing the 
development of cancer, playing a crucial role in orchestrating the cellular stress response. The 
microarray analyses showed that TP53 was significantly overexpressed in HGSC compared 
with both OSE (p=1.2x10-3, FC=2.0) and SBOT (p=2.5x10-4, FC=2.4). This may seem 
surprising since TP53 should inhibit the mRNAs in the pathway except for VEGFA. 
However, TP53 is mutated in almost all HGSC (65), and the increase may represent a 
compensatory mechanism as a result of high levels of dysfunctional TP53 protein. We 
therefore postulated that a mutation in the TP53 gene results in a decreased inhibition and 
consequently an upregulation of BIRC5, FOXM1, TOP2A and TPX2. In support of our 
hypothesis, the high rate of TP53 mutation in HGSC has been suggested to contribute to 
FOXM1 overexpression (65;196), since a normal TP53 represses FOXM1 after DNA damage 
(195). 
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In accordance with our findings, The Cancer Genome Atlas Research Network (65) recently 
identified several genes in a FOXM1 transcription factor network, including BIRC5, 
consistently overexpressed and significantly altered in 87% of HGSC. Interestingly, these 
mRNAs were not altered by DNA copy number changes, indicating a transcriptional 
regulation. This study concluded that the FOXM1 pathway provides opportunities for 
therapeutic treatment. 
BIRC5 was highly overexpressed in HGSC compared with OSE and SBOT, which is in 
accordance with other studies (65;91;197). Survivin, the protein product of BIRC5, is 
regarded as one of the most cancer specific proteins identified, and has a crucial function in 
the cell cycle, inhibiting apoptosis and promoting cell proliferation (198). BIRC5 is repressed 
by TP53 protein and is overexpressed in the majority of cancers (199-201). Survivin is 
expressed in more than 90% of OC (202;203), and appears to be a prognostic marker for OC 
(203-206). Strategies for inhibiting BIRC5 are now utilized in several ongoing clinical trials 
on different cancer forms (198), but so far not in ovarian cancer. Our results suggest that 
BIRC5 might be a potential target for therapy in OC. Recently, an increased sensitivity to 
paclitaxel has been found in ovarian cancer cells with a decreased survivin level (206).  
Similar differential mRNA expression was found for several mRNAs in HGSC when 
compared to both OSE and SBOT (Paper II; Table 4). A lower potential of malignancy 
combined with a reduced proportion of tumour cells in SBOT compared with HGSC may at 
least partly explain the similarity. 
In Paper III, several miRNAs significantly differentially expressed between HGSC, CCC and 
OSE were identified (Paper III; Table 2B). The most differentially expressed miRNAs in 
HGSC compared with OSE were, as for CCC, miR-200 family members, including miR-
200a-3p, miR-200b-3p, miR-200c-3p and miR-141-3p. The miR-200 family is aberrantly 
expressed in a number of cancer forms (207-210). Members of this miRNA family have been 
found overexpressed in SC in a few studies. Two studies have found miR-200a, miR-200b, 
miR-200c and miR-141 to be overexpressed (101;106), and another study found elevated 
expression of miR-200a (104). However, the SC was unfortunately of mixed grading. 
miR-200 family members have been demonstrated to regulate epithelial-mesenchymal 
transition (EMT) by targeting ZEB1 and ZEB2, resulting in altered expression of the cell-cell 
adhesion molecule E-cadherin (211-214). E-cadherin down-regulation is apparently important 
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in cancer progression and metastasis, as the strength of cellular adhesion is decreased, 
facilitating cell detachment and metastasis. At a favorable distant location, the cells may 
thereafter undergo mesenchymal-epithelial transition (MET) and re-express E-cadherin 
resulting in reversion to an epithelial state and attachment to other cells. In concordance, the 
expression of E-cadherin has been shown to be elevated whereas the level of ZEB1 is reduced 
in metastatic OC (215). ZEB1 and ZEB2 are also targets of miR-205-5p (211), which was the 
most overexpressed miRNA in HGSC compared with OSE, and also significantly expressed 
in HGSC when compared with CCC (Paper III; Table 2B). 
miR-200c-3p and miR-200b-3b, having similar seed sequences, have been shown to decrease 
VIM expression and thereby its protein vimentin (213). Vimentin is found in various non-
epithelial cells, especially mesenchymal cells, and is used as a marker for EMT during 
metastasis. An elevated expression of miR-200c-3p and miR-200b-3b, resulting in reduced 
VIM and vimentin levels, is therefore expected in metastatic cancer, where epithelial cell 
features are important for re-colonization.  
miR-200c-3p was the most differentially expressed miRNA in both SC and CCC compared 
with OSE separately, according to p-values and FC values as a whole (Paper III; Table 2B). 
Accordingly, this miRNA has previously been found to be overexpressed in SC (101;106), 
HGSC cell lines (216), serum from HGSC patients (216) and also in a small series of CCC 
(101). A high level of miR-200c-3p was associated with short PFS and OS in HGSC, 
indicating that this miRNA may be a potential prognostic marker for HGSC. Kaplan-Meier 
curves showed that patients with the highest tertile level had the shortest PFS and OS (Paper 
III; Figure 3A, B). This finding is supported by a study analysing miRNA expression in SC 
vs. normal ovaries (106). Moreover, miR-200c-3p has also been associated with survival in 
stage I OC patients (217) and chemotherapy response (218). The HGSC comprised only 
FIGO stages IIIc and IV, strengthening the association between survival and miRNA 
expression.  
Based on the global miRNA expression analyses in Paper III, associations between miRNAs 
with signal values>7 (n=297) and PFS (FDR q<0.1) and OS (FDR q<0.25) were evaluated in 
HGSC and CCC separately. No statistically significant associations were found. However, 
when not corrected for multiple testing, 11 miRNAs had p<0.05, indicating a possible 
association with survival. For HGSC, high expression of miR-29b-2-5p, miR-31-5p, miR-
486-5p, miR-505-5p and miR-1281 had a potential association with short OS, whereas high 
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expression of all these miRNAs but miR-31-5p had a potential association with short PFS. 
Moreover, high expression of miR-26b-5p and miR-141-3p had a potential association with 
long PFS in HGSC. In CCC, high expression of miR-106b-3p had a potential association with 
short OS and PFS. Furthermore, high expression of miR-25-5p as well as miR-30a-3p, miR-
30a-5p and miR-31-5p had a potential association with short and long PFS, respectively. 
When applying a significance level of 3%, high miR-505-5p expression had a potential 
association with short PFS and OS in HGSC, whereas high miR-1281 and miR-29b-2-5p 
expression had a potential association with short PFS in HGSC. These three miRNAs were 
evaluated for association with survival in the extended patient cohort analysed by RT-qPCR. 
However, they were not found to be associated with survival.  
Through the use of IPA, interactions between differentially expressed mRNA and miRNA in 
HGSC were identified. The vast majority of these RNA molecules has previously been related 
to cancer and cancer-related functions, and may represent potential important key molecular 
pathways in this subgroup of OC (Paper III; Table 3). Differentially expressed miRNAs 
targeting the HGSC pathway identified in Paper II were also identified (Paper III; Figure 4). 
Interestingly, VEGFA, which we found to be overexpressed and positively associated with 
PFS in HGSC in Paper II, is a target of miR-200c-3p with high predicted confidence. Since 
both RNAs were overexpressed, an interaction may be explained by activation of gene 
expression (16;219;220). However, these interactions should be experimentally evaluated in 
HGSC.  
In addition to the five overexpressed mRNAs included in the molecular pathway for HGSC, 
we further identified eight differentially expressed mRNAs (p<0.01) in HGSC compared with 
OSE (Paper II). These mRNAs were also linked to differentially expressed miRNAs (FC>±2) 
of the global gene expression analyses in HGSC compared with OSE (Paper III). Inclusion 
criteria for these interactions were similar as for the interactions between differentially 
expressed miRNAs and the mRNAs of the HGSC pathway (Paper III). Four of the mRNAs 
were interacting with the miRNAs. CTCFL was a predicted target for miR-23a-3p, miR-449a 
and miR-370 and LCN2 for miR-491-5p, all miRNAs participating in the HGSC pathway 
identified in Paper II (Paper III; Figure 4).  ZNF385B, found to be associated with OS in 
HGSC, and CRIPS2 were not included in this pathway. However, they were both predicted 
target for miR-625-5p, which also target NTRK3 (221), encoding the receptor tyrosine kinase 
TrkC receptor, which is involved in the oncogenic PIK3CA pathway. Further miRNAs 
targeting CRISP2 included miR-27a, miR-502-3p and miR-510.  
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8.3.2 Differential mRNA and miRNA expression and correlation with prognostic factors 
and survival in CCC 
In Paper I (Paper I; Figure 3 and Table 2), KSP37 was identified as overexpressed (FC=4.3) 
in stage I CCC compared with advanced stage disease, including stage II-IV CCC (FC=0.5) 
and stage III-IV PDSC (FC=0.7) and MDSC (FC=0.5). Additionally, KSP37 associated 
positively (p<0.05) with FIGO stage I disease as well as PFS and OS (Paper I; Table 3). 
These findings are to the best of our knowledge novel for OC. In concordance with our 
findings, a high KSP37 expression level has been found to associate positively with survival 
also in patients with high-grade gliomas, even more closely correlated than histological grade 
(222).   
KSP37, also known as FGFBP2, encodes a serum protein which is a member of the fibroblast 
growth factor binding protein 2 family. This protein is secreted by cytotoxic lymphocytes, and 
may be involved in cytotoxic lymphocyte-mediated immunity (223).  
Global mRNA analyses were unfortunately not available for CCC. However, global miRNA 
expression was analysed in CCC, along with HGSC and OSE (Paper III). The most 
differentially expressed miRNAs in CCC compared with OSE were, as for HGSC, miR-200 
family members, including miR-200a-3p, miR-200b-3p, miR-200c-3p and miR-141-3p 
(Paper III; Table 2B). In accordance with these findings, miR-200a (101;104) and miR-200c 
(101) have previously been found to be overexpressed in CCC. However, the sample size for 
the CCC has unfortunately been very small; n= 4 (101), n=3 (104). Important functions of the 
miR-200 family members are described under the HGSC part of this section. 
Among the other most aberrantly expressed miRNAs, miR-182-5p had the highest FC in CCC 
compared with OSE (Paper III; Table 2B). This miRNA regulate the expression of PIK3CA, 
a frequently mutated gene in CCC and a candidate for targeted therapy (224).  
To our knowledge, we are the first to identify differentially expressed miRNAs in a relatively 
large CCC series. The miRNAs most clearly separating CCC from HGSC were miR-509-3-5p 
and miR-509-5p, having similar seed sequences, and also miR-509-3p (Paper III; Table 2B). 
MiR-509-3p has been shown to target NTRK3 (221), and miR-509-3-5p, miR-509-3p and 
miR-513a-5p have been found overexpressed in stage I disease of SC and endometrioid 
ovarian carcinoma (107). miR-509-5p have been shown to  inhibit cancer cell proliferation 
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(225). miR-510 targets SPDEF (226), which have been found underexpressed in OC 
compared with breast carcinomas (227). 
A larger patient cohort is warranted to explore associations between miRNAs and survival in 
CCC. The correlation of clinical parameters with miRNA expression revealed miR-202-3p 
and miR-1281 to be associated with RD in CCC. However, the CCC, comprising FIGO stage 
I-IV, could not be adjusted for FIGO stage due to the small series of this subgroup.  
 
8.3.3 General remarks 
When evaluating associations between gene expression and prognostic factors as well as 
survival, other factors than gene expression of potential influence should ideally be recorded. 
Factors that might influence apart from the tumour biology in relation to first line treatment 
are briefly described below.  
General preoperative issues that might delay treatment include lack of symptoms, patient 
delay of consulting a doctor, doctor delay, general condition and comorbidity. Perioperative 
factors that might influence the outcome include tumour resectability and the volume of RD, 
standard surgery routine, the patient’s general condition and comorbidity, the skills of the 
surgeon and perioperative complications. Ovarian cancer surgery has during the last few years 
become more aggressive, aiming zero RD and bilateral para-aortic and pelvic lymph node 
resection (123). However, some years ago, removal of lymph-nodes was not routinely 
performed, and the aim was RD of 2 cm, since this was believed to be the correct cut-off in 
relation to survival. An increased short-term survival for patients operated by gynaecologic 
oncologists compared to general gynaecologists has been shown (228), and ovarian cancer 
surgery is now recommended to be performed by a gynaecologic oncologist (123). 
Primary surgery was performed in all patients included, but the volume of RD varied 
markedly. Furthermore, removal of lymph nodes and consequently complete staging was not 
performed in all patients. Since RD after initial surgery has been shown to be one of the most 
important factors influencing survival in ovarian cancer (32;34), it will have an impact on the 
survival also in the patients included in this thesis.  
Postoperative factors that might influence the prognosis include postoperative complications, 
time until start of chemotherapy, the patient’s general condition, comorbidity and 
chemotherapy treatment and toxicity. Among the patients included, the vast majority received 
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standard adjuvant chemotherapy. However, a few patients did not receive standard 
chemotherapy treatment, received a reduced dose, or chemotherapy was delayed or 
discontinued due to poor general condition, toxicity or comorbidity. There was also some 
variation of the time from surgery to start of chemotherapy, as shown in the manuscripts. 
However, the impact of time from surgery to start of chemotherapy is uncertain, though start 
of chemotherapy within or after six weeks does not seem to influence short-term survival 
(229).  
The survival analyses in this thesis had high test power for the patients with HGSC, since all 
but five (Paper I), three (Paper II) and two (Paper II) had died from ovarian cancer. As for the 
CCC patients, several were still alive at last follow-up, implying a lower test power for the 
survival analyses in these cases.  
Inclusion of patients with comparable stages of disease, would reduce the influence of stage 
on outcome. The CCC series comprised small numbers at each FIGO stage due to lack of 
available samples, and a larger patient cohort would have increased the probability of 
identifying associations. However, the HGSC assessed in the RT-qPCR analyses comprised 
mainly FIGO stages III and IV, with comparable expected prognosis. In Paper I, only stage III 
and IV tumours were included, in Paper II all but three were at stage III (of which all but one 
were stage IIIc) and IV and in Paper III only stage IIIc and IV tumours were included.  
Several mRNAs and miRNAs differing markedly between HGSC, CCC and OSE have been 
identified through global miRNA expression and RT-qPCR analysis, suggesting a role for 
these RNA molecules in ovarian carcinogenesis. The different transcriptional profiles of 
HGSC and CCC emphasize the biological distinctiveness of these OC subgroups, and support 
the relevance of the current subgrouping of OC (38).  
The mere identification of differentially expressed genes in OC is insufficient to understand 
the underlying molecular carcinogenesis, since these changes may not necessarily have any 
physiological impact on the OC development. The translation of mRNA to protein, the 
distribution of gene products and interaction with other genes are decisive for a physiological 
effect. Gene expression levels are not necessarily correlated with protein levels, but 
differences in gene expression levels in general indicate similar differences also at the protein 
level. 
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Since entire molecular pathways apparently are deregulated in cancer, it is crucial to identify 
key deregulated pathways, as we might have done in Paper II. Identification of 
mRNA/miRNA interactions will moreover improve the understanding of the molecular 
mechanism underlying this disease. Hopefully, some of these pathways represent therapeutic 
targets. However, these pathways need to be experimentally validated in OC.  
Although the present thesis is based on a relatively small number of patients, the strong 
associations found between some of the genes and outcome parameters suggest that the 
identified mRNAs and miRNAs may be potential cancer markers and targets for therapy.  
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9. CONCLUSIONS  
1. Several mRNAs and miRNAs differentially expressed in HGSC and CCC have been 
identified, including some with apparent prognostic relevance (Paper I, II and III). 
2. POLD2 is significantly overexpressed in both MDSC and PDSC compared with OSE, and 
also significantly overexpressed in PDSC compared with MDSC, a difference which 
might reflect the slightly worse prognosis for PDSC compared with MDSC (Paper I). 
3. KSP37 is overexpressed in stage I CCC compared with CCC and HGSC at higher FIGO 
stages and is positively associated with PFS and OS (Paper I).  
4. Gene expression profiles for HGSC and CCC are similar when compared with OSE and 
BBOC, but differ when compared with BNO (Paper I). 
5. Several mRNAs are similarly differentially expressed in HGSC when compared with OSE 
or SBOT (Paper II). 
6. PDSC and MDSC have similar mRNA expression profile (Paper I and II). 
7. CCC displays a different mRNA and miRNA expression profile compared with HGSC 
(Paper I and III). 
8. ZNF385B is strongly underexpressed in HGSC and is inversely associated with OS  
(Paper II).  
9. VEGFA is markedly overexpressed in HGSC and is inversely associated with PFS   
(Paper II).  
10. TPX2 and FOXM1 are highly overexpressed in HGSC and associated with optimal 
normalization of CA125 after treatment (Paper II). 
11. A molecular pathway generated through IPA was identified for HGSC, encompassing 
VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, five of the most overexpressed mRNAs in 
HGSC and all directly interacting with TP53 (Paper II).  
12. miR-205-5p was identified as the most differentially expressed (overexpressed) miRNA in 
HGSC compared with OSE, followed by miR-200 family members and miR-182-5p 
(Paper III). 
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13. miR-200 family members, miR-182-5p and miR-200a-5p were identified as the most 
differentially expressed (overexpressed) miRNAs in CCC compared with OSE (Paper III). 
14. miR-509-3-5p was identified as the strongest differentiator between HGSC and CCC, 
followed by miR-509-5p, miR-509-3p, miR-510 and miR-508-5p, all being significantly 
overexpressed in CCC compared with HGSC (Paper III). 
15. High miR-200c-3p expression is inversely associated with PFS and OS in patients with 
HGSC (Paper III).  
16. Reduced levels of miR-202-3p and miR-1281 are associated with macroscopic RD in 
patients with CCC, unadjusted for FIGO stage (Paper III). 
17. For HGSC, several interacting differentially expressed miRNAs and mRNA targets are 
mapped through the use of IPA, including those of the TP53-related pathway of HGSC 
(Paper III). 
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10. FUTURE PERSPECTIVES 
Increased biological knowledge is the basis for the development of novel and more 
individualized treatment strategies that hopefully will improve the poor prognosis for ovarian 
cancer patients. The high frequency of early recurrence of ovarian cancer, and the low 
response rates to cytotoxic agents available for recurrent disease (230) reveal that the search 
for novel therapeutic agents is required.  
Recent research has shed some light on the molecular mechanisms involved in ovarian 
carcinogenesis. In this thesis, mRNA and miRNA expression analyses have been used to 
improve the understanding of ovarian carcinogenesis and the molecular characteristics of 
HGSC and CCC. Global gene expression profiling is a reasonable approach for identifying 
the most differentially expressed genes in cancer, and some of these are likely to be relevant 
to cancer development. It is important that future gene expression studies are clinically and 
histopathologically optimally designed with appropriate control material for identifying 
biomarkers of clinical relevance. MIAME have aimed to improve and conform microarray 
analyses and to make results from different investigations comparable, and their advice should 
be implemented in future studies. To validate the findings of the retrospective studies, 
prospective studies are needed.  
Although it has long been known that OC is not a single disease, but comprises several 
different subgroups, patients with different OC disease are currently treated as though they 
had one homogenous disease. This treatment approach will hopefully in the future be replaced 
by more knowledge based and individualized therapies targeting specific genes and molecular 
pathways involved in ovarian carcinogenesis. OC biomarker studies should therefore in the 
future be subgroup specific, in contrast to most of the studies so far. Development of separate 
trials are now advised for most of the OC subgroups, including CCC (123).  
The clinical heterogeneity among OC patients with similar tumour subgroup and comparable 
clinically prognostic factors is apparently due to biological differences. A better 
understanding of the molecular biology of OC should enable the identification of new 
subgroups of ovarian cancer patients that are most likely to benefit from a particular 
treatment.  
Since a neoplastic tumour encompasses tumour cells and their surrounding tumour stroma, 
both these tumour compartments should be investigated, aiming a combined treatment 
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targeting both compartments. Ideally, the different aspects of a tumour should be investigated 
separately to achieve an optimal biological understanding. Moreover, based on the lower 
response rate of recurrent disease, samples from recurrent disease should also be analysed. 
Improved insight into the roles of miRNAs in OC will hopefully in the future improve ovarian 
cancer therapy. Since miRNAs regulate the expression of several mRNAs and thus entire 
pathways, miRNAs might be promising treatment targets. Normalization of aberrantly 
expressed tumour suppressor miRNAs and oncogenic miRNAs are suggested approaches 
(231). The inactivation of oncogenic miRNAs using complementary anti-miRNA 
oligonucleotides (AMOs) and the induction of overexpression of tumour suppressor miRNAs 
have already shown a potential as therapeutic targets (99). Likewise, miRNAs could 
potentially be used to manipulate the expression of tumour suppressor genes and oncogenes. 
The identification of miRNAs with a therapeutic potential is likely to be a major focus in 
future OC research. However, extensive knowledge of differential miRNA expression in 
different subgroups of OC is crucial for obtaining useful miRNA based treatment. 
Circulating miRNAs have apparently a potential as biomarkers (115;232;233). In the search 
for circulating biomarkers of OC patients, we have already an ongoing study on circulating 
miRNAs in the same patient cohort as in Paper III. Identification of circulating miRNAs that 
are able to distinguish between individuals with and without cancer may facilitate an earlier 
cancer diagnosis.  
Global mRNA profiling of CCC were not performed in the studies included in this thesis. 
However, it would be of great interest to perform global mRNA profiling on the same CCC 
material as used in Paper III, and to compare these profiles with those of HGSC and also to 
identify differentially expressed mRNA targets of the differentially expressed miRNAs in 
CCC identified in Paper III.  
The identified differentially expressed mRNAs and miRNAs should be analysed in future 
studies as candidates for biomarkers and targets for therapy, and the identified pathways 
should be experimentally validated and further explored in OC. The identification of mRNAs 
and miRNAs responsible for cancer development and progression as well as a better 
understanding of their interactions will hopefully in the future increase the biological 
knowledge and improve therapy and outcome in ovarian cancer patients.  
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11. ERRATUM
x Page 37, Table 3 
Row number 6 and 12, concerning RT-qPCR in Paper III, has been corrected from 3 and 
36 to 2 and 35, respectively. 
x Paper I, Figure 1 
The three columns (vertical) representing SNO (first column), BBOC (second column) 
and BNO (third column) should have been visualized underneath all heatmaps, not only 
underneath the heatmap of the clear cell carcinomas.  
x Paper II, page 5 
“Progression-free survival (PFS) and overall survival (OS) were defined as the time 
interval from the date of surgery to the date of first confirmed disease recurrence and to 
the date of death, respectively.”
Should read:  
“Time until progression and time until death were defined as the time interval from the 
date of surgery to the date of first confirmed disease recurrence and to the date of death, 
respectively.”
x Paper III, page 3 
“Selected candidate miRNAs were validated by RT-qPCR in all samples analyzed by 
global miRNA expression profiling and in additional samples, totaling 35 HGSC, 19 CCC 
and 9 OSE samples.”
Has been corrected to: 
“Selected candidate miRNAs were validated by RT-qPCR in all samples analyzed by 
global miRNA expression profiling (except one excluded) and in additional samples, 
totaling 35 HGSC, 19 CCC and 9 OSE samples.”
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Abstract
Background: Epithelial ovarian cancer (EOC) constitutes more than 90% of ovarian cancers and is associated with high
mortality. EOC comprises a heterogeneous group of tumours, and the causes and molecular pathology are essentially
unknown. Improved insight into the molecular characteristics of the different subgroups of EOC is urgently needed, and
should eventually lead to earlier diagnosis as well as more individualized and effective treatments. Previously, we reported a
limited number of mRNAs strongly upregulated in human osteosarcomas and other malignancies, and six were selected to
be tested for a possible association with three subgroups of ovarian carcinomas and clinical parameters.
Methodology/Principal Findings: The six selected mRNAs were quantified by RT-qPCR in biopsies from eleven poorly
differentiated serous carcinomas (PDSC, stage III–IV), twelve moderately differentiated serous carcinomas (MDSC, stage III–
IV) and eight clear cell carcinomas (CCC, stage I–IV) of the ovary. Superficial scrapings from six normal ovaries (SNO), as well
as biopsies from three normal ovaries (BNO) and three benign ovarian cysts (BBOC) were analyzed for comparison. The gene
expression level was related to the histological and clinical parameters of human ovarian carcinoma samples. One of the
mRNAs, DNA polymerase delta 2 small subunit (POLD2), was increased in average 2.5- to almost 20-fold in MDSC and PDSC,
respectively, paralleling the degree of dedifferentiation and concordant with a poor prognosis. Except for POLD2, the serous
carcinomas showed a similar transcription profile, being clearly different from CCC. Another mRNA, Killer-specific secretory
protein of 37 kDa (KSP37) showed six- to eight-fold higher levels in CCC stage I compared with the more advanced staged
carcinomas, and correlated positively with an improved clinical outcome.
Conclusions/Significance: We have identified two biomarkers which are markedly upregulated in two subgroups of ovarian
carcinomas and are also associated with stage and outcome. The results suggest that POLD2 and KSP37 might be potential
prognostic biomarkers.
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Introduction
In Norway and the United States, ovarian cancer is the fourth
and fifth most frequent cause of cancer death in women,
respectively [1,2]. At the time of diagnosis, almost 70% of the
patients have distant spread of disease (stage III–IV), and their 5-
year relative survival rate is only about 30% [1,2]. The cause(s)
and mode of progression are poorly understood, and the patients
are treated similarly in spite of tumour heterogeneity [3–6].
EOC comprises several subtypes of histopathologically different
tumours [7]. There is growing evidence for the existence of at least
two distinct tumourigenetic pathways, corresponding to the devel-
opment of type I and type II tumours [3,6,8–10]. Type I tumours
include highly differentiated serous carcinomas, mucinous carcino-
mas, endometroid carcinomas, clear cell carcinomas and malignant
Brenner tumours. They are thought to arise from precursor lesions
such as cystadenomas, borderline tumours or endometriosis and
suggested to be a result of mutations in e.g. KRAS, BRAF, CTNNB1
or PTEN genes [4,6,8,9]. Type II carcinomas include moderately
and poorly differentiated serous carcinomas, carcinosarcomas and
undifferentiated carcinomas, and appear to originate de novo from as
yet no known identified precursor lesions, possibly resulting from
mutations in e.g. TP53 [4,6,8,9,11]. Thus, ovarian carcinogenesis
appears to be associated with abnormalities in multiple gene families.
How these genetic alterations are reflected in changes in transcrip-
tional activity and carcinogenesis are not understood.
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Previously, we reported a limited number of mRNAs strongly
upregulated in human osteosarcomas and several other malignan-
cies [12]. Further analyses on various types of human malignant
cell lines and normal tissues showed that six mRNAs were highly
expressed: KSP37, C9orf89, PRAT4A, NOLA2, ANT2 and POLD2
(Table 1). Apart from C9orf89 and PRAT4A (unknown at project
start), these mRNAs code for proteins known to be associated with
malignancy [13–16]. We hypothesized that these mRNAs might as
well be associated with ovarian cancer. In the present study, we
quantified these mRNAs by RT-qPCR in biopsies from eleven
PDSC (stage III–IV), twelve MDSC (stage III–IV) and eight CCC
(stage I–IV) as well as control tissue representing six SNO, three
BNO and three BBOC. The expression levels were related to
histological, clinical and laboratory parameters. We found that two
of the mRNAs were markedly upregulated in two subgroups of
ovarian carcinomas and also associated with stage and outcome.
Results
Mean expression levels of six selected mRNAs in three
subgroups of ovarian carcinomas compared with three
different control groups
Expression levels of the six selected mRNAs in PDSC, MDSC
and CCC are presented in Figures 1,2,3. Figure 1 shows heat-
maps of log10 transformed p-values (t-test) comparing the mean
expression levels as DCq (delta quantification cycles) values in
PDSC, MDSC and CCC with SNO, BNO and BBOC. P-values
less than 0.05 were used as cut-off value for significance. When
comparing PDSC with SNO and BBOC, respectively, the
following mRNAs were significantly differentially expressed:
PRAT4A (p = 8.161025 and 2.661023), NOLA2 (p = 1.361024
and 3.561023), ANT2 (p = 6.361025 and 2.661023) and POLD2
(p = 3.461028 and 2.461025), whereas comparing these carcino-
mas with BNO, ANT2 (p = 1.961022) and POLD2 (p = 3.161022)
showed a differential expression. For MDSC, POLD2
(p = 9.161024) showed differential transcription when compared
with SNO. NOLA2 (p = 1.161022) and POLD2 (p = 4.361022)
were differentially expressed when CCC were compared with
BNO. These significantly differentially expressed mRNAs were all
upregulated in PDSC and MDSC, while downregulated in CCC
(data not shown). Thus, several of the six previously shown
upregulated mRNAs in osteosarcomas were also differentially
expressed in the ovarian carcinomas. Furthermore, the overall
transcriptional activity of these genes was similar when comparing
BBOC with SNO and BNO, while PRAT4A and POLD2 showed
significant differential expression (p,0.05) when BNO and SNO
were compared (data not shown).
Individual expression levels of six selected mRNAs in
three subgroups of ovarian carcinomas compared with
SNO controls
Figure 2 shows mRNA expression profiles of all 31 carcinomas
employing SNO as a control group, depicted as heat-maps of
normalized log2 transformed original fold change (FC) values.
Higher mRNA levels were detected in PDSC and MDSC for
PRAT4A, NOLA2, ANT2 and POLD2. PRAT4A, NOLA2 and ANT2
showed a similar mRNA expression in PDSC and MDSC in
contrast to POLD2, being clearly more upregulated in PDSC
compared with MDSC. The mRNA levels were reduced for
KSP37 and C9orf89 in both PDSC and MDSC. Furthermore,
except for C9orf89, a distinct mRNA expression pattern of the
mRNAs was present in CCC. The heat-maps looked almost
identical when BBOC were used as the control group, but differed
slightly when BNO were used (Figure S1).
Mean expression levels of six selected mRNAs in three
subgroups of ovarian carcinomas compared with SNO
controls
Figure 3 shows bar plots of mean mRNA expression (loge
transformed original FC values) in PDSC, MDSC and different
stages of CCC, using SNO for comparison. In PDSC, POLD2 was
almost 20-fold upregulated (FC 19.4), whereas C9orf89, PRAT4A,
NOLA2 and ANT2 were only moderately upregulated (FC 1.2–3.1)
and KSP37 slightly downregulated (FC 0.7). In MDSC, transcrip-
tion levels of KSP37 and C9orf89 were reduced (FC 0.5 and 0.7
respectively), while the other mRNAs showed moderate upregula-
tions (FC 1.8–2.5). In CCC stage I, KSP37 was markedly
upregulated (FC 4.3), but downregulated in the more advanced
stages of CCC (FC 0.5). In both stage I and stages II–IV of CCC,
PRAT4A, ANT2 and POLD2 were slightly upregulated (FC 1.4–
1.7), whereas C9orf89 and NOLA2 were slightly downregulated (FC
0.6–0.96). Thus, when comparing KSP37 expression levels in CCC
stage I with the more advanced stages of CCC, MDSC and
PDSC, a six- to eight-fold difference was detected. Further
analyses of the FC values in Figure 3 are shown in Table 2. The
mean mRNA profiles were almost identical when BBOC were
used as control tissue, but differed more when BNO were used
(Figure S2).
The mean mRNA expressions, given as loge transformed
original FC values, in the different ovarian carcinoma subgroups
were also compared (t-test). P-values less than 0.001 were used as
cut-off value for significance. POLD2 mRNA levels were
significantly higher in PDSC compared with both MDSC (FC
19.4 vs. 2.5; p = 1.761028) and CCC (FC 19.4 vs. 1.5;
p = 5.661028), whereas transcription levels of NOLA2 and ANT2
Table 1. Title and assumed function of six selected mRNAs [12].
Title Assumed function
Killer-specific secretory protein of 37 kDa; KSP37 Cytotoxic lymphocyte-mediated immunity [13]
Chromosome 9 open reading frame 89; C9orf89 CARD binding region* [29]
Protein associated with TLR4,A; PRAT4A TLR4 associated* [30]
Nucleolar protein family A, member 2; NOLA2 Associated with telomerase and snoRNPs [14]
Adenine nucleotide translocator 2; ANT2 ADP/ATP exchange [15]
DNA polymerase delta 2 small subunit; POLD2 DNA replication and repair [16]
*Unknown at project start. CARD: Caspase Recruitment Domain. TLR: Toll-like receptor. SnoRNPs: small nucleolar ribonucleoproteins. KSP37 is synonymous with
fibroblast growth factor binding protein 2; FGFBP2 (www.ncbi.nlm.nih.gov/genebank).
doi:10.1371/journal.pone.0013837.t001
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were significantly higher in PDSC compared with CCC (FC 3.0
vs. 0.8; p = 3.061026 and FC 3.1 vs. 1.5; p = 5.761024,
respectively). The results were similar irrespectively of the control
tissue used (data not shown).
Correlation of mRNA expression to clinical, laboratory
and histological parameters
In a single-factor linear regression model, normalized FC values
of the six mRNAs, employing SNO as controls, were correlated
with clinical, laboratory and histological parameters. The
parameters shown in Table S1 as well as histological subgroups
were included in the regression analysis. The significant positive
correlations (p,0.05) between mRNA expression levels and these
parameters are shown in Table 3. Only KSP37 was significantly
associated with several clinical parameters, being positively
associated with favourable prognostic factors such as localized
disease, long progression-free survival (.18 months) and long
overall survival (.36 months). Furthermore, it was negatively
associated with unfavourable prognostic factors such as more
advanced disease, short progression-free survival and short overall
survival (data not shown). When correlating the FC values with
histological subgroups, KSP37 expression was positively associated
with CCC, whereas PRAT4A, NOLA2 and POLD2 were positively
associated with PDSC. The transcriptional levels of C9orf89 and
ANT2 did not correlate with any of the parameters.
Discussion
A major finding in this study was the strong upregulation of
POLD2 in PDSC compared to control tissues and other
histological subgroups of ovarian carcinomas examined. POLD2
is a subunit of the DNA polymerase delta complex, encoding a
protein involved in DNA replication and repair [16]. It is
downregulated by the PTEN tumour suppressor gene [17],
already known to be involved in ovarian carcinogenesis
[4,6,8,9]. In gliomas, a consistent pattern of chromosomal
Figure 1. Mean differential expression levels of six selected mRNAs (horizontal) in three subgroups of ovarian carcinomas
compared with three different control tissues (vertical). Log10 p-values of the T-test of delta Cq values are shown as heat-maps, where the
smaller the p-value, the brighter the blue colour (scale bar). P,0.05 represents significant differential expression. SNO: superficial scrapings from
normal ovaries. BBOC: biopsies from benign ovarian cysts. BNO: biopsies from normal ovaries.
doi:10.1371/journal.pone.0013837.g001
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alterations were found involving altered regions which harboured
seven ‘‘landscape genes’’ associated with patient survival, among
these POLD2 [18].
KSP37 mRNA levels were clearly and distinctly regulated in
early stage of CCC, another histological subgroup of ovarian
cancer. KSP37 is identified as FGFBP2, a member of the fibroblast
growth factor binding protein 2 family (www.ncbi.nlm.nih.gov/
genebank). It is expressed in cytotoxic T lymphocytes and natural
killer cells, and is suggested to have a ‘‘cytotoxic potential’’ which
so far has not been identified [13]. Yamanaka et al. found that a
high KSP37 expression in high-grade gliomas was positively
correlated with survival. Furthermore, KSP37 was more closely
correlated with survival than histological grade [19], while in the
present study, a positive correlation with histological type, clinical
stage as well as good prognosis was observed.
A challenge related to the understanding of molecular portraits of
ovarian cancer has been the lack of representative control tissue.
Histologically, EOC is thought to originate from the single layer of
ovarian surface epithelium (OSE) [5,7,20–22], which therefore
should be the most representative control tissue. Because the OSE
represents only a small fraction of the total ovary, the availability of
OSE RNA is limited. Zorn et al [23] compared the gene expression
profiles of OSE brushings, whole ovary samples, cultures of normal
OSE and immortalized OSE cell lines. The transcriptional profiles
were markedly distinct, but it was concluded that OSE brushings
were most representative as control material, since it is not exposed
to in vitro manipulations and does not contain stromal components.
In the present study, OSE, as represented by six superficial
scrapings from normal ovaries (SNO) was used as reference
material. Furthermore, three biopsies from normal ovaries (BNO)
and three biopsies from benign ovarian cysts (BBOC) were included
for additional comparisons. Our results showed that the investigated
six mRNAs were similarly expressed in SNO and BBOC, but
differed more in BNO (data not shown). Furthermore, the mRNA
levels of the carcinomas were similar both when compared to SNO
and BBOC, but different when compared to BNO (Figures 1,2,3
and Figure S1, S2). Apparently, SNO and BBOC showed
comparable transcriptional activity for these six mRNAs. The
findings are not unexpected, since the benign ovarian cysts used for
control tissue are believed to originate from OSE, whereas BNO
mainly consist of stromal tissue [7]. Thus, for study purposes, benign
cysts originating from OSE, being simpler to obtain than OSE, and
superficial scrapings of normal ovaries appear to be alternative
choices as control tissue for EOC.
Except for the marked upregulation of POLD2 in PDSC, the
expression levels of the other mRNAs in PDSC and MDSC were
similar, in agreement with a common tumourigenetic pathway for
moderately and poorly differentiated serous carcinomas as previously
suggested [10]. Thus, the fact that POLD2 mRNA expression
paralleled the dedifferentiation of MDSC to PDSC, increasing from
2.5-fold in MDSC to almost 20-fold in PDSC, underscores the
uniqueness of this transcript. Since patients with PDSC generally
have a worse clinical outcome than patients with MDSC, the
significantly higher POLD2 expression in PDSC compared with
MDSC could have a bearing on a poor prognosis, possibly through a
replication advantage in cells overexpressing POLD2.
The marked upregulation of KSP37 confined to CCC stage I, as
well as its positive association with clinical variables of good
prognosis, suggest also a possible predictive role of this transcript.
Even though these results are very much in concordance with
overall results from studies on other malignancies, the present
results are novel related to ovarian carcinomas and need to be
confirmed. The different transcriptional profiles for clear cell
carcinomas and serous carcinomas are in agreement with distinct
Figure 2. Differential expression levels of six selected mRNAs
(vertical) in 31 individual tissue samples (horizontal) of three
subgroups of ovarian carcinomas compared with superficial
scrapings from normal ovaries. Normalized log2 transformed
original FC values (Z-scores) are shown as heat-maps, where the
higher/lower the FC value, the brighter the red/green colour,
respectively (scale bar). Black colour illustrates no difference in FC
values of cancer tissue and control tissue.
doi:10.1371/journal.pone.0013837.g002
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tumourigenetic pathways for these carcinomas and also consistent
with other studies [24,25]. Although the present study is based on
a limited patient cohort of only three subgroups of ovarian
carcinomas, the strong association of two of the mRNAs with
histology, stage and outcome suggest that they may have potential
as cancer markers.
Materials and Methods
Patients and tissue material
The study was approved by the Regional Committee of Medical
and Health Research Ethics (REK) in Eastern Norway and all
participating women signed informed consent. Tissue specimens as
well as clinical and laboratory information were obtained from
women primarily operated for gynecological tumours at Oslo
University Hospital, Ulleval, in the period 2003 to 2008. All tissue
samples were snap-frozen in liquid nitrogen, except SNO, which
were transferred to 500 ml TRIzol solution (Invitrogen.com)
immediately after harvesting in order to avoid mRNA degrada-
tion. The samples were stored in a biobank at 280uC until
processed.
The expression of the six selected mRNAs was studied in a total
of 31 epithelial ovarian carcinomas and twelve benign samples.
The carcinomas included twelve MDSC (stage III–IV), eleven
PDSC (stage III–IV) and eight CCC (stage I–IV). Six SNO, three
BNO and three BBOC were used for comparison. SNO were
taken from the surface of normal ovaries by scraping the ovaries
with a scalpel, as cervical pap smear brushings yielded too little
material (data not shown). By this method, the vast majority of
harvested cells were immunologically verified as epithelial (data
not shown). The three benign cysts were cystadenofibromas,
containing both epithelial and stromal cells. BNO consisted almost
exclusively of stromal cells as confirmed by histology. In
accordance with the literature [23], we used OSE, represented
by SNO, as reference material. The histological diagnoses of all
samples were confirmed by an experienced pathologist.
Clinical and laboratory information was collected from hospital
records and additional preoperative patient interviews, shown in
Table S1. All patients and controls were of Western European
descent, postmenopausal (apart from two being perimenopausal)
and had no diseases influencing survival other than the ovarian
cancer. All patients but four (two with MDSC and two with
PDSC) were primarily operated by at least a total hysterectomy or
a uterus amputation, a bilateral salpingo-oophorectomy and an
omentectomy. No patients received neoadjuvant chemotherapy,
whereas all patients but three (one in each histological group)
received adjuvant chemotherapy. The effect of treatment was
evaluated by clinical examinations and serum CA125 measure-
ments at minimum.
Selected mRNAs
Six mRNAs were selected from a subtraction cDNA library of
human osteosarcoma [12]. They represented interesting candi-
date genes, being strongly upregulated in several osteosarcoma
and other malignant human cell lines, and showed a differential
expression between human cancers and normal tissues. Except
for C9orf89 and PRAT4A, whose identities and functions were
unknown at project start, these mRNAs code for proteins
possibly associated with malignancies. The titles and assumed
protein functions of the selected candidate mRNAs are shown in
Table 1.
Primer sequences
PCR primers (Table S2) were designed by using the Invitrogen
database and tested for homology with other sequences at the
Figure 3. Mean expression levels of six selected mRNAs in moderately and poorly differentiated serous carcinomas (stage III–IV)
and clear cell carcinomas (stage I and II–IV) compared with superficial scrapings from normal ovaries. Loge transformed original FC
values with standard deviation are shown as bar plots.
doi:10.1371/journal.pone.0013837.g003
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NCBI gene website (www.ncbi.nlm.nih.gov). All primers were
intron spanning to avoid co-amplification of genomic DNA.
RNA isolation
Tissue specimens were either crushed frozen or homogenized
directly for 262 minutes in 750 ml TRIzol using a Tissuelyzer
(Qiagen.com). Total RNA was extracted using the TRIzol method
according to the manufacturer’s instructions. Isolated total RNA
was quantified (Nano Drop spectrophotometer, Saveen Werner
AB) and quality controlled by the RNA Nano 6000 assay on the
Bioanalyzer 2100 system (Agilent). RNA integrity number (RIN)
and 28S/18S ratios were calculated to ensure a satisfactory RNA
quality and integrity of the samples. To remove genomic DNA,
total RNA was treated using RNase-free DNase I (Roche.com).
Total RNA was further purified on RNeasy MinElute clean up
spin columns (Qiagen.com), eluted with RNase free water,
aliquoted and stored at 280uC until analyzed.
Quantitative reverse transcription-polymerase chain
reaction (RT-qPCR)
One mg of total RNA from each sample was reversely
transcribed using 2.5 U/ml Omniscript enzyme (Qiagen.com), 1
X RT-buffer, 1 mM dNTPs, 2.5 mM oligo-d(T)-primer and 1 U/
ml RNase inhibitor (final concentrations) in a total volume of 20 ml
for one hour at 37uC. For all samples, a negative RT-control
without Reverse Transcriptase enzyme was included. cDNA was
PCR-amplified with primers from the six specific mRNAs and two
endogenous reference genes (b-actin and GAPDH) in replicate sets
of two to six, with a coefficient of variation of less than 1.6 percent.
The samples were analyzed on a real-time fluorescence Light-
Cycler instrument (Roche.com) according to the manufacturer’s
instructions in a final volume of 20 ml using a LightCycler Fast
start SYBR Green kit. PCR conditions essentially contained 2 ml
cDNA, 25 mM MgCl2 and 0.5 mM of forward and reverse
primers. The following cycle conditions were used: 10 min
denaturation at 95uC before 45 cycles at 95uC for 0 s, 56uC for
10 s and 70uC for 5 s.
Gene expression patterns for the six selected mRNAs were
calculated using the comparative crossing threshold method of
relative quantification (DDCq method) [26], and presented as
relative (DCq) and fold change (FC) values. All expression levels
were normalized to the reference genes separately, giving overall
similar results. b-actin quantification was most linear over a wide
dilution range and preferred as reference gene. DCq was
designated as the mean quantification cycle of an mRNA in a
tissue subtracted with the mean quantification cycle of a reference
RNA in the same tissue. DDCq was calculated as mean DCq of
each of the three different control groups subtracted by DCq of
each cancer tissue sample (mean of replicates), whereas FC was
2DDCq.
Table 3. Results of single-factor regression analysis.
KSP37 PRAT4A NOLA2 POLD2
Clinical parameters
FIGO stage I (all CCC) 7.961027
Progression-free survival $18 months 1.661022
Overall survival $36 months 3.361022
Status at last follow-up: Alive, no relapse of EOC 8.061025
Status at last follow-up: Alive, relapse of EOC 1.261022
Histological parameters
PDSC 1.861022 2.161023 1.261025
CCC 6.861023
CCC: Clear cell carcinomas. PDSC: Poorly differentiated serous carcinomas. EOC: Epithelial ovarian cancer. Significant positive correlations (p-values) between mRNA
expression levels and parameters are shown. Detailed explanation is given in Table 1 and Table S1.
doi:10.1371/journal.pone.0013837.t003
Table 2. Statistical analyses of the FC values shown in
Figure 3.
KSP37 C9orf89 PRAT4A NOLA2 ANT2 POLD2
PDSC,
stage III–IV
Average 0.70 1.17 2.77 3.03 3.12 19.42
Stdev 0.62 0.93 1.06 1.43 1.11 14.79
Min 0.07 0.50 1.24 1.36 1.51 5.90
Max 1.64 3.27 4.82 6.73 4.92 59.30
MDSC,
stage III–IV
Average 0.52 0.69 1.98 1.78 2.40 2.50
Stdev 0.39 0.46 1.15 1.42 2.36 1.13
Min 0.06 0.29 0.60 0.74 0.77 1.38
Max 1.42 1.79 3.97 6.06 9.42 4.66
CCC, stage I
Average 4.28 0.69 1.42 0.96 1.35 1.66
Stdev 3.11 0.46 1.32 0.50 0.28 1.54
Min 0.95 0.17 0.39 0.57 1.17 0.67
Max 8.40 1.29 3.34 1.68 1.77 3.94
CCC, stage II–IV
Average 0.49 0.64 1.38 0.73 1.60 1.43
Stdev 0.40 0.23 0.65 0.12 0.91 0.35
Min 0.12 0.36 0.90 0.56 0.82 1.11
Max 1.04 0.90 2.31 0.83 2.76 1.75
PDSC: Poorly differentiated serous carcinomas. MDSC: Moderately differentiated
serous carcinomas. CCC: Clear cell carcinomas. Stdev: Standard deviation. Min:
minimal value. Max: Maximal value. mRNA description is given in Table 1.
doi:10.1371/journal.pone.0013837.t002
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Statistical analysis
Mean DCq values of each histological subgroup of ovarian
carcinomas were compared to mean DCq values of each control
group by performing a two-tailed t-test, presented in heat-maps by
log10 transformed p-values (Figure 1). Log2 transformed original
FC values of each individual sample (n = 31) were normalized (Z-
scores) and shown as heat-maps by applying a two-way clustering
method [27] (Figure 2 and Figure S1). Mean original FC values of
the three ovarian carcinoma subgroups were presented by loge
transformed bar plots (Figure 3 and Figure S2). Finally, a linear
regression model [28], testing the correlation of histological,
clinical and laboratory parameters with mRNA expression levels
given as normalized FC values, was used (Table 3).
Supporting Information
Figure S1 Differential expression levels of six selected mRNAs
(vertical) in 31 individual tissue samples (horizontal) of three
subgroups of ovarian carcinomas compared with biopsies from
benign ovarian cysts (a) and biopsies from normal ovaries (b).
Normalized log2 transformed original FC values (Z-scores) are
shown as heat-maps, where the higher/lower the FC value, the
brighter the red/green color, respectively (scale bar). Black color
illustrates no difference in FC values of cancer tissue and control
tissue.
Found at: doi:10.1371/journal.pone.0013837.s001 (1.92 MB TIF)
Figure S2 Mean expression levels of six selected mRNAs in
moderately and poorly differentiated serous carcinomas (stage III–
IV) and clear cell carcinomas (stage I and II–IV) compared with
biopsies from benign ovarian cysts (a) and biopsies from normal
ovaries (b). Loge transformed original FC values with standard
deviation are shown as bar plots.
Found at: doi:10.1371/journal.pone.0013837.s002 (2.74 MB
TIF)
Table S1 Clinical and laboratory information for patients
included.
Found at: doi:10.1371/journal.pone.0013837.s003 (0.05 MB
DOC)
Table S2 Primer sequences of six selected mRNAs.
Found at: doi:10.1371/journal.pone.0013837.s004 (0.04 MB
DOC)
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Figure S1 
 
Figure S2 
 
Table S1. Clinical and laboratory information for patients included.
Parameters MDSC (n=12) PDSC (n=11) CCC (n=8)
$JH n=6 n=5 n=4
Preoperative condition
Good n=11 n=11 n=7
Poora n=1 n=0 n=1
Preoperative CA 125
<35 kU/L (normal) n=1
35-500 kU/L n=3 n=4 n=3
>500 kU/L n=9 n=7 n=4
FIGO stage
I n=4 (1 IA, 3 IC)
II n=1 (IIA)
III n=10 (IIIC) n=8 (1IIIA, 7IIIC) n=2 (IIIC)
IV n=2 n=3 n=1
Start of chemotherapyb
< 28 days after surgery n=3 n=3 n=1
GD\VDIWHUVXUJHU\ n=8 n=7 n=6
Standard chemotherapy treatmentc n=5 n=9 n=4
Optimal CA 125 normalizationd n=5 (of 11) n=8 (of 10) n=5 (of 6)e
Progression-free survivalf
<18 months n=10 n=7 n=3
PRQWKV n=2 n=4 n=5
Overall survival 
<36 months n=9 n=6 n=4
PRQWKV n=3 n=5 n=4
Status at last follow-up
Alive, no EOC n=1 n=1 n=4
Alive, with EOC n=2
Dead of EOC n=11 n=7 n=4
Dead of other disease n=1
MDSC: Moderately differentiated serous carcinomas. PDSC: Poorly differentiated serous 
carcinomas. CCC: Clear cell carcinomas. EOC: Epithelial ovarian cancer. aDVFLWHVPODW
surgery, haemoglobin <10 g/dL and albumin<36 g/L. b: one patient in each group did not receive 
chemotherapy. c: four to nine cycles of Carboplatine and Paclitaxel. d: normalization of CA125 (< 35 
kU/L) within four cycles of chemotherapy. e: two patients had normal preoperative CA 125. f:
progression: Doubling of pathologic CA 125 levels or clinical relapse.
 
Table S2. Primer sequences of six selected mRNAs.
mRNAs Primer sequences
KSP37, fw 5´- TGG GAA CAT TGT TGG AAA CC -3´
KSP37, rv 5´- GGT TGT CTG TCA GGG AGA GG -3´
C9orf89, fw 5´- GTA CTG CTA TCC GCC AGA CC -3´
C9orf89, rv 5´- CAG GAA GGC CAG CAG GTA G -3´
PRAT4A, fw 5´- AGA GGT GGC TGA CCT CAA GA -3´
PRAT4A, rv 5´- AGG TCT TCC TCC TGG TGG TT -3´
NOLA2, fw 5´- TTT TGG CAG GAG ACA CAC TG -3´
NOLA2, rv 5´- CAC CCA GGT CCG TCT TAG AG -3´
ANT2, fw 5´- ATC TAC CGA GCC GCC TAC TT -3´
ANT2, rv 5´- ATC CAG CTG ATG ACG ATG TG -3´
POLD2, fw 5´- TCC AAA TGA GAC CCT TCC TG -3´
POLD2, rv 5´- CCA CAC AGC ACT TCT CCT CA -3´
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Abstract
Background: The oncogenesis of ovarian cancer is poorly understood. The aim of this study was to identify mRNAs
differentially expressed between moderately and poorly differentiated (MD/PD) serous ovarian carcinomas (SC), serous
ovarian borderline tumours (SBOT) and superficial scrapings from normal ovaries (SNO), and to correlate these mRNAs with
clinical parameters including survival.
Methods: Differences in mRNA expression between MD/PD SC, SBOT and SNO were analyzed by global gene expression
profiling (n = 23), validated by RT-qPCR (n = 41) and correlated with clinical parameters.
Results: Thirty mRNAs differentially expressed between MD/PD SC, SBOT and SNO were selected from the global gene
expression analyses, and 21 were verified (p,0.01) by RT-qPCR. Of these, 13 mRNAs were differentially expressed in MD/PD
SC compared with SNO (p,0.01) and were correlated with clinical parameters. ZNF385B was downregulated (FC=2130.5,
p = 1.261027) and correlated with overall survival (p = 0.03). VEGFA was upregulated (FC= 6.1, p = 6.061026) and correlated
with progression-free survival (p = 0.037). Increased levels of TPX2 and FOXM1 mRNAs (FC = 28.5, p = 2.7610210 and
FC= 46.2, p = 5.661024, respectively) correlated with normalization of CA125 (p = 0.03 and p= 0.044, respectively).
Furthermore, we present a molecular pathway for MD/PD SC, including VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all
significantly upregulated and directly interacting with TP53.
Conclusions: We have identified 21 mRNAs differentially expressed (p,0.01) between MD/PD SC, SBOT and SNO. Thirteen
were differentially expressed in MD/PD SC, including ZNF385B and VEGFA correlating with survival, and FOXM1 and TPX2
with normalization of CA125. We also present a molecular pathway for MD/PD SC.
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Introduction
Ovarian cancer is the fourth and fifth most frequent cause of
cancer death in women in Norway and the United States,
respectively [1,2]. When diagnosed, about 65% of the patients
have distant spread of disease (stage III–IV), and their 5-year
relative survival rate is less than 30% [1,2].
Epithelial ovarian cancer (EOC) constitutes more than 90% of
ovarian cancers and comprises a heterogeneous group of tumours.
Serous ovarian carcinomas (SC) are the most common histological
subtype [3,4], of which the moderately differentiated (MD) and
poorly differentiated (PD) are predominant compared with the
well differentiated (WD) [3]. It is generally understood that MD
and PD SC represent a common tumour subclass distinct from
that of WD SC and serous ovarian borderline tumours (SBOT)
with respect to origin, pathogenesis, molecular profile and clinical
outcome [5–11].
Several previous DNA microarray expression analyses of EOC
have identified genes related to histology or clinical outcome
parameters [12,13]. A few DNA microarray expression analyses,
restricted to the molecular differences between MD/PD SC and
SBOT have been carried out [9,10,14,15]. However, the
differentially expressed mRNAs were not correlated with clinical
parameters. Moreover, only one of these studies [9] included
normal ovarian surface epithelium (OSE), which has been shown
to be a valid control tissue [16].
Improved insight into the molecular characteristics of the
different subgroups of EOC should eventually lead to more
individualized and effective treatments. The aim of this study was
to identify mRNAs differentially expressed between MD/PD SC,
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SBOT and superficial scrapings from normal ovaries (SNO), using
global gene expression profiling and validation by RT-qPCR, and
to correlate differentially expressed mRNAs of MD/PD SC with
clinical parameters. In contrast to previous studies, we initially
analyzed gene expression based on histological subgroups and
then linked the differentially expressed mRNAs to clinical
parameters. We have identified several subgroup characteristic
mRNAs, including some with apparent clinical relevance.
Materials and Methods
Ethics Statement
The study was approved by the Regional Committee of Medical
and Health Research Ethics (REK, ref.no. 530-02163) in Eastern
Norway and all participants signed informed consent.
Patients and Tissue Material
Women were recruited prior to operations for gynaecological
diseases at Oslo University Hospital, Ulleval, in the period 2003 to
2007. Clinicopathological and laboratory information were
obtained from hospital records and additional preoperative patient
interviews. Tissue specimens were obtained from women previ-
ously not receiving chemotherapy, during their primary operation.
SNO samples collected from patients operated for benign
gynaecological diseases were used as control material [17]. By
scraping the surface of normal ovaries gently with a scalpel, the
vast majority of the harvested cells were verified cytologically as
normal OSE cells, being positive for pankeratin by immunocyto-
chemistry (data not shown). Immediately after harvesting the tissue
samples were snap-frozen in liquid nitrogen, whereas the SNO
samples were transferred to 500 ml TRIzol solution (Invitrogen.-
com) in order to avoid mRNA degradation. The samples were
stored at 280uC until processed.
The histological classification and clinical stage were according
to the World Health Organization classification of tumours and
the International Federation of Gynecology and Obstetrics
classification, respectively. The tumours were reviewed by two
experienced and independent pathologists, and prior to RNA
isolation a frozen section of all biopsies was examined to ensure
satisfying sample quality and representativeness. By histological
evaluation, only carcinomas presenting more than 50% tumour
cells were included in the RT-qPCR analyses.
Global gene expression was carried out in eleven MD/PD SC,
eight SBOT and four SNO samples. The tumours were selected
Table 1. Histological classification and group selection for
patients selected for global gene expression analyses.
Group Histological classification
1 (n = 3) SC, MD, FIGO stage IIIC
2 (n = 3) SC, PD, FIGO stage IIIC
3 (n = 3) SC, 2MD, 1PD, FIGO stage IV
4 (n = 2) SC, PD, FIGO stage IV
5 (n = 3) SBOT, FIGO stage IA
6 (n = 1) SBOT, FIGO stage IB
7 (n = 1) SBOT, FIGO stage IC
8 (n = 3) SBOT, FIGO stage II–III
SC: Serous ovarian carcinomas. MD: Moderately differentiated. PD: Poorly
differentiated. SBOT: Serous ovarian borderline tumours. FIGO: International
Federation of Gynecology and Obstetrics. A minor sarcoma component was
retrospectively discovered in one SC, but was not found in the biopsy used, still
excluded from RT-qPCR.
doi:10.1371/journal.pone.0046317.t001
Table 2. Clinicopathological and laboratory information for patients selected for RT-qPCR analyses.
Parameters MD/PD SCa, n=21 SBOT, n=13
Age; mean 6 SD (range) 69.069.9 (51–84) 58.5614.9 (36–82)
Preoperative CA125 (kU/L); mean 6 SD 332064761 3506714
FIGO stage
I n = 2 (IC) n = 10 (6IA, 3IB, 1IC)
II n = 1 (IIC) n = 2 (1IIB, 1IIC)
III n = 14 (1IIIB, 13IIIC) n = 1 (IIIB)
IV n = 4 n= 0
Residual tumour
0 cm n= 5 n= 12
,2 cm n= 5 n= 1
.2 cm n= 11
Start of chemotherapy (days after surgery); mean 6 SD 30.4611.6
CA125 response n = 20
Optimal CA125 normalization n = 14
Median time (months) until progression (95%CI) 13 (10–16)
Median time (months) until death (95%CI) 29 (17–41)
Status at last follow-up
Alive, no EOC n= 3 n= 12
Dead of EOC n= 18 n= 0
a12 MD, 9 PD. SD: Standard deviation. CI: Confidence Interval. Further abbreviations are given in Table 1.
doi:10.1371/journal.pone.0046317.t002
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and some pooled (n= 2–3) according to histological classification
and stage, resulting in four MD/PD SC groups and four SBOT
groups (Table 1). The SNO samples were analyzed individually.
Differentially expressed candidate mRNAs were validated by RT-
qPCR in all but three of these samples and in additional samples
totalling 21 MD/PD SC, 13 SBOT and seven SNO, analyzed
individually.
RNA Preparation
Tissue specimens were homogenized directly for 262 minutes
in 750 ml TRIzol using a Tissuelyzer (Qiagen.com). Total RNA
was extracted using Trizol (Invitrogen, Carlsbad, CA) and further
purified by the RNeasy MinElute cleanup kit (Qiagen catalog
no. 74204) according to the manufacturer’s instructions. The
isolated total RNA was quantified (Nano Drop spectrophotometer;
Saveen Werner AB) and quality controlled using the Agilent
BioAnalyzer 2100 system and the RNA 6000 Nano assay. All
samples showed high RNA quality.
Global Gene Expression Profiling
Five micrograms of total RNA were used for analysis with the
one-cycle cDNA synthesis kit following the manufacturer’s
(Affymetrix) recommended protocol for gene expression analysis.
Biotinylated and fragmented cRNA was hybridized to the
Affymetrix HG U133 Plus 2.0 array, representing 47000
transcripts for 38500 well characterized human genes. The signal
intensities were detected with the Hewlett-Packard gene array
scanner 3000 7G (Hewlett-Packard, Palo Alto, CA). Complete
microarray expression data have been deposited in NCBI’s Gene
Expression Omnibus [18] (accession number GSE36668).
Quantitative Reverse Transcription-Polymerase Chain
Reaction (RT-qPCR)
RT-qPCR reactions were performed by using ABI Prism 7900
HT sequence detection system (Applied Biosystems). Microfluidic
Taqman arrays were designed to measure the mRNA expression.
Briefly, total RNA was reversely transcribed using Omniscript
(Qiagen Ltd., Crawley, United Kingdom). 300 nanograms of
cDNA were used per sample-loading port, each allowing 48 q-
Table 3. Differentially expressed mRNAs selected for RT-qPCR validation.
Symbol Title Biological function
ALPP Alkaline phosphatase, placental Metabolism
BIRC5 Baculoviral IAP repeat containing 5 Cell proliferation
CRABP2 Cellular retinoic acid binding protein 2 Transcription
CRISP2 Cysteine-rich secretory protein 2 Cell-cell adhesion
CRISP3 Cysteine-rich secretory protein 3 Immune response
CTCFL CCCTC-binding factor (zinc finger protein)-like Transcription
DNAH9 Dynein, axonemal, heavy chain 9 Cell motility
DYNLRB2 Dynein, light chain, roadblock-type 2 Metabolism
FOXM1 Forkhead box M1 Transcription
GRIA2 Glutamate receptor, ionotropic, AMPA 2 Ion transport
HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 Immune response
HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 Immune response
KLK8 Kallikrein-related peptidase 8 Proteolysis
LCN2 Lipocalin 2 Immune response
MMP10 Matrix metallopeptidase 10 (stromelysin 2) Proteolysis
PRAME Preferentially expressed antigen in melanoma Transcription
PROM1 Prominin 1 Signal transduction
PTH2R Parathyroid hormone 2 receptor Signal transduction
RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 RNA processing
S100A8 S100 calcium binding protein A8 Inflammatory response
SCEL Sciellin Cell differentiation
SFRP2 Secreted frizzled-related protein 2 Cell differentiation
SST Somatostatin Signal transduction
TMEM190 Transmembrane protein 190 Unknown
TOP2A Topoisomerase (DNA) II alpha 170 kDa Transcription
TPPP3 Tubulin polymerization-promoting protein family member 3 Microtubule bundle formation
TPX2 Microtubule-associated, homolog (Xenopus laevis) Cell proliferation
VEGFA Vascular endothelial growth factor A Cell proliferation, angiogenesis
ZIC1 Zic family member 1 Cell differentiation
ZNF385B Zinc finger protein 385B DNA binding
According to Ingenuity Systems.
doi:10.1371/journal.pone.0046317.t003
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PCR reactions following the manufacturer’s instructions. Each
mRNA was run in triplicates. Based on high expression and
negligible variation, the reference gene GAPDH was used to
normalize gene expression levels.
Gene expression patterns were calculated using the comparative
crossing threshold method of relative quantification (DDCq
method) [19], and presented as relative (DCq) and fold change
(FC) values. DCq was designated as the mean quantification cycle
(mean of triplicates) of an mRNA in a sample subtracted by the
mean quantification cycle (mean of triplicates) of GAPDH in the
same sample. DDCq was calculated as mean DCq of the SNO
subtracted by DCq of each tumour sample, whereas FC was
2DDCq. DCq values were imported into Patrek Genomics Suite
(Partek Inc., St Louis, MO, USA), and subjected to a non
supervised cluster analysis using the euclidean/average linkage
algorithm.
Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (Redwood City, CA) was used for
classifying genes into biological functions and signalling pathways.
Statistical Analyses
The eight groups classified in Table 1 and four samples of SNO
were processed using GCOS 1.4 (Affymetrix). The CEL files were
imported into Array Assist software (v5.2.0; Iobion Informatics
LLC, La Jolla, CA) and normalized using the PLIER (probe
logarithmic intensity error) algorithm in Array Assist to calculate
relative signal values for each probe set. In order to filter for low
signal values, the MAS5 algorithm in Array Assist was used to
create a data set of absolute calls, showing the number of present
and absent calls for each probe set. The filtration was performed
by eliminating probe sets containing$10 absent calls across the
data set, resulting in a reduction of probe sets from 47000 to
32707. For expression comparisons of different groups, unpaired t-
tests and Benjamini Hochberg correction of p-values for multiple
testing were used.
When comparing DCq values in different histological sub-
groups, a two-sided independent sample t-test was used since the
DCq values were close to normally distributed. Differentially
expressed mRNAs given as FC values were correlated with clinical
parameters. In order to decide whether an mRNA expression was
significantly associated with time until death or time until
progression, Cox regression analyses were used. When significant,
Kaplan-Meier plots were used to estimate survival curves for
tertiles of the expression variable. To compare mRNA expression
levels in two groups of patients, a two-sided Mann-Whitney U-test
was used, since the FC expression levels were not normally
distributed. The results for each group are presented as medians. A
significance level of 1% was used for differential mRNA
expression, and 5% for correlating mRNAs with clinical param-
eters. The statistical analyses were performed by employing SPSS
version 18.
Results
Patient Characteristics
Clinicopathological and laboratory information regarding
patients selected for the RT-qPCR analyses is given in Table 2.
The patients had no other diseases than ovarian cancer influencing
Table 4. Differentially expressed mRNAs (p,0.01) between MD/PD SC, SBOT and SNO.
MD/PD SC vs. SNO MD/PD SC vs. SBOT SBOT vs. SNO
mRNAs p-values FC values p-values FC values p-values FC values
ALPP 4.361026 217.0 4.461024 10.3
BIRC5 1.261023 24.4 1.6610210 8.5
CRABP2 2.661027 20.4 8.861028 10.9
CRISP2 2.161023 257.9
CRISP3 7.661024 260.4
CTCFL 1.561023 34.7 3.461026 60.8
DNAH9 1.6610210 2414.5 2.361025 32.7
DYNLRB2 2.261023 26.9 1.061027 223.1 1.461023 3.4
FOXM1 5.661024 46.2 1.4610210 14.8
KLK8 1.361023 40.1 5.561025 28.1
LCN2 2.261025 113.7 2.061023 170.4
PTH2R 8.061026 41.3 4.361027 50.3
RBFOX1 2.961023 214.2
S100A8 1.661023 5.6
TMEM190 4.161029 266.4 5.061027 50.3
TOP2A 1.561029 30.4 1.461026 5.2 1.561024 5.9
TPPP3 6.3610211 221.9 2.161025 7.8
TPX2 2.7610210 28.5 1.5610213 10.5 2.861023 2.7
VEGFA 6.061026 6.1 8.361026 3.1
ZIC1 8.661023 11.3
ZNF385B 1.261027 2130.5 8.161024 211.4 6.661023 211.5
- illustrate downregulation. FC: Fold change. Further abbreviations are given in Table 1and 3.
doi:10.1371/journal.pone.0046317.t004
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survival, were in good preoperative condition [17] and were
Caucasian except for one Latino SBOT patient. All were
postmenopausal except for three SBOT patients, and no cancer
patients were currently receiving hormone therapy. Primary
debulking surgery was performed in all carcinoma patients, and
with the exception of two patients, all received platinum-based
adjuvant treatment.
Follow-up data (Table 2), including clinical examinations,
standard laboratory analyses and complementary diagnostic
imaging were available for all patients. The protein CA125
(cancer antigen 125) was measured prior to each chemotherapy
cycle and was used as a marker for response to therapy. A CA125
response was defined according to The Gynecologic Cancer
Intergroup (GCIG) criteria, including at least a 50% reduction in
CA125 levels from a pre-treatment sample. A CA125 normaliza-
tion was defined as optimal when normalized (,35 kU/L) within
four cycles of chemotherapy. After completion of treatment, the
patients were evaluated every third months for two years, every six
months for the next three years, and thereafter once a year.
Progression-free survival (PFS) and overall survival (OS) were
defined as the time interval from the date of surgery to the date of
first confirmed disease recurrence and to the date of death,
respectively. Disease progression was based on an increase in the
CA125 level according to the GCIG criteria and a verified clinical
relapse, and the date of the first event was used. Clinical data was
current as of 25 August 2011.
Global Gene Expression Analyses and RT-qPCR Validation
From 47000 transcripts a comparison between MD/PD SC,
SBOT and SNO was made to detect differentially expressed
mRNAs. Based on p-values (,0.005), FC values (.10) and visual
investigation of the microarray cluster analysis heatmap, 30
mRNAs (Table 3) were selected for RT-qPCR validation. The
global mRNA expression results were largely confirmed by the
RT-qPCR analyses. By applying a significance level of 1%, 21 of
30 mRNAs were verified as differentially expressed between MD/
PD SC, SBOT and SNO (Table 4). Twenty of these mRNAs were
markedly differentially expressed (p,0.005), including 14 with a
p,1025. Thirteen mRNAs distinguished MD/PD SC from SNO
Figure 1. Cluster analysis heatmap. Cluster analysis heatmap of the expression levels (DCq values) of 21 differentially expressed mRNAs (p,0.01)
in moderately (MD) and poorly differentiated (PD) serous ovarian carcinomas (SC), serous ovarian borderline tumours (SBOT) and superficial scrapings
from normal ovaries (SNO). Each column represents an mRNA and each row a sample. The more over-and under-expressed the mRNA, the brighter
the red and blue colour, respectively. Due to technical analysis errors for DYNLRB2, CRABP2, CRISP2, CRISP3 and LCN2 in sample nr 7, 21 and 26, these
values are calculated as the mean DCq values of each subgroup. Further abbreviations are given in Table 3.
doi:10.1371/journal.pone.0046317.g001
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(ten up- and three down-regulated). ZNF385B was the most
differentially expressed mRNA according to the FC value
(p = 1.261027, FC=2130.5), followed by LCN2, CRISP2 and
FOXM1. When comparing MD/PD SC with SNO and SBOT,
respectively, ten mRNAs were similarly differentially expressed.
Eight mRNAs were differentially expressed in MD/PD SC only
when compared with SBOT, including DNAH9 (p= 1.6610210,
FC=2414.5). Comparison of SBOT and SNO showed an
entirely different pattern (Table 4). When SC were subgrouped
into MD and PD tumours and separately compared with SNO
and SBOT (t-test of DCq values), similar profiles were found for
the two subgroups (data not shown).
Figure 1 visualises a cluster analysis heatmap of the expression
levels of the 21 differentially expressed mRNAs (p,0.01), showing
that MD/PD SC, SBOT and SNO are almost perfectly
segregated. Generally, the MD/PD SC mRNA expression levels
clustered together as did those of SBOT and SNO. Two distinct
portraits appeared, illustrating differential expression of these
mRNAs in MD/PD SC versus both SBOT and SNO, whereas
SBOT and SNO showed more similar patterns. The SC was
separated into MD and PD, and their portraits overlapped
considerably. Notably, the expression of BIRC5, FOXM1, TPX2
and TOP2A clustered together, adjacent to the cluster with
VEGFA.
Ingenuity Pathway Analysis
The 21 differentially expressed mRNAs (Table 4) were mapped
in the Ingenuity Pathways of Knowledge Base. Comparison of
MD/PD SC with SNO revealed two connecting networks linked
together by FOXM1. These two networks included all the 13
differentially expressed mRNAs in MD/PD SC. One of the
networks (Fig. S1) included nine of the 13 mRNAs (BIRC5,
CRABP2, DYNLRB2, FOXM1, KLK8, LCN2, TOP2A, TPX2
and VEGFA), whereas the other network (not shown) included five
of the 13 mRNAs (CRISP2, CTCFL, FOXM1, PTH2R and
ZNF385B). Direct interactions between five of the most signifi-
cantly upregulated mRNAs shown in Figure S1 (VEGFA,
FOXM1, TPX2, BIRC5 and TOP2A) and the tumour suppressor
gene TP53 (tumour protein p53) were found, and a core pathway
for MD/PD SC was generated (Fig. 2). In retrospect, the
microarray analyses showed that TP53 was highly, although not
among the most differentially expressed mRNAs in MD/PD SC
compared with both SBOT (p= 2.561024, FC= 2.4) and SNO
(p= 1.261023, FC= 2.0). The molecular interactions of the
pathway were related to mRNAs, DNA and proteins.
Correlation of mRNA Expression with Clinical Parameters
The 13 differentially expressed mRNAs in MD/PD SC
compared with SNO (Table 4) were correlated with OS, PFS,
optimal CA125 normalization after treatment and residual tumour
amount after surgery. ZNF385B and VEGFA were associated with
OS (p= 0.03) and PFS (p= 0.037), respectively. The ZNF385B
and VEGFA expression levels for MD/PD SC were divided into
tertiles, and Kaplan-Meier plots made (Fig. 3A–B). Patients with
the lowest tertile of ZNF385B expression level had a much longer
OS than patients with the highest tertile level, with median time
until death of 48 and 16 months, respectively. In the intermediate
ZNF385B tertile group the average median time until death was
32 months, averaging the survival times for the high and low
ZNF385B tertile groups. Patients with the lowest VEGFA
expression levels had a much longer PFS than patients with the
highest and intermediate levels, with median time until progres-
sion of 28 and 11 months, respectively. When adjusting for FIGO
stage, the associations between ZNF385B and OS as well as
VEGFA and PFS were still significant (p = 0.030 and p=0.031,
respectively).
TPX2 and FOXM1 correlated with optimal CA125 normali-
zation (p = 0.03 and p= 0.044, respectively). Patients with optimal
CA125 normalization had higher expression levels of TPX2 and
FOXM1 (n= 14; median FC=33.0 and 51.2, respectively) than
patients without optimal CA125 normalization (n= 7; median
FC=14.2 and 20.7, respectively). No association between the 13
differentially expressed mRNAs and residual tumour amount was
found.
Discussion
The mRNA profile of MD/PD SC was clearly different from
that of SBOT and SNO, while the latter two showed marked
similarities. In fact, the mRNAs differentially expressed in MD/
PD SC showed predominantly inverse heatmap portraits com-
pared with SBOT/SNO. A lower potential of malignancy
combined with a reduced proportion of tumour cells in SBOT
compared with MD/PD SC may at least partly explain the similar
gene expression in SBOT and SNO. The similar mRNA
expression profiles of MD and PD SC have been recognized
previously [10].
Expression of ZNF385B was 130 times less in MD/PD SC
compared with SNO, and the degree of downregulation correlated
positively with OS. ZNF385B belongs to the family of zinc-finger
genes, which encode transcription factors, playing an essential role
in gene expression. This mRNA is supposed to be a transcription
repressor, but the specific target genes have not been identified
[20]. We hypothesize that its repression of transcription somehow
inhibits neoplasia and/or tumour cell metastasis. Thus, when the
transcriptional inhibition of ZNF385B decreases and mRNA levels
increase, tumour growth/metastasis is promoted, resulting in
shorter OS. The present study is to our knowledge the first to link
ZNF385B to ovarian cancer.
VEGFA, a major mediator of tumour angiogenesis [21], was
significantly upregulated in MD/PD SC, and a high expression
was associated with a short progression-free survival. Consistent
with our findings, a high expression of VEGFA as well as an
Figure 2. Molecular pathway for moderately and poorly
differentiated serous ovarian carcinomas. .acts on (– direct
interaction, -- indirect interaction), ) inhibits. The pathway was
facilitated through Ingenuity Pathway Analysis. Abbreviations are given
in Table 3.
doi:10.1371/journal.pone.0046317.g002
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Figure 3. Kaplan-Meier survival curves. Overall survival curves according to ZNF385B mRNA expression level (FC) tertiles (A) and progression-
free survival curves according to VEGFA mRNA expression level (FC) tertiles (B) in patients with moderately and poorly differentiated serous ovarian
carcinomas. A: High expression. B: Intermediate expression. C: Low expression.
doi:10.1371/journal.pone.0046317.g003
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association with poor prognosis have previously been found in
malignant tumours including EOC [22–25], indicating that
VEGFA may be a possible prognostic marker. A humanized
monoclonal antibody targeting VEGFA, Bevacizumab, has been
approved for the treatment of several tumour types, including
EOC [21,26,27]. For ovarian cancer patients Bevacizumab in
combination with standard chemotherapy has shown improve-
ment in PFS in several phase III trials, including front line [26,27]
and platinum-resistant recurrent [28] treatment.
High expression levels of TPX2 and FOXM1 correlated with
optimal CA125 normalization, and were among the most
markedly upregulated mRNAs in MD/PD SC compared with
both SNO and SBOT. Thus, effective chemotherapy appears to
be associated with upregulation of these genes.
TPX2 has an important function in spindle assembly during cell
division [29] and has previously been shown to be overexpressed
in ovarian cancer, including MD/PD SC, and other malignancies
[10,30–32]. TPX2 is an activator of AURKA (aurora kinase A)
[33,34], which is overexpressed in cancer and regarded as a key
regulator of mitosis [33]. There is an overexpression of both
AURKA and TPX2 in many different cancer forms, including
ovarian cancer [24,33], and it has been proposed that TPX2 and
AURKA is a functional unit with oncogenic properties [33]. In
concordance we found that AURKA was upregulated in MD/PD
SC compared with SNO (p= 0.10, FC=3.8) and SBOT
(p= 5.961024, FC= 6.3).
FOXM1 encodes a transcriptional activator involved in cell
proliferation, and is overexpressed in various human malignancies,
including ovarian carcinomas [35,36]. FOXM1 promotes metas-
tasis [37], and correlates with poor prognosis [36]. FOXM1
regulates several genes involved in the cell cycle progression,
including BIRC5 and TP53 and is regulated by TP53 [38,39].
TP53 represses FOXM1 after DNA damage [39], and the high
rate of TP53 mutation in MD/PD SC has therefore been
suggested to contribute to FOXM1 overexpression [11], in
support of our presented MD/PD SC pathway.
Overexpression of FOXM1 [11,14] and BIRC5 [11,14,40] in
MD/PD SC has previously been described, also when compared
with SBOT [14], strengthening the relevance of the present
results. Also, a FOXM1 transcription factor network, including
BIRC5 has recently been identified for MD/PD SC, in support of
our findings [11]. BIRC5, also repressed by TP53 protein [41,42],
encodes survivin, which is regarded as one of the most cancer
specific proteins identified, inhibiting apoptosis and promoting cell
proliferation [41–43]. Survivin is expressed in about 90% of EOC,
and appears to be a prognostic marker [44,45]. Strategies for
inhibiting BIRC5 are now utilized in several ongoing clinical trials
on different cancer forms [43], but so far not in ovarian cancer.
Our results suggest that BIRC5 might be a potential target for
therapy in EOC.
A molecular pathway for MD/PD SC was identified, involving
five markedly upregulated mRNAs (VEGFA, FOXM1, TPX2,
BIRC5 and TOP2A), all directly interacting with TP53. The fact
that TP53 was upregulated in MD/PD SC may represent a
compensatory mechanism, since TP53 is mutated in almost all
MD/PD SC [11], resulting in high levels of dysfunctional proteins.
A normal TP53 protein inhibits all mRNAs in the pathway, but
VEGFA. We postulate that a mutation in the TP53 gene results in
a decreased inhibition and consequently an upregulation of
FOXM1, TPX2, BIRC5 and TOP2A.
Conclusions
We have identified several known and hitherto partly unrecog-
nized mRNAs as significantly differentially expressed between
MD/PD SC, SBOT and SNO, including a set with apparent
clinical relevance. In spite of the relatively small sample size, we
have found several significant associations between mortality/
morbidity and gene expressions in patients with MD/PD SC.
Survival curves indicate that these associations are strong and of
clinical importance. ZNF385B, previously unrecognized as a
potential ovarian tumour marker, and VEGFA correlated with
overall and progression-free survival, respectively, whereas TPX2
and FOXM1 with optimal CA125 normalization. However, the
novel findings should be interpreted with caution until verified in
larger studies. We also present a molecular pathway facilitated
through Ingenuity Pathway Analysis for MD/PD SC, including
VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all directly
interacting with TP53, possibly representing a carcinogenic
hierarchical molecular structure. Mechanistic studies will be
needed to test the functional associations postulated in this
pathway in MD/PD SC. The identified mRNAs should be
explored in future studies as candidates for potential biomarkers
and targets for therapy.
Supporting Information
Figure S1 Network of molecular interactions for mod-
erately and poorly differentiated serous ovarian carci-
nomas. .acts on (– direct interaction, -- indirect interaction), )
inhibits. The network was generated by Ingenuity Pathway
Analysis.
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Abstract 
Background: Improved insight into the molecular characteristics of the different ovarian cancer subgroups is 
needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a) 
identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovarian 
carcinoma (CCC) and ovarian surface epithelium (OSE), b) evaluate selected miRNAs for association with 
clinical parameters including survival and c) map miRNA/mRNA interactions.  
Methods: Differences in miRNA expression between HGSC, CCC and OSE were analyzed by global miRNA 
expression profiling (Affymetrix GeneChip miRNA 2.0 Arrays, n=30), validated by RT-qPCR (n=63), and 
evaluated for associations with clinical parameters. For HGSC, differentially expressed miRNAs were linked to 
differentially expressed mRNAs identified previously. 
Results: Differentially expressed miRNAs between HGSC, CCC and OSE were identified, of which 18 were 
validated (p<0.01) using RT-qPCR in an extended cohort. Compared with OSE, miR-205-5p was the most 
overexpressed miRNA in HGSC. miR-200 family members and miR-182-5p were the most overexpressed in 
HGSC and CCC compared with OSE, whereas  miR-383 was the most underexpressed. miR-509-3-5p, miR-509-
5p, miR-509-3p and miR-510 were among the strongest differentiators between HGSC and CCC, all being 
significantly overexpressed in CCC compared with HGSC. High miR-200c-3p expression was associated with 
poor progression-free (p=0.031) and overall (p=0.026) survival in HGSC patients. Interacting miRNAs and 
mRNA targets, including those of a TP53-related pathway presented previously, were identified in HGSC.  
Conclusions: Several miRNAs are overexpressed in HGSC and CCC compared with OSE, including the miR-
200 family, among which miR-200c-3p is associated with survival in HGSC patients. A set of miRNAs 
differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several 
interactions between miRNAs and mRNAs in HGSC were mapped.  
 
Keywords : ovarian carcinoma; microRNA; microarray; quantitative PCR; survival  
 
Background  
Ovarian cancer is the fourth and fifth most frequent cause of cancer death in women in Norway and the U.S., 
respectively [1,2]. Two-thirds of patients have advanced-stage disease (International Federation of Gynecology 
and Obstetrics [FIGO] stage III-IV) at diagnosis, resulting in 5-year survival at <30% [1,2].  
Ovarian carcinoma (OC) constitutes about 90% of ovarian cancers, and is a heterogeneous group of tumors, 
encompassing several distinct subgroups with respect to molecular profiles, biological behavior and clinical 
features [3]. Nevertheless, OC patients generally receive similar, non-individualized treatment. Therefore, 
improved insight into the molecular characteristics of the different OC subgroups may aid in development of a 
more subgroup-specific treatment, thereby improving prognosis.  
microRNAs (miRNAs) are short, non-coding RNA molecules, which by targeting mRNAs cause mRNA 
degradation or translational repression [4]. Involvement of miRNAs in translational activation has also been 
described [5-7]. Since functional interactions with mRNA targets do not seem to require perfect base 
complementarity, a single miRNA may have multiple different mRNA targets and conversely, a given mRNA 
might be targeted by multiple miRNAs. Therefore, miRNAs play a central role in regulating gene expression 
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post-transcriptionally and are involved in many biological processes. Alterations in miRNA expression level 
may consequently alter the level of a wide spectrum of mRNAs and subsequently cellular functions.     
miRNAs show abnormal expression patterns in different cancer forms [8]. Some act as tumor suppressor 
genes or oncogenes and may therefore be important in cancer development. Various gene expression analysis 
approaches, including microarrays, have identified aberrantly expressed miRNAs in OC [9-25], of which some 
are related to progression [12], outcome [17-23] and chemotherapy resistance [22-24]. However, the studies have 
in general utilized non-subgroup specific tumors [9], and only a few included normal ovarian surface epithelium 
(OSE) [14-16], which has been shown to be valid control material [26,27]. 
The aim of this study was to identify miRNAs differentially expressed between moderately and poorly 
differentiated serous OC, referred to as high-grade serous OC (HGSC), clear cell OC (CCC) and scrapings from 
ovarian surface epithelium (OSE), and to evaluate their association with clinical parameters, including survival. 
To identify potential key molecular pathways of the carcinogenesis of HGSC, differentially expressed miRNAs 
and mRNAs identified previously [28] were linked. We have identified several miRNAs differentially expressed 
between HGSC, CCC and OSE, including miR-200c-3p with apparent clinical relevance in HGSC. Several 
interactions between aberrantly expressed miRNAs and mRNAs in HGSC have also been mapped.  
 
Material and methods 
Ethics statement 
The study was approved by the Regional Committee of Medical and Health Research Ethics of South-Eastern 
Norway (ref.no.530-02163 and S-04300) and all participants signed informed consent.  
 
Patients and material 
Women were enrolled prior to operations for gynecological diseases at OUH during 2003-2012. Patient 
information was obtained from hospital records and preoperative interviews. Patients were evaluated routinely 
[28] and follow-up data, including clinical examinations, laboratory analyses and imaging were available for all 
patients. CA125 level was used as marker for therapy response. CA125 normalization (<35 kU/L) was defined as 
optimal when achieved within four cycles of chemotherapy. Time until progression and time until death were 
defined as the time interval from the date of surgery to the date of first confirmed disease recurrence and to the 
date of death, respectively. Disease progression was based on CA125 level increase according to GCIG criteria 
(www.gcig.igcs.org) and verified clinical relapse, and the date of first event was used. Clinical data were current 
as of March 20, 2013.  
Tumors comprised primary OC obtained pre-chemotherapy. OSE samples were collected from patients with 
benign diseases, as previously described [26]. Tumors were snap-frozen in liquid nitrogen immediately after 
harvesting, whereas OSE samples were transferred to QiaZol solution (Invitrogen, Carlsbad, CA). All samples 
were stored at -80°C until processed.  
The histological classification and clinical staging were according to the World Health Organization 
classification and FIGO, respectively. Tumors were reviewed by a gynecological pathologist (BD) to confirm the 
histological type and grade. A frozen section from all biopsies was examined prior to RNA isolation to ensure a 
tumor component of at least 50% and absence of necrosis. 
 
RNA preparation 
Frozen tumors (<50mg) were homogenized directly for 3 minutes in 700μl QIAzol using a TissueLyzer 
(Qiagen, Hilden, Germany). Total RNA was extracted using the miRNeasy Mini Kit (Qiagen) and Phase Lock 
Gel™ Heavy (5 PRIME GmbH, Hamburg, Germany). RNA was quantified with a NanoDrop® ND-1000 
Spectrophotometer (Saveen Werner, Malmö, Sweden), and quality assessed on Agilent 2100 Bioanalyzer RNA 
6000 Nano Kits (Agilent Technologies, Palo Alto, CA). All samples showed adequate RNA quantity and quality. 
 
Global miRNA expression profiling  
Global miRNA expression was analyzed in 12 HGSC, 9 CCC and 9 OSE samples. Total RNA (400ng) was 
used for biotin labeling of miRNA by the Genisphere FlashTag HSR kit following the manufacturer's 
recommendations (Genisphere, Hatfield, PA). Labeled miRNAs were hybridized to the GeneChip miRNA 2.0 
Array (Affymetrix, Santa Clara, CA), representing 1,105 mature human miRNAs, as recommended by the 
manufacturer. Arrays were washed and stained using the FS-450 fluidics station (Affymetrix). Signal intensities 
were detected by Hewlett Packard Gene Array Scanner 3000 7G (Hewlett Packard, Palo Alto, CA). Microarray 
data were deposited in NCBI's Gene Expression Omnibus [29] and are accessible through GEO Series accession 
number GSE47841 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47841). 
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Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) 
Selected candidate miRNAs were validated by RT-qPCR in all samples analyzed by global miRNA 
expression profiling (except one excluded) and in additional samples, totaling 35 HGSC, 19 CCC and 9 OSE 
samples. Custom-made TaqMan® Low Density Array (TLDA) cards for human miRNA expression analysis 
(Applied Biosystems, Life Technologies, Carlsbad, CA) were used for quantification of specific miRNAs, each 
card allowing 384 simultaneous qPCR reactions of 24 different miRNAs run in duplicates. Included were two 
selected reference genes and one mandatory control (U6(mammu6)snRNA).  
Total RNA (350ng) was applied for reverse transcription (RT) with stem-looped RT primer-mix, enabling 
synthesis of cDNA from mature miRNAs. Unbiased custom-based pre-amplification was performed according to 
protocols, using gene-specific forward and reverse primers. The PCR reactions were performed on Unocycler 
(VWR International, B-3001 Leuven, Belgium). The TLDA cards were used for further PCR-amplification on a 
ViiA7™ Real Time PCR system thermocycler and analyzed with ViiA7 RUO Software (Applied Biosystems, 
Life Technologies).  
Relative gene expression levels were calculated using the comparative crossing threshold method of relative 
quantification (∆∆Cq method) [30], and presented as relative quantification cycle (ΔCq) and fold change (FC) 
values. ΔCq was designated as the mean Cq (mean of duplicates) of a miRNA in a sample subtracted by the 
mean Cq (mean of duplicates) of two reference genes in the same sample. Based on recommendations from the 
manufacturer and comparison between the microarray and RT-qPCR analyses, Cq expression cutoff was set to 
30, which was applied for calculations. For analyzing associations with clinical parameters, ΔΔCq was 
calculated as mean ΔCq of the OSE controls subtracted by ΔCq of each tumor sample. For comparison of mean 
expression levels between different groups, ΔΔCq was calculated as mean ΔCq of one group subtracted by mean 
ΔCq of another group. FC was designated as 2ΔΔCq.
All miRNAs analyzed were from Homo sapiens (hsa) and the prefix hsa was therefore excluded.  
Ingenuity Pathway Analysis (IPA)
Data were analyzed through the use of IPA (Ingenuity® Systems, www.ingenuity.com). 
Statistical analysis 
For computational analysis of the microarray data, scanned images were processed using the AGCC 
(Affymetrix GeneChip Command Console) software, and the CEL files were imported into Partek Genomics 
Suite software (PGS; Partek, Inc., St Louis, MO). The Robust Multichip Analysis (RMA) algorithm was applied 
for generation of relative signal values and normalization. For expression comparisons of different groups, a 1-
way ANOVA model followed by calculation of FDR was used. Results were expressed as FC and p-values. 
Signal values were subjected to a non-supervised cluster analysis using the Euclidean/average linkage algorithm.  
Associations between signal values and progression-free survival (PFS) and overall survival (OS) were 
evaluated by Cox regression analyses followed by FDR correction. FDR q-values of 0.1 and 0.25 were used as 
significance levels for PFS and OS, respectively. 
When comparing ΔCq values in different histological subgroups, a two-sided independent samples t-test was 
used since the ΔCq values were close-to-normally distributed. Associations between FC values of the RT-qPCR 
analyses and clinical parameters were evaluated. In order to decide whether expression of a miRNA was 
significantly associated with PFS and OS, Cox regression analyses were used. When significant, Kaplan-Meier 
plots were used to estimate survival curves for tertiles of the expression variable. To compare miRNA expression 
levels in two groups of patients, a two-sided Mann-Whitney U-test was used, since the FC expression levels 
were not normally distributed. The results for each group are presented as medians. 
A significance level of 1% was used for differential miRNA expression, and 5% when analyzing associations 
with clinical parameters. Statistical analyses were performed using the SPSS-PC package (Version 20, Chicago 
IL).   
Results 
Patient characteristics 
Clinicopathologic data for the RT-qPCR cohort are shown in Table 1. All HGSC patients were diagnosed 
with FIGO stage IIIc/IV, whereas CCC patients were diagnosed at all stages due to limited patient material. The 
patients had no disease other than OC influencing survival, were Caucasian, and except for 1 with HGSC and 2 
with CCC all were in good preoperative condition [26].
Primary surgery was performed in all patients. With the exception of 4 HGSC and 5 CCC patients, all 
received platinum-based chemotherapy. The 4 HGSC patients were considered to be in too poor general 
condition to tolerate chemotherapy. Among CCC patients, 1 received paclitaxel-based treatment, 1 was in too 
poor general condition, and 3 did not receive chemotherapy due to FIGO stage IA.  
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Global miRNA expression analyses 
Seventy-eight miRNAs were differentially expressed between HGSC, CCC and OSE applying a FDR 
<0.01%. Principal component analysis showed that these miRNAs could distinguish the 3 groups almost 
perfectly (Figure 1). Cluster analysis, visualized by a heatmap (Figure 2) showed almost perfect segregation of 
the 3 groups. Striking differences were observed between HGSC and OSE samples, whereas CCC had an 
intermediate profile. Moreover, miR-508-5p, miR-509-3p, miR-509-5p, miR-509-3-5p, miR-510 and miR-514b-
5p clearly distinguished HGSC from CCC. OSE control samples were homogeneous. 
 
Evaluation of associations between global miRNA expression and survival 
Associations between miRNAs with signal values >7 (n=297) and PFS (FDR q<0.1) and OS (FDR q<0.25) 
were separately evaluated in HGSC and CCC. No statistically significant associations were found. However, 
when not corrected for multiple testing, 11 miRNAs had p<0.05, indicating an association with survival. Of 
these, miR-505-5p, miR-1281 and miR-29b-2-5p had the lowest p-values (p<0.03), all with potential association 
with survival in HGSC. These miRNAs were among the miRNAs chosen for RT-qPCR validation and 
subsequent evaluation for association with outcome in the extended patient cohort. Noteworthy, only miR-29b-2-
5p was among the differentially expressed miRNAs shown in Figure 2.  
 
RT-qPCR validation of selected miRNAs  
Twenty-one miRNAs and 2 reference genes were selected for RT-qPCR validation in the extended patient 
material. Of these, 18 miRNAs (Table 2A) were predominantly selected based on differential expression 
(Figure 2). All miRNAs with FC>±20 (n=16) and 2 of the mRNAs with FC>±15 were included, reaching a 
highest FC value of 105. Additionally, the 3 above-mentioned miRNAs were selected based on possible 
association with survival. miR-24 and miR-26a were selected as reference genes, having the lowest expression 
variation (0.11 and 0.10, respectively) in the global miRNA analysis. Their mean value reduced the variation to 
0.029, and their mean Cq value was therefore used for calculations. 
All miRNAs selected based on differential expression were verified as markedly differentially expressed, 
with p-values varying from 10-7 to 10-21 and FC values up to 95 (Table 2B). When comparing HGSC with OSE, 
7 and 6 miRNAs were over- and under-expressed in HGSC, respectively. According to FC values, miR-205-5p 
was the most overexpressed (FC=74), followed by miR-200c-3p, miR-182-5p, miR-141-3p and miR-200b-3p. 
When comparing CCC with OSE, 11 and 2 miRNAs were over- and underexpressed, respectively, including 8 
common with the HGSC vs. OSE analysis. miR-182-5p best distinguished CCC from OSE (FC=66), followed by 
miR-200a-3p, miR-200c-3p, miR-200a-5p and 200b-3p. All these miRNAs were overexpressed, whereas miR-
383 was the most underexpressed in both HGSC and CCC. 
Twelve miRNAs distinguished CCC from HGSC, all except 1 being overexpressed in CCC. The miRNA 
with highest FC values was miR-509-3-5p (FC=95), followed by miR-509-5p, miR-509-3p, miR-510 and miR-
508-5p. 
Experimental information annotated from IPA for these miRNAs is provided in Table 2C.  As shown, these 
miRNAs are active regulators of the expression of several cancer-related mRNAs, including ZEB1, ZEB2, VIM, 
VEGFA, NTRK3 and SPDEF, and most of the miRNAs are cancer-related. 
 
Associations between validated miRNA expression and clinical parameters  
All miRNAs validated by RT-qPCR were evaluated for association with PFS, OS, optimal CA125 
normalization and residual disease (RD). In HGSC, miR-200c-3p was found to be associated with PFS (p=0.031) 
and OS (p=0.026). The miR-200c-3p FC expression level was divided into tertiles, and Kaplan-Meier plots made 
(Figure 3). Patients with highest tertile level had shorter OS than patients with intermediate or lowest levels, 
with median time until death of 18 and 30 months, respectively (Figure 3A). Patients with the highest tertile 
level had shorter PFS compared with patients with lowest levels, with median time until progression of 7 and 11 
months, respectively (Figure 3B). No association was found between the miRNAs and CA 125 normalization or 
RD (cut-off at 2 cm) in HGSC. The 3 miRNAs selected for RT-qPCR based on possible association with 
survival were not found to be associated with outcome.  
In CCC, no associations with PFS or OS were found. However, patients with macroscopic RD (cut-off at 0 
cm) had significantly lower miR-202-3p (p=0.018) and miR-1281 (p=0.035) levels (n=6; median FC=-5.3 and -
2.0, respectively) than patients without RD (n=13; median FC=1.6 and -1.2, respectively). Associations with CA 
125 normalization could not be evaluated in CCC, since all but 3 patients achieved optimal CA 125 
normalization.  
 
Ingenuity Pathway Analysis (IPA)  
To identify miRNAs/mRNA interactions in HGSC, differentially expressed miRNAs were linked to 
differentially expressed mRNAs identified previously [28]. miRNAs and mRNAs of the microarray analyses 
(ANOVA, FDR 5%) were imported to the IPA software and filtered for interactions. When including only 
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miRNAs and mRNAs with FC±10, interactions of inverse miRNA/mRNA expression pairing, interactions 
experimentally observed and of high predicted confidence, 19 miRNAs targeting 47 mRNAs (Table 3) were 
found. All but 3 miRNAs are included in Figure 2. Core analysis was performed, and selected cancer-related 
functions are shown in Table 3. Fifty-four RNAs were cancer-related, of which 11 mRNAs and 8 miRNAs were 
OC-related. Thirty-one and 10 molecules were related to cell proliferation and cell cycle, respectively.  
We previously presented a HGSC pathway comprising VEGFA, FOXM1, TPX2, BIRC5 and TOP2A, all 
significantly overexpressed and directly interacting with TP53 [28]. These mRNAs were linked to differentially 
expressed miRNAs (FC>±2) in HGSC (ANOVA, FDR 5%). When inverse and similar miRNA/mRNA 
expression pairing and all confidence levels were included, 26 miRNAs and 30 interactions were found (Figure 
4). Of these, 7 and 12 were experimentally observed and of high predicted confidence, respectively. Among the 
miRNAs, 16 were under- and 10 overexpressed. All but 9 miRNAs are included in Figure 2. 
 
Discussion 
In this study, a number of miRNAs distinguishing HGSC and CCC from OSE, as well as CCC from HGSC 
have been identified, including a set validated by RT-qPCR. These miRNAs could be involved in the biology of 
these OC subgroups. 
The most differentially expressed miRNAs in both HGSC and CCC compared with OSE were miR-200 
family members, including miR-200a-3p, miR-200b-3p, miR-200c-3p and miR-141-3p. These miRNAs are 
aberrantly expressed in different cancers [31-34], and have been found to be overexpressed in serous and clear 
cell OC, although few CCC were analyzed [16,21,25]. 
miR-200 family members have been demonstrated to regulate epithelial-mesenchymal transition (EMT) by 
targeting ZEB1 and ZEB2, resulting in altered expression of the cell-cell adhesion molecule E-cadherin [35-38]. 
E-cadherin down-regulation is apparently important in cancer progression, facilitating cell detachment and 
metastasis. At a favorable distant location, cells may undergo mesenchymal-epithelial transition (MET) and re-
express E-cadherin. This is supported by the finding of elevated E-cadherin and reduced ZEB1 in metastatic 
epithelial ovarian cancer [39]. ZEB1 and ZEB2 are also targets of miR-205-5p [35], which was highly 
overexpressed in HGSC compared with OSE and CCC.  
miR-200c-3p and miR-200b-3b, having similar seed sequences, have been shown to decrease VIM 
expression and thereby its protein vimentin [37]. Vimentin is found in various non-epithelial cells, especially 
mesenchymal cells, and is used as marker for EMT during metastasis. Elevated expression of miR-200c-3p and 
miR-200b-3b, resulting in reduced vimentin levels, is therefore expected in metastatic cancer, where epithelial 
features are important for re-colonization.  
miR-182-5p had the highest FC in CCC compared with OSE. This miRNA regulates the expression of 
PIK3CA, a frequently mutated gene in CCC and a candidate for targeted therapy [40]. Little is known about 
miR-200a-5p, although it has been related to colorectal cancer [34].  
To the best of our knowledge, the present study is the first to identify differentially expressed miRNAs in a 
relatively large CCC series. The miRNAs most clearly separating CCC from HGSC were miR-509-3-5p and 
miR-509-5p, having similar seed sequences, as well as miR-509-3p and miR-510. miR-509-3p has been shown 
to target NTRK3 [41], encoding the receptor tyrosine kinase TrkC, which is involved in the oncogenic PIK3CA 
pathway. miR-509-3p, miR-509-3-5p and also miR-513a-5p have been found overexpressed in stage I OC [22], 
and miR-509-5p have been found to inhibit cancer cell proliferation [42]. miR-510 targets SPDEF [43], which 
have been found underexpressed in OC compared with breast carcinoma [44]. 
High level of miR-200c-3p was found to be associated with short PFS and OS in HGSC, indicating it may be 
a prognostic marker for HGSC. This finding is in accordance with a study analyzing miRNA expression in SC 
vs. normal ovaries [21]. This miRNA has also been associated with survival in stage I OC patients [45] and 
chemotherapy response [46]. miR-200c-3p was among the most differentially expressed miRNAs in both HGSC 
and CCC compared with OSE separately, and had the lowest  p-value in both comparisons. miR-200c-3p has 
previously been found to be overexpressed in SC [21,25], HGSC cell lines [47], serum from HGSC patients [47] 
and in a small series of CCC [25].  
A larger cohort is warranted for CCC to explore the associations between miRNAs and survival. However, 
miR-202-3p and miR-1281 were found to be associated with RD in CCC, although this could not be adjusted for 
stage due to the small series. 
We further identified interactions between differentially expressed mRNAs and miRNAs in HGSC. The vast 
majority of these RNAs has previously been associated with cancer and cancer-related functions, and may 
represent important key molecular pathways in HGSC. VEGFA, which we previously found to be overexpressed 
and associated with PFS in HGSC, is a target of miR-200c-3p. Since both RNAs were overexpressed, an 
interaction may be explained by activation of gene expression [5-7]. The identified interactions should be 
experimentally evaluated in HGSC. 
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Conclusions 
Several miRNAs significantly differentially expressed between HGSC, CCC and OSE were identified 
through global miRNA expression profiling and RT-qPCR validation analysis, suggesting a role for these 
miRNAs in OC. The differences emphasize the biological distinctiveness of these OC subgroups. Highly 
overexpressed miRNAs including miR-205-5p in HGSC and members of the miR-200 family in HGSC and CCC 
target EMT drivers, and may be important in OC progression. Overexpression of miR-182-5p and miR-200a-5p 
and underexpression of miR-383 was also found in HGSC and CCC. Some miRNAs separating CCC from 
HGSC were also identified, including miR-509-3-5p, miR-509-5p, miR-509-3p and miR-510. miR-200c-3p, the 
most significantly differentially expressed miRNA in both HGSC and CCC according to p-values, was found to 
be associated with PFS and OS in HGSC, representing a potential prognostic marker for HGSC. In HGSC, 
several interacting differentially expressed miRNAs and mRNAs were mapped, but need to be experimentally 
verified. The identified miRNAs should be explored in future studies as candidate biomarkers and therapeutic 
targets. 
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Table 1. Clinicopathological and laboratory information for patients selected for 
RT-qPCR analysis. 
Parameter HGSC a, n=35 CCC a, n=19 
Age; mean ± SD (range) 64.0 ± 11.3 (45-87) 63.9 ± 15.3 (28-83) 
Preoperative CA125 (kU/L); mean ± SD 3023 ± 4129 1438 ± 2198 
FIGO stage I 0 10 
II 0 3 
III 25 5 
IV 10 1 
Residual disease 0 cm 3 13 
<2cm 9 4 
>2cm 23 2 
Start of chemotherapy (days after surgery); mean ± SD 27.7 ± 11.6 25.7 ± 13.8 
CA125 response b Yes 31 15 
No 1 0 
Optimal CA125 normalization b Yes 20 13 
No 14 3 
Median time (months) until progression (95%CI) 10 (7-13) NA c 
Median time (months) until death (95%CI) 26 (18-34) 105 (35-175) 
Status at last follow-up d NED  1 11 
AWD 1 1 
DOD 33 6 
DOUC 0 1 
a HGSC: High-grade serous ovarian carcinoma; CCC: Clear cell ovarian carcinoma. bAccording to the 
GCIG criteria (www.gcig.igcs.org). For HGSC: Two patients who received no postoperative treatment 
due to poor general condition, one patient with preoperative CA125<70; For CCC: One patient who 
received no postoperative treatment due to poor condition, three patients with preoperative CA125<70. c 
Could not be calculated since the Kaplan-Meier survival curve stays above 50%. d NED = No evidence of 
disease; AWD = Alive with disease; DOD = Dead of disease; DOUC = Dead of unrelated cause. 
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Table 2A. Differentially expressed miRNAs between HGSC, CCC and OSE 
selected for RT-qPCR validation. 
 HGSC vs. OSE a CCC vs. OSE a CCC vs. HGSC a 
miRNAs p-values FC values p-value FC value p-value FC value 
miR-134 8.3x10-8 -16.7  b   1.0x10-4 5.8 
miR-141-3p 1.1x10-11 46.1 2.4x10-10 34.9   
miR-182-5p 6.0x10-9 30.2 1.4x10-8 32.7   
miR-200a-3p 7.3x10-10 33.6 1.3x10-9 38.8   
miR-200a-5p 3.0x10-13 33.5 6.9x10-12 26.5   
miR-200b-3p 1.1x10-9 29.1 2.9x10-8 21.1   
miR-200c-3p 1.2x10-12 16.5 1.2x10-11 15.0   
miR-202-3p 8.0x10-6 -36.9   2.3x10-4 16.3 
miR-205-5p 4.9x10-5 105.1   3.1x10-3 -23.1 
miR-383 8.2x10-12 -33.7 1.5x10-11 -38.7   
miR-424-5p 2.6x10-9 -26.0 4.0x10-6 -10.1   
miR-508-5p   4.4x10-3 11.6 3.1x10-6 75.0 
miR-509-3p 4.3x10-3 -10.3   2.6x10-6 83.4 
miR-509-5p   5.6x10-4 11.4 1.8x10-6 34.0 
miR-509-3-5p 3.9x10-3 -10.2   1.9x10-6 84.6 
miR-510 9.3x10-3 -5.2 7.9x10-3 6.1 3.0x10-6 31.7 
miR-513a-5p   4.8x10-3 7.4 4.1x10-6 33.5 
miR-514b-5p 9.7x10-3 -6.5 3.8x10-3 9.8 1.3x10-6 63.6 
a HGSC: High-grade serous ovarian carcinoma. OSE: ovarian surface epithelium. CCC: Clear cell 
ovarian carcinoma. b ‘-‘ illustrates underexpression. FC: Fold change.  P-values are calculated on 
original data (before FDR corrections). 
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Table 2B. Differentially expressed miRNAs (p<0.01) between HGSC, CCC 
and OSE verified by RT-qPCR. 
 HGSC vs. OSE a CCC vs. OSE a CCC vs. HGSC a 
miRNAs p-values FC values p-values FC values p-values FC values 
miR-134 8.7x10-11 -5.7 b   3.1x10-6 4.3 
miR-141-3p 1.7x10-18 40.3 7.2x10-11 45.3   
miR-182-5p 9.5x10-15 42.4 1.2x10-8 66.2   
miR-200a-3p 3.6x10-5 33.0 9.3x10-10 57.8   
miR-200a-5p 3.1x10-15 33.8 4.3x10-11 53.0   
miR-200b-3p 5.3x10-18 38.8 3.7x10-11 51.0   
miR-200c-3p 6.0x10-21 48.2 3.2x10-12 53.4   
miR-202-3p 1.3x10-14 -14.7   1.6x10-7 10.1 
miR-205-5p 9.0x10-9 74.3   4.4x10-3 -8.4 
miR-383 2.2x10-14 -36.6 9.8x10-10 -15.1 2.2x10-3 2.4 
miR-424-5p 3.1x10-13 -10.7 3.5x10-4 -4.2 1.6x10-3 2.5 
miR-508-5p   3.5x10-3 10.1 1.0x10-8 27.5 
miR-509-3p     2.0x10-7 46.3 
miR-509-5p 5.0x10-3 -4.1 2.4x10-3 13.3 1.3x10-8 54.7 
miR-509-3-5p 1.1x10-4 -11.0   2.2x10-8 95.3 
miR-510   2.5x10-3 9.0 8.7x10-10 32.9 
miR-513a-5p   6.6x10-4 6.2 9.1x10-7 8.3 
miR-514b-5p   9.7x10-5 12.1 2.3x10-9 25.8 
a HGSC: High-grade serous ovarian carcinoma. OSE: ovarian surface epithelium. CCC: Clear cell 
ovarian carcinoma. b ‘-‘ illustrates underexpression. FC: Fold change.   
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Table 2C. Experimentally observed information for differentially expressed miRNAs 
(p<0.01) between HGSC, CCC and OSE.  
miRNAs Regulated mRNAs Cancer association 
OC 
association
miR-134  x  
miR-141-3p TGFB2, ZEB2, JAG1, BAP1, CLOCK, ELMO2, ERBB2IP, 
KLHL20, MAP2K4, PLCG1, PTPRD, WDR37 
x x (EC) 
miR-182-5p FOXO3, ADCY6, CASP2, CLDN17, NCAM1, NFASC, RARG, 
BCL2L14, CARD11, CASP10, CASP12, CDH1, CDH4, CDK6, 
CLDN15, COL11A2, COL4A4, FNDC3A, FOXO1, GADD45G, 
GJA3, IGF1R, INHBC, ITGA4, LRP6, MALAT1, MITF, MTSS1, 
NLGN2, PGF, PIK3CA, RPS6KB1, SOS1, VWF 
x x (EC) 
miR-200a-3p CTNNB1, VIM, ZEB1, ZEB2, BAP1, CDK6, CDKN1B, CTBP2, 
CYP1B1, ELMO2, ERBB2IP, KLHL20, PLCG1, PTPRD, TUBB, 
WDR37, ZFPM2 
x x (EC, 
ROC) 
miR-200a-5p  x  
miR-200b-3p VIM, ZEB1, ZEB2, BAP1, ELMO2, ERBB2IP, ERRFI1, KLHL20, 
PLCG1, PTPRD, RERE, WASF3, WDR37, ZFPM2 
x x (ROC) 
miR-200c-3p CDH1, PTPN13, ZEB1, ZEB2, FHOD1, PPM1F, JAG1, MARCKS, 
VIM, CDKN1B, ERRFI1, PLCG1 
x x  (EC) 
miR-202-3p    
miR-205-5p ERBB3, F Actin, INPPL1, MED1, VEGFA, ZEB1, ZEB2, PRKCE x x  (EC) 
miR-383    
miR-424-5p FGFR1, MAP2K1, NFIA, PLAG1 x  
miR-508-5p    
miR-509-3p NTRK3   
miR-509-5p    
miR-509-3-
5p 
   
miR-510 HTR3E, SPDEF x  
miR-513a-5p CD274 x  
miR-514b-5p    
OC: Ovarian carcinoma. EC: Endometrioid OC. ROC: Recurrent OC. Data were according to IPA. Further 
abbreviations are given in Table 2A. 
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Table 3. Differentially expressed (FC±10) interacting miRNAs and mRNAs in 
HGSC. 
miRNAs mRNAs 
miR-1341,5 KLHL141, PAX81,3,5 
miR-141-3p1,2,6/ miR-
200a-3p1,2,6 
FOXP21,2,5, HLF1, PCDH95, PEG31,6, SCN7A1, SDC21,2,3,4,5,6 
miR-182-5p1,2 ANGPTL11,2,5, CACNB21,5, FOXP21,2,5, KCNMB21,5, PID11, SDC21,2,3,4,5,6, 
TMEM150C 
miR-183-5p1,2,6 ABCA81, HLF1 
miR-187-3p1 TSPAN51,2 
miR-200b-3p1,2,6/ 
miR-200c-3p1,2,6 
CACNB21,5,CDH111,2,5,6, COL4A31,2,5,6, GPM6A1, HLF1, HS3ST3A11, 
LEPR1,2,4,5,6, MCC1,2, NEGR11,2,6, SDC21,2,3,4,5,6 
miR-202-3p RRM21,2,4,6 
miR-203-3p1,2,6 ANGPTL11,2,5, EDNRA1,2,6, FOXP21,2,5,GNG42,6, IGFBP51,2,3,4,5,6, 
NEGR11,2,6,SMAD91 
miR-205-5p1,6 BAMBI1,2,5,6, NR3C21,2,5,6, PEG31,6 
miR-376c-3p1 EHF1,2,3,6, LRP81,5,6 
miR-379-5p KLHL141 
miR-381-3p1 EGFL61, NOTCH31,2,3,5,6, RRM21,2,4,6 
miR-383 MAL2 
miR-424-5p1,2,3,4,5,6 AHNAK21, CCNE11,2,3,4,6, ESRP11,6, HMGA11,2,3,4,6, LAMP31,2, PSAT11, 
UCP22,5, VAMP81,2 
miR-485-5p1 KRT71,3,4, LRP81,5,6, ST141 
miR-887 TMEM139 
miR-4324 ERBB31,2,3,5,6, GALNT6 
1, 2, 3, 4, 5, 6 Related to cancer (underlined for ovarian cancer), cellular growth and proliferation, cell 
cycle, DNA replication, recombination and repair, cell-to-cell signaling and interaction, cellular 
development, respectively. Results were generated through the use of IPA. 
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Figure Legends 
Figure 1. Principal component analysis (PCA). 
A two-dimensional PCA showing different expression patterns of differentially expressed miRNAs based on 
global miRNA expression analyses (ANOVA, FDR<0.01%) in high-grade serous ovarian carcinomas (HGSC; 
blue), clear cell carcinomas (CCC; red) and ovarian surface epithelium (OSE; green).  
 
Figure 2. Cluster analysis heatmap.  
Cluster analysis heatmap of miRNA expression levels (signal values) of differentially expressed miRNAs based 
on global miRNA expression analyses (ANOVA, FDR<0.01%) in high-grade serous ovarian carcinomas 
(HGSC; blue), clear cell carcinomas (CCC; red) and ovarian surface epithelium (OSE; green). Each column 
represents a miRNA and each row a sample. The more over- and under-expressed the miRNA, the brighter the 
red and blue color, respectively. 
 
Figure 3. Kaplan-Meier survival curves for miR-200c-3p expression. 
Overall survival curves (A) and progression-free survival curves (B) according to miR-200c-3p expression level 
(FC) tertiles in patients with HGSC. A: High expression. B: Intermediate expression. C: Low expression. 
 
Figure 4. Differentially expressed (FC2) miRNAs targeting a molecular pathway of 
HGSC [28].  
ĺ acts on (ņ direct interaction, -- indirect interaction), ŏ inhibits. FC: Fold change. 1: Experimentally observed 
interactions. 2: Interactions of high predicted confidence. 3: Interactions of moderate predicted confidence. 
Results were generated through Ingenuity Pathway Analysis. 
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